Clinical Development
LDK378 (ceritinib)
Protocol CLDK378X2103 / [STUDY_ID_REMOVED]
A Phase I, open -label, dose escalation study of LDK378 in 
pediatric patients w ith malignancies that hav e a genetic 
alteration in anaplastic ly mphoma kinase ( ALK)
Authors
Document type Amended Protocol Version
EUDRACT number 2012 -002074 -31
Version number 08 (Clean )
Development phase I
Document status Final
Release date 18-May-2018
Property of [COMPANY_001]
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of [COMPANY_001]
 

[COMPANY_001] Confidential Page 2
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Table of contents
Table of contents ................................................................................................................. [ADDRESS_124461] of abbreviations ............................................................................................................ 9
Glossary  of terms ............................................................................................................... 12
Amendment 8 (18 -May-
2018)........................................................................................... 13
Amendment 7 (24 -Jan-2017) ............................................................................................. 15
Amendment 6 .................................................................................................................... 17
Amendment 5
.................................................................................................................... 18
Summary  of previous amendments ................................................................................... 21
Protocol summary .............................................................................................................. 31
1Background ........................................................................................................................ 35
1.1 Overview of disease pathogenesis, epi[INVESTIGATOR_64000]
t treatment .............. 35
1.2 Introduction to investigational treatment(s) and other study  treatment(s) ............. 36
1.2.1 Overview of LDK378 ........................................................................... 36
2Rationale ................................ ................................ ................................ ............................ 43
2.1 Study  rationale and purpose ................................................................................... 43
2.2 Rationale for the stud y design ............................................................................... 44
2.3 Rationale for dose and regimen selection .............................................................. 45
2.4
Rationale for choice of combination drugs............................................................ 46
2.5 Rationale for choice of comparators ...................................................................... 46
2.6 Risks and benefits .................................................................................................. 46
3Objectives and endpoints ................................ ................................ ................................ ...49
4Study  design ...................................................................................................................... 52
4.1 Description of stud y design ................................ ................................ ................... 52
4.2 Timing of interim anal yses and design adaptations ............................................... 54
4.3 Definition of end of the study ................................................................................ 54
4.4 Early study termination .......................................................................................... 54
5Population .......................................................................................................................... 54
5.1 Patient population .................................................................................................. 54
5.2 Inclusion criteria .................................................................................................... 55
5.3 Exclusion criteria ................................................................................................... 55
6Treatment ........................................................................................................................... 58
6.1 Study  treatment ...................................................................................................... 58
6.1.1 Dosing regimen ..................................................................................... 58
 

[COMPANY_001] Confidential Page 3
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
6.1.2 LDK378 administration ........................................................................ 58
6.1.3 Treatment duration ................................................................................ 59
6.2 Dose escalation guidelines ..................................................................................... 59
6.2.1 Starting dose rationale ........................................................................... 60
6.2.2 Provisional dose levels .......................................................................... 60
6.2.3
Guidelines for dose escalation and determination of (MTD/RD E)......61
6.2.4 Definitions of dose limiting toxicities (DL Ts)...................................... [ADDRESS_124462] to follow -
up................................................................................... 92
7.2 Assessment ty pes................................................................................................... 92
7.2.1 Efficacy ................................................................................................. 92
7.2.2 Safety  and tolerability ........................................................................... 93
7.3 Pharmacokinetics ................................................................................................... 98
7.3.1
Pharmacokinetic blood sample collection and handling....................... 98
100
100
101
 

[COMPANY_001] Confidential Page 4
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
8Safety  monitoring and reporting ................................ ................................ ...................... [ADDRESS_124463] ....................................................... 103
8.2 Serious adverse events ......................................................................................... 103
8.2.1
Definitions........................................................................................... 103
8.3 Data Monitoring Committee ................................................................................ 105
8.4 Steering Committee ............................................................................................. 105
9Data collection and management ..................................................................................... 106
106
9.2 Site monitoring .................................................................................................... 106
9.3
Data collection..................................................................................................... 107
9.4 Database management and quality  control .......................................................... 107
10Statistical methods and data anal ysis.............................................................................. 107
10.1 Analy sis sets ........................................................................................................ 108
10.1.1 Full anal ysis set ................................................................................... 108
10.1.2 Safety  set............................................................................................. 108
10.1.3
Per-protocol set ................................................................................... 108
10.1.4 Dose -
determining anal ysis set............................................................. 108
10.1.5 Pharmacokinetic anal ysis set
............................................................... 108
109
10.2 Patient demographics/other b aseline characteristics ........................................... 109
10.3 Treatments (stud y treatment, concomitant therapi[INVESTIGATOR_014], compliance) ..................... 109
10.3.1 Study  treatment ................................................................................... 109
10.3.2 Concomitant therapi[INVESTIGATOR_014] ......................................................................... 109
109
10.4 Primary  objective ................................................................................................. 109
10.4.1 Variable ............................................................................................... 109
10.4.2 Statistical hy pothesis, model, and method of analy sis........................ 110
10.5 Handling of missing values/censoring/discontinuati ons
..................................... 111
10.6 Supportive analy ses............................................................................................. 112
10.7 Secondary  objectives ........................................................................................... 112
10.7.1 Safety  objectives ................................................................................. 112
10.7.2 Pharmacokinetics ................................................................................ 113
10.7.3 Efficacy ............................................................................................... 114
 

[COMPANY_001] Confidential Page 5
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
116
116
116
116
10.9 Interim anal ysis.................................................................................................... 117
10.10
Sample size calculation........................................................................................ 117
10.10.1 Dose Escalation ................................................................................... 117
10.10.2 Dose Expansion ................................................................................... 117
10.11 Power for anal ysis of key secondary  variables
.................................................... 118
11Ethical considerations and administrat ive procedures .................................................... 118
11.1 Regulatory
 and ethical compliance ...................................................................... 118
11.2 Responsibilities of the investigator and IRB/ IEC/REB ....................................... [ADDRESS_124464] keepi[INVESTIGATOR_79556] ..................... 119
11.7 Confidentiality  of study  documents and patient records ..................................... 120
11.8
Audits and inspections......................................................................................... 120
11.9 Financial disclosures ............................................................................................ 120
12Protocol adherence .......................................................................................................... 120
12.1 Amendments to the protocol ................................................................................ 120
13References (available upon request) ................................................................................ 122
14Appendices ...................................................................................................................... 125
125
125
125
127
128
131
134
135
14.3 Appendix 3: Karnofsky  Performance Status Scale (for patients greater than 
12 years old) ........................................................................................................ 138
14.4 Appendix 4: Lansk
y score (for patients less than or equal to 12 years old) ........ 139
 

[COMPANY_001] Confidential Page 6
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
14.5 Appendix 5: Response Evaluation Criteria in Solid Tumors (RECI ST 1.1) 
Harmonization of Efficacy  Analy sis of Solid Tumor Studies ............................. 140
14.6 Appendix 6: Guidelines for efficac y evaluation in ly mphoma studies (based 
on Cheson response criteria). International Working Group guidelines for 
hematological malignancies................................................................................. 165
Appendix A: 
Definition of index nodal lesion, non -index nodal lesion, index 
extranodal lesion, non- index extranodal lesion ................................ ................... 184
Appendix B: Calculation of the response for ind ex lesions ............................................ 186
Appendix C: Calculation of the response for non -index lesions ..................................... 188
Appendix D: Calculation of the overall disease response
............................................... 190
Appendix E: Adaptation for use in maintenance/adjuvant settings
................................. 192
 

[COMPANY_001] Confidential Page 7
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
List of figures
Figure [ADDRESS_124465] of tables
Table 1
-1 All grades (at least 10%) and associated grade 3 -4 adverse events, 
regardless of study  drug relationship, by  [CONTACT_111806] 750 mg dose group (Data cut -off date: ).....[ADDRESS_124466] overall response based on investigator assessment 
in NSCL C patients in the 750 mg dose group, b y prior ALK 
inhibitor status (Full Analy sis Set NSCL C 750 mg) (Cut -off date: 
) ......................................................................................... 42
Table 3
-1 Objectives and related endpoints .......................................................... 50
Table 6
-1 Provisional dose levels for fasted pediatric dose escalationa................ 60
Table 6-2 Criteria for defining dose -limiting toxicities......................................... 63
Table 6-3 Dose reduction steps for LDK378 at RDE (fasted and fed states)........ 65
Table 6-4 Criteria for interruption and re- initiation of LDK378 treatment ........... 67
Table 6-5 Follow up evaluations for selected toxicities ................................ ........ 77
Table 7-1 Visit evaluation schedule ...................................................................... 84
Table 7
-2 Maximum blood volumes ..................................................................... 95
Table 7
-3 Local clinical laboratory  parameters collection plan ............................ 96
Table 7-4 Central ECG collection plan ................................................................. 98
Table 7
-5 Pharmacokinetic blood collection log –dose escalation (fasted and 
fed)........................................................................................................ 99
Table 7
-6 Pharmacokinetic blood collection log –dose expansion (fasted and 
fed)...................................................................................................... 100
101
Table 10
-1 Noncompartmental pharmacokinetic paramet ers................................ 114
 
126
127
127
129
130
131
133
 

[COMPANY_001] Confidential Page 8
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
 
 
135
136
136
137
Table 14-12 Table radiological status based on SPD calculation for all index 
lesions .................................................................................................. 171
Table 14
-13 Radiological response criteria for index extranodal lesions in case 
of CR in index nodal lesions ............................................................... 171
Table 14
-14 Radiological response for index lesions .............................................. 172
Table 14
-15 Response criteria for non -index lesions (nodal, splenic and/or 
hepatic nodules and other extranodal lesions) .................................... 173
Table 14
-16 Overall radiological response at each assessment ............................... 174
Table 14-17 Censoring reasons ............................................................................... 180
Table 14
-18 Options for event dates used in PFS, TTP, duration of response ........ 181
 

[COMPANY_001] Confidential Page 9
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
List of abbreviations
AE Adverse event
ALCL Anaplastic large cell ly mphoma
ALK Anaplastic lymphoma kinase
ALT Alanine aminotransferase
ANC Absolute neutrophil count
ANOVA Analysis of variance
AST Aspartate aminotransferase
ATC Anatomic therapeutic chemical
AUC Area under the plasma (serum, or blood) concentration versus time curve
AUClast Area under the concentration -time curve from time zero to the last measureable 
concentration time
AUCtau Area under the plasma (serum, or blood) concentration versus time curve from time zero 
to end of dosing period
BCRP Breast cancer resistance protein
BLRM Bayesian logistic regression model
BOR Best overall response
BSA Body surface area
BUN Blood urea nitrogen
CDP Clinical development plan
CI Confidence interval
CL Clearance
Cmax Maximum (peak) concentration of drug
Cmin Minimum (trough) concentration of drug
CMV Cytomegalovirus
CNS Central nervous sy stem
CR Complete response
CRO Contract Research Organization
CRP C-reactive protein
CSF Cerebrospi[INVESTIGATOR_111743] P450
DAR Dosage Administration Record (DAR)
DDS Dose -determining set
DILI Drug Induced Liver Toxicity
DLT Dose limiting toxicity
DM Data manager/data management
DOR Duration of response
DS & E Drug safety and epi[INVESTIGATOR_111744] -Barr virus
EC Ethics committee
ECG Electrocardiogram
 

[COMPANY_001] Confidential Page 10
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
eCRF Electronic Case Report Form
EDC Electronic data capture
EMEA European Medicines Agency
EML4 -ALK Echinoderm microtubule associated protein like 4 -anaplastic ly mphoma kinase
EOT End of treatment
EWOC Escalation with overdose control
F Bioavailability
FAS Full analy sis set
FCBP Females of childbearing potential
FDA Food and Drug Administration
FISH Fluorescent in situ hybridization
FSH Follicle -stimulating hormone
G Gastric
GCP Good Clinical Practice
GI Gastrointestinal
HA Health Authorities
HED Human equivalent dose
Hgb Hemoglobin
HIV Human immunodeficiency virus
HSV Herpes simplex virus 
IC50 Half maximal (50%) inhibitory concentration
ICF Informed consent form
ICH International Conference on Harmonization
IEC Independent Ethics Committee
ILD Interstitial Lung Disease
IMT Inflammatory  myofibroblastic tumor
IRB Institutional Review Board
IV Intravenous(ly)
Ki Inhibition constant
LDH Lactate dehydrogenase
LLOQ Lower limit of quantification
MedDRA Medical Dictionar y for Regulatory Activities
MIBG Metaiodobenzylguanidine
MRI Magnetic resonance imaging
MRP2 Multidrug resistance protein 2
MTD Maximum tolerated dose
N/A Not applicable
NCI National Cancer Institutes
NG Naso -gastric
NPM Nucleophosmin
NPM- ALK Nucleophosmin -anaplastic ly mphoma kinase
NSCLC Non-small cell lung cancer
ORR Overall response rate
 

[COMPANY_001] Confidential Page 11
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
PAS Pharmacokinetic Analy sis Set
PD Progressive disease
PFS Progression -free survival
PHI Protected health information
PI [INVESTIGATOR_111745]/once daily
QTc Corrected QT interval
QTcF Corrected QT interval using Fridericia formula
R Value ALT/ALP in X ULN
Racc Accumulation ratio
RAP The Report and Analy sis Plan (RAP) is a regulatory document which provides evidence 
of preplanned analysis
RDE Recommended dose for expansion
REB Research Ethics Board
RECIST Response Evaluation Criteria In Solid Tumors
RP2D Recommended phase two dose
SAE Serious adverse event
SD Stable disease
SEC Study evaluation completion
SGOT Serum glutamic oxaloacetic transaminase
SGPT Serum glutamic pyruvic transaminase
STAT3 Signal transducer and activator of transcription 3
S[LOCATION_003]Rs Suspected unexpected serious adverse reactions
T1/2 Half-life
T1/2,acc Effective half -life calculated from Racc
TBIL Total bilirubin
TI Therapeutic index
TKD Tyrosine kinase domain
Tmax The time to reach maximum plasma concentration
ULN Upper limit of normal
USPI [INVESTIGATOR_111746] 12
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Glossary  of terms
Assessment A procedure used to generate data required by [CONTACT_111807] A biological specimen including, for example, blood (plasma, serum), 
saliva, tissue, urine, stool, etc. obtained from a study subject or study 
patient
Cohort A group of patients treated at a specific dose and regimen (i.e. 
treatment gro up) at the same time
Cycles Number and timing or recommended repetitions of therapy are usually 
expressed as number of days (e.g., 21 day s)
Enrollment Point/time of patient entry into the study; the point at which molecular 
pre-screening or main informed consent must be obtained (i.e., before 
starting any of the study procedures described in the protocol)
Patient number A unique identifier number (consisting of the center number and a 
patient -specific number) assigned to each patient who enrolls in the 
study
Period A subdivision of the study timeline; divides stages into smaller functional 
segments such as screening, baseline, titration, washout, etc.
Personal Data Patient information collected by [CONTACT_5336]. This data includes subject 
identifier information, study information and biological samples.
Stage in cancer The extent of a cancer in the body. Staging is usually based on the size 
of the tumor, whether ly mph nodes contain cancer, and whether the 
cancer has spread from the original site to other parts of the body
LDK378 discontinuation Point/time when patient permanently stops taking LDK378 for any 
reason; 
Variable A quantity subject to variation of values used in the da ta analy sis; 
derived directly or indirectly from data collected using specified 
assessments at specified time points
Withdrawal of Consent Withdrawal of consent from the study occurs only when a patient does 
not want to participate in the study any longer, and does not allow any 
further collection of personal data
 

[COMPANY_001] Confidential Page 13
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Amendment 8 ( 18-May-2018)
Amendment rationale
Interim safet y, efficacy and pharmacokinetics data for this study  have been presented 
previously  for both the fasted (n=22 patients) and fed (n=22 patients) cohorts, and no 
particular safety  concerns have been identified (Geoerger et al, 2015, Fischer et al, 2016). 
Recruitment of all planned patients was completed inOctober 31, 2017; eighty-three patients 
have been enrolled in total and treated in both escalat ion and expansion phases. As ofrelease 
of this amendment (18-May- 2018 ), the study  has been ongoin g for approximately  5yearsand 
3 months and twelve patients are still on treatment and currently  ongoing.
The main purpose of this global amendment is to allow patients who are still deriving clinical 
benefit from study  treatment as per the investigator to be transitioned to a separate rollover 
study  or another option for continued treatment with LDK378 (i.e. managed access program), 
as soon as they  become available. The end of study  will occur once: 
All patients have discontinued study  treatment and completed the required Study  
Evaluation Completion (SEC) follow -up visit, or 
All patients have died, been lost to follow -up, have withdrawn consent, or the last patient 
has been enrolled into a separate rollover stud y (or other option for continued study  
treatment), whichever comes first  
As per original protocol, a primary  analysis and clinical study  report (CSR ) were to prepared 
after all patients have completed at least [ADDRESS_124467] 6 cycles of treatment and will be allowed to be 
transitioned into a separate rollover study  (or other options for continued study  treatment 
access), a single final analy sis/CSR will be conducted once the end of study criteria are met. 
In addition, format and grammatical corrections are made throughout the protocol to improve 
flow and consistency .
Changes to the protocol
Glossary  of terms has been updated to align with the new Withdrawal of Consent 
language 
Section 4.3: Text has been updated to allow patients’ transition to the rollover study  or 
other options for continued treatment .It has been clarified that aCSR will be prepared at 
the end of the study . 
Table 6-4: Text has been updated to remove the PK sample collection in case of QTc 
prolongation Grade 3
Section [IP_ADDRESS]: Text has been updated to remove the PK sample collection in case of liver 
laboratory  abnormalities
Section [IP_ADDRESS]: Text has been updated to align with the new Withdrawal of Consent 
language 
 

[COMPANY_001] Confidential Page 14
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Section 10: Text has been clarified that anal ysis and CSR will be prepared at the end of 
the study .
IRB/IEC/REB A pproval
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amende d protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol ame ndment.
 

[COMPANY_001] Confidential Page 15
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Amendment 7 (24-Jan -2017 )
As of release of this amendment (4-Jan-2017), the recruitment is still ongoing. In total, sixty-
six patients have been enrolled and treated in both escalation and expansion phases. The 
escalation phase is now closed to enrollment and the expansion phase is currentl y recruiting. 
Eighteen patients are currently  ongoing.
The primary  purpose of this amendment is to address  concerns regarding 
the cardiac safet y monitoring conducted until Cy cle 6 only  and not afterwards for patient who 
remain on treatment, and the recent changes at Cycle 1 Day 1 (ECG monitoring at [ADDRESS_124468] dose of study  drug) for the patients to be treated in the expansion phase of the 
study . [COMPANY_001] decided to strengthen the cardiac safet y monitoring:   all patients will be 
monitored with an ECG at Cycle 1 Day 1 (4-hpost dose and 6-hpost dose), and at each first 
day of every  cycle of treatment. The ECG collection is expanded throughout the entire 
treatment duration. This is done in alignment with the ceritinib cardiovascular safet y 
monitoring recommendations . 
In addition, guidelines for dose modification in case of Grade [ADDRESS_124469] elevation after a dose reduction as allowed across the ceritinib development program in 
adults patients. This is to avoid unnecessary  withdrawal of patients who may continue to 
derive clinical benefit from ceritinib.
The guidelines in relation to concomitant medications use are also clarified to optimize the 
patient’s safet y.
Moreover, ALK status inclusion criteri onis clarified and it is specified that 15% threshold for 
rearrangement is applicable only when assessed by [CONTACT_4656]. Furtherm ore the ALK tyrosine 
kinase domain (TKD) mutation inclusion criterion is simplified .
At last, editorial changes and text corrections were made for clarification, where required.
Changes to the specific section of the protocol are shown in the track changes version of the 
protocol using red strike through font for deletions and red underlined font for insertions.
The following sections were updated:
List of abbreviations: updated .
Amendment 6 IRB/IEC/REB Approval : the wording was revised.
Section 5.2: update d to clarify  ALK status inclusion criteria in case of rearrangement and 
simplify  description of ALK TKD mutation accepted for inclusion.
Section 6.1.3: wording revised to bring more clarity.
Table 6 -4 Criteria for interruption and re -initiation of LDK378 t reatment : revised to delete 
the criteria of permanent discontinuation of the patients from LDK378 in case a Grade [ADDRESS_124470]/AL T reoccurs after dose reduction.
Section [IP_ADDRESS]: Permitted concomitant medication -Palliative radiotherapy  and surgery : 
modified to align with other ceritinib protocols.
Table 7- 1: ECG collection schedule modified to include assessments at each on -site visit.
 

[COMPANY_001] Confidential Page 16
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Table 7 -4: revised to capture collection of ECG at all visits (including 4h and 6h post dose 
at C1D1 in the expansion phase) up to Cycle 16, then at each on-site visit (even number 
cycles post cy cle 18) and up to End Of Treatment included.
Appendix 2: Aligned Lists of prohibited concomitant medications (Table 14-8), 
concomitant medications requiring caution with LDK378 (Table 14-9) and prohibited 
enzy me-
inducing anti-epi[INVESTIGATOR_006] (Table 14-10) to align with the ceritinib protocol
language.
IRB/IEC/REB A pproval
A copy of this amended protocol will be sent to the Institutional Review 
Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.
 

[COMPANY_001] Confidential Page 17
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Amendment [ADDRESS_124471] been 
enrolled and treated (25 fasted and 15 fed). Similar recommended LDK 378doses (RDE) were
established for both fasted state (510 mg/m2 once daily , declared on 4 Dec 2014), and fed 
state (500 mg/m2 once daily , declared on 
12 April 2016). As fed state is more convenient for 
pediatric patients, it has been decided to complete the recruitment of theexpansion phase 
using this preferred regimen only. The expansion phase, to confirm the dose, is currentl y 
recruiting and as of [ADDRESS_124472] been enrolled (7 fasted and 13 fed). 
Overall, 19 patients are currentl y ongoing in total (6 recruited in escalation phase and 13 in 
the expansion phase).
The primary  purpose of this amendment is to revise thedose reduction steps for LDK378. 
Considering the recommended doses established for fed and fasted state are similar, the dose 
reduction schedule has been revised to be applicable for both states.
In addition, the schedule of assessments has been revised to reduce frequency  of on-site visits 
after cycle 16: on-site visits on day [ADDRESS_124473], editorial changes and text corrections were made for clarification, where required.
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using red strike through font for deletions and red underlined font for insertions.
The following sections were updated:
Section 6.3.1: Table 6-3 dose reduction steps for LDK378 was revised based on the 
recommended dose for expansion
Table 7-1: revised to include telephone call and local laboratory  tests  instead of on-site 
visits on day  1 of odd numbered cy cles from C ycle 17 
Section 7.2.2: revised to include information about monitoring of patients’ safety  by 
[CONTACT_25600]
Section 
[IP_ADDRESS].4, Table 7-4: Cycle [ADDRESS_124474] been specified as not needed in the expansion phase as no longer required
Section 
7.3.1, Table 7-6: Expansion Cycle 1 Day1 pre-dose PK sample has been removed 
as no longer required
Section  8.1.1: revised to capture collection of downgrading Adverse E vents in the CRF
IRB/IEC/REB A pproval
A copy of this amended protocol will be sent to the Institutional Review 
Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
 

[COMPANY_001] Confidential Page 18
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Amendment 5
Amendment rationale
The study  was initiated in February 2013. The dose escalation phase of this study  for the 
fasted state has been completed and the recommended LDK 378dose was established at 510 
mg/m2 administered orally once daily. The dose escalation phase for the fed state is still 
ongoing. As of 17 February  2016, 40 patients were treated in the dose escalation phase of the 
study (fed and fasted) and 5 in the expansion phase (fasted). Of the 45 patients who entered 
the treatment phase, 34 patients discontinued treatment.
The primary  purpose of this amendment is to clarify  the LDK378 dose modification 
recommendations, the guidelines for follow up of toxicities to LDK378 (including follow up 
evaluations for hepatic toxicities and work up guidelines for potential DILI cases) and the use 
of concomitant medications in order to optimize the patient safety .Furthermore, this 
amendment provides updated parameters for study  visits for patients who are on study  drug 
for more th an [ADDRESS_124475], editorial changes and text corrections were made for clarification, where required.
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using red strike through font for deletions and red underlined font for insertions.
The following sections were updated:
List of abbreviations: updated
Glossary  of terms: updated
Protocol Summary : updated to match exclusion criteria list from section5.3
Section 1.2.1: Inclusion of FDA approval of LDK378 (ceritinib) under trade name [CONTACT_111932]
Section [IP_ADDRESS]: Clinical experience updated from data available from ongoing clinical 
studies
 
Figure 4 -1: number of pat ients for fed escalation corrected
Section 5.3 Exclusion criteria: time period for using highl y effective contraception and 
highl y effective contraception methods have been revised
Section 6.1.3 Treatment duration: Modified to allow patients who have disea se 
progression, but who have evidence of continued clinical benefit from LDK378, to 
 

[COMPANY_001] Confidential Page 19
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
continue receiving the study  treatment. General rules for dose interruption and 
discontinuation were clarified.
Section 6.2.4 : dose modification recommendations related toDose Limiting Toxicities 
(DLTs) were moved from section 6.3 to this section
Table 6- 2: Reference to table 6 -5 for additional follow up of toxicities was added
Section 6.3.1: Dose modification and dose delay  were aligned to match with other 
LDK378 protocol s. In particular, addition of dose reduction steps for LDK378 fasted state 
(Table 6-3) and criteria for the interruption and re-initiation of LDK378 treatment based 
on updated safet y information (Table 6-4), including addition of follow up guidance for 
AST or ALT and concurrent total bilirubin elevation, and for Electrocardiogram QT 
corrected (QTc) interval prolonged.
Section 
6.3.2- Follow -up for toxicities: modified to align with other LDK378 protocols. 
Table 6
-3 replaced by  [CONTACT_111808]:
Section [IP_ADDRESS]: Guidelines for the follow -up of laboratory  hematologic abnormalities, 
including addition of guidance for concomitant use of hematopoietic growth factors
Section [IP_ADDRESS]: Guidelines for the follow -up of liver laboratory  abnormalities, 
including guidelines for potential drug- induced liver injury
Section [IP_ADDRESS]: Guidelines for the follow -up of renal laboratory  abnormalities
Section [IP_ADDRESS]: Guidelines for monitoring pneumonitis
Section [IP_ADDRESS]: Guidelines for the treatment of study  treatment -induced diarrhea
Section [IP_ADDRESS]: Guidelines for the treatment of study  treatment -induced nausea and 
vomiting
Section [IP_ADDRESS]: Guidelines for the treatment of h ypophosphatemia
Section [IP_ADDRESS]: Guidelines for the follow up of laboratory  pancreatic abnormalities
Table 6
-5 Follow up evaluations for selected toxicities
Section 6.4: Concomitant medications was updated with permitted and prohibited 
therapi[INVESTIGATOR_014]
Table 7-[ADDRESS_124476] (alread y 
collected in the CRF but not mentioned in Table 7 -1).
Section [IP_ADDRESS].2: Clarification of screening ALK testing process
Section 7.1.3 Clarification for MIBG and bone marrow aspi[INVESTIGATOR_111747]; 
End of treatment visit: Modified to allow patients who have disease progression, but who 
have evidence of continued clinical benefit from LDK378, to continue receiving the study 
treatment.
Section [IP_ADDRESS]: Withdrawal consent section added
Section 7.1.5: L ost to follow up section added
Section 7.2.1: the frequency  of tumor assessment was reduced post C ycle 14. Clarification 
about collection of Bone marrow bilateral aspi[INVESTIGATOR_111748]. 
 

[COMPANY_001] Confidential Page 20
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Addition of the option to stop collecting MIBG scans after screening if it becomes 
negative on 2 consecutive assessments and the concomitant tumor assessments 
demonstrate a complete or partial response.
Section 7.3.1: Updated with capture of meal records
Section 7.4.1: Clarification about sample collection date
Table 7-7: Updated with more precise information about collection timepoint of tumor 
biopsy  at End Of Treatement
Section 8.1.3: section created for AEs of special interest
Section 8.2.1: Clarification about the pregnancy  which should be followed up from the 
estimated date of delivery  plus 3 months
Section 10.1.5: Clarification about the pharmacokinetic anal ysis set
Section 10.7.2: Clarification about PK analy ses
Table 10
-1: Alignment with section 10.7.2
Section 11.3: Added the use of highl y effective methods of contraception must be carried 
on during dosing and 3 months after stoppi[INVESTIGATOR_111749].
Appendix 2: Aligned Lists of prohibited concomitant medications (Table 14-1), 
concomitant medications requiring caution with LDK378 (Table 14
-2) and prohibited
enzy me-inducing anti -epi[INVESTIGATOR_006] (Table 14 -3) to match with other LDK378 protocols.
Editorial changes and text corrections have been made in the following sections: 
Amendment 1 rationale, 1.1, 4.3, 6.2.4, Table 6 -2, 7.1.3, 9.2, 10.7.3, Appendix 5.
IRB/IEC/REB A pproval
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementat ion. In addition, the changes herein affect the Informed Consent. Sites are 
required to update and submit for approval a revised Informed Consent that takes into account 
the changes described in this amended protocol.
 

[COMPANY_001] Confidential Page 21
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Summary  of previous amendments
Amendme nt 4
Amendment rationale
Under this amendment, a consistent approach is being implemented across ongoing studies 
with LDK378 to monitor and manage safety  signals identified as the clinical experience with 
LDK378 has grown. Specificall y, changes are made that address hepatic toxicity , pancreatitis 
and pneumonitis. T he protocol has therefore been amended :
to exclude 
patients with history  of pancreatitis or history  of increased amylase or lipase 
that was due to pancreatic disease
to include additional dose modification and follow -up monitoring language for patients 
who may  experience pancreatic enzy me elevations in the absence of clinical sy mptoms
to update dose modification language and the guidelines for the management of hepatic 
toxicity
to specify  that f or patients meeting biochemical criteria for Hy ’s law (AST or ALT >3.[ADDRESS_124477] and total bilirubin >2.[ADDRESS_124478] in the absence of cholestasis or hemoly sis), study 
treatment must be permanently  discontinued
to update adverse events of special interest including hepatotoxicity , interstitial lung 
disease/pneumonitis, QT interval prolongation, bradycardia, hypergly cemia, 
gastrointestinal toxicity  (nausea, vomiting and diarrhea) and pancreatitis (including lipase 
and am ylase elevations).
Hypergl ycemia has also been observed in patients treated with LDK378. Patients with 
abnormally  high fasting glucose levels are now excluded from participating in this study .For 
consistency  across the LDK378 program clinical trials, other changes as outlined below have 
been made to dose modifications for patients who experience toxicity .
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using red strike through font for deletions and red underlined font for inse rtions.
Protocol Summary
Updated exclusion criteria to reflect new pancreatic and hepatic safety  parameters
Section [IP_ADDRESS] Clinical Experience
Updated to delineate overall Adverse Event occurrence and to denote adverse events of 
interest
Section 5.3 Exclusion criteria
Updated exclusionary  point 3 with further labs for safety
Added exclusionary  point 21 to exclude patients with significant pancreatic history
Section 6.2.4 Definition of Dose Limiting Toxicities
Added clarit y around DTLs and how to appl y the follow up criteria
 

[COMPANY_001] Confidential Page 22
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Table 6- 2 Dose limiting toxicities
Updated safet y language for Hematology , hepatic, and pancreatic events
Section 6.3 Dose modifications
Provided additional clarity and parameters for study drug dose modifications, 
discontinuation, with special focus on pneumonitis, hepatic, renal and pancreatic toxicities
Table 6- 3 Follow up toxicity  guidelines
Updated follow up parameters for Hematology , hepatic, pancreatic and renal events
Section 8.1.1 Safety  monitoring and reporting for adverse event s, definitions and reporting
Updated with additional information on adverse events of interest
Table 7- 3 Local clinical laboratory  parameters collection plan
Updated with serum amylase, serum lipase and ALP
IRB/IEC/REB A pproval
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into account 
the changes described in this amended protocol.
 

[COMPANY_001] Confidential Page 23
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Amendment [ADDRESS_124479] of dosing LDK378 with food in pediatric cancer patients, the protocol 
has been modified to include a fed state (low-fat light snack) dose escalation part following 
the determination of the fasted MTD/RDE. Further expansion at the fed MTD/RDE will be 
allowed if the safety , PK or efficacy  suggest that administering LDK378 with food is 
preferred. The age range in the inclusion criteria has been changed to ‘up to 18’ to make it 
clear that patients are eligible until they  turn18 years of age.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using red strike through font for deletions and red underlined font for insertions.
Protocol Summary
Updated purpose and rationale, objectives, and study  design to refl ect planned 
determination of the MTD of LDK378 in both fed and fasted states.
Clarified the nomenclature for inclusion of patients up to their 18thbirthday .
Section [IP_ADDRESS].1 Clinical safet y and tolerability
Updated to reflect most recent cardiac safety  information
Section [IP_ADDRESS].3 Clinical pharmacokinetics
Updated to reflect most recent clinical pharmacokinetics data
Section 2.1 Study  rational and purpose
Rationale added for a dose escalation arm in the fed state (low -fat snack).
Section 2.2 Rationale f or the study  design
Clarified the nomenclature for inclusion of patients up to their 18thbirthday .
Section 2.3 Rationale for dose and regimen section
Added language describing planned rationale for the starting dose for fed dose escalation 
part.
Table 3
-1 Objectives and related endpoints
Clarification added that the primary  and secondary  objectives and related endpoints will 
be evaluated in both the fed and fasted states.
Section 4.1 Description of study  design
Updated to reflect addition of the fed dose escalation part and the addition of fed patients 
enrolled during expansion part.
 

[COMPANY_001] Confidential Page 24
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Figure 4 -1: Overview of study  design
Updated to reflect addition of the fed dose escalation part and the addition of fed patients 
enrolled during expansion part.
Section 6.1.2 LDK378 administration
Clarification of administration guidance for LDK378 in both the fasted and the fed states 
for patients who are able and unable to swallow capsules.
Section 6.2.2 Provisional dose levels
Language added to describe the plan for initiating a fed-state dose escalation part and 
opening the expansion part.
Section 6.2.3 Guideline for dose escalation and determination of MTD/RDE
Language added to allow for a fed -state dose escalation
Section [IP_ADDRESS] Change from Fasted to Fed Dosing
Language added to clarify  the required parameters prior to allowing a patient enrolled on a 
fasted cohort to change to dosing with a low -fat snack.
Section 6.2.4. Definition of dose limiting toxicities
Clarification that DLTs are attributed during cy cle 1
Section 6.4.2. Permitted concomitant therap y requiring caution
Update of medications that should be used with caution if needed during the study  because 
of potential drug -drug interactions from LDK378 Investigator’s Brochure edition 7
Table 7-6 Pharmacokinetic blood collection log- dose expansion
Modification of sample collection for patients during dose expansion part
Section 10.4.2 Statistical hy pothesis, mode, and method of anal ysis
Updated to reflect BRLM plan for the fed and fasted states. It will be used to estimate the 
dose-DLT relationships separately  for fasted and fed patients.
Section 10.10.1 Dose Escalation
Updated to reflect plan for sample size calculation in the fed and fasted states
IRB/IEC/REB A pproval
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into account 
the changes described in this amended protocol.
 

[COMPANY_001] Confidential Page 25
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Amendment 2
Amendment rationale
The following changes were requested :
To address the management of QTc prolongation separately  from the broader array  of 
DLTs a specific approach including a detailed monitoring plan, need for physician 
evaluation, and recommendations for dose reduction or permanent discontinuation have 
been adde d to Section 6.3.1. and Table 6 -3.
Cases of pneumonitis/interstitial lung disease (ILD) have been reported with LDK378 in 
patients treated at the [ADDRESS_124480] cases improved or resolved with 
interruption of LDK378 and treatment with antibiotics and/or steroids. Fatal outcome of 
treatment -related pneumonitis has been reported. Exclusion criteria, the definition of dose 
limiting toxicity , and the guidance for dose modification have been amended to address 
this newly  observed risk.
Background safety, efficacy  and clinical pharmacology  information was updated for 
consistency  with the current L DK378 Investigator’s Brochure.
Due to the possibility  that a dose level reduction in patients with a low BSA may not actuall y 
result in a calculated dose reducti on due to rounding, the protocol has been modified to 
require a minimum dose reduction of 50mg.
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using red strike through font for de letions and red underlined font for insertions.
Protocol Summary
Added exclusion of patients with history  of interstitial lung disease or interstitial 
pneumonitis, including clinically  significant radiation pneumonitis (i.e., affecting 
activities of daily  living or requiring therapeutic intervention).
Section [IP_ADDRESS].4 Safety  pharmacology  and toxicology
Omitted line “suggesting that there is no clinical risk for QTc prolongation” describing 
pre-
clinical data. There is now clinical evidence for risk of QTc prolongation.
Section [IP_ADDRESS] Clinical Experience
Updated to reflect the most recent safet y, efficacy  and clinical pharmacology  information 
from LDK378 Investigator’s Brochure edition 4
Language added that cases of pneumonitis/ILD have been reported with LDK378 in 
patients treated at the [ADDRESS_124481] cases improved or resolved with 
interruption of LDK378 and treatment with antibiotics and/or steroids. Fatal outcome of 
treatment -related pneumonitis has been reported.
 

[COMPANY_001] Confidential Page 26
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Section 5.3 Exclusion Criteria
Exclusion criteria added “history  of interstitial lung disease or interstitial pneumonitis, 
including clinically  significant radiation pneumonitis (i.e., affecting activities of daily 
living or requiring therapeutic intervention).
Exclusion criteria added “Radiotherap y to lungs ≤ [ADDRESS_124482] not recovered from radiotherap y
-related toxicities. For all 
other anatomic sites, radiotherap y ≤ 2 weeks prior to starting the study  treatment”
Table 6-2
Language added that dose limiting pulmonary  toxicity  includes pneumonitis or ILD of an y 
grade without infectious etiology
Section 6.3.1 Dose modification and dose delay
Clarification that a minimum dose reduction of 50 mg is required following a DLT to 
account for patients with low BSA.
Language added that if pneumonitis/ILD is suspected, LDK378 should be held during the 
evaluation. If pneumonitis/ILD of grade [ADDRESS_124483] be discontinued.
Clarification that in the case of a DLT of QTc prolongation (QTc >500 ms) LDK378 
should be held until resolution to grade [ADDRESS_124484] 1 dose level.
Clarification that in the case of grade 4 QTc prolongation (QTc >500 ms complicated by 
[CONTACT_111809], polymorphic ventricular tachy cardia, or signs/s ymptoms of serious 
arrhythmia; or >60 ms change from baseline complicated by [CONTACT_111809], 
polymorphic ventricular tachycardia, or signs/symptoms of serious arrhythmia) LDK378 
should be permanentl y discontinued.
Table 6-3
Language added that in the case of QTc >500 ms blood electroly tes, including calcium , 
magnesium, phosphorus and potassium, should be measured and abnormalities corrected 
and concomitant medications should be reviewed for other potential causes of QTc 
prolongation. An ECG should be repeated dail y until the QTc prolongation has resolved to 
grade 1 or less, and the patient should be evaluated by  a qualified phy sician before leaving 
the clinic or treatment facility .
Section 6.4.1 Permitted concomitant therap y
Clarification added that palliative radiotherap y to sites of pre -existing disease that do not 
represent progressive disease is permitted. (Previously  only stated in Section 6.4.3.)
[IP_ADDRESS].4 Electrocardiogram (ECG)
Language added that in the event of QTc >500 ms ECGs should be repeated daily  until 
resolved to grade 1 or less.
 

[COMPANY_001] Confidential Page 27
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
IRB/IEC/REB Approval
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into account 
the changes described in this amended protocol.
 

[COMPANY_001] Confidential Page 28
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Amendment 1
Amendment rationale
The followin g changes were requested :
In order to clarify  the eligibility  criteria in the protocol, a detailed definition of “a genetic 
alteration of ALK” has been added to the inclusion criteria.
Due to the observation that LDK378 use is sometim es associated with hy pophosphatemia, 
patients with abnormalities of phosphate as well as potassium, calcium or magnesium > 
CTCAE grade 1 are excluded from the study .
The table defining dose-limiting toxicities (Table 6-2) has been reorganized to clarify  that 
any adverse event of CTCAE grade 3 or higher is a DLT, except as noted in the table.
Due to the possibility  that taking LDK378 mixed with a small amount of food may affect 
its bioavailability , the protocol has been modified to require that all patients take LDK378 
with a small amount of food. If patients can swallow intact capsules, they must eat 1-2 
tablespoons (15
-30 mL) of food, such as apple sauce or non- fat yogurt at the time that they 
take LDK378. If patients open the capsules, the contents are mixed with a food carrier, 
such as apple sauce or non-fat yogurt (or other carriers as defined in the separate 
instructions for patients who cannot swallow capsules). This will prevent unexpected 
differences in bioavailability  between those patients who swall ow intact capsules and 
those who open the capsules.
The amendment summarizes the results of preliminary  ECG data from approximately  [ADDRESS_124485] on the QT interval; therefore the inclusion/exclusion criteria were also 
updated to exclude patients taking concomitant medications with a known risk of prolonging 
the QT interval or inducing Torsades de Pointes. The list of excluded concomitant 
medications in Secti on 6.4.[ADDRESS_124486] prior to drawing the PK sample. This is to 
prevent 
any anxiet y associated with PK sampling from affecting the ECG.
The protocol has been updated with additional clinical pharmacokinetic data now available for 
LDK378, both from the ongoing phase 1 study  in adults (CLDK378X2101), and the single -
dose food effect stud y performed in healthy  volunteers (CLDK378A2101).
References have been reformatted for consistency  throughout the document, and with the list 
of references (Section 13).
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
List of abbreviations
Addition of CSF (Cerebrospi[INVESTIGATOR_872])
 

[COMPANY_001] Confidential Page 29
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Protocol Summary
Addition of exclusion of patients with potassium, magnesium, calcium or phosphate 
abnormalities > CTCAE grade 1
Patients receiving medications that are a known risk of prolonging the QT interval or 
inducing Torsades de Pointes
Section 1.1 Overview of disease pathogenesis, epi[INVESTIGATOR_111750]
Corrected some references to proper format
Section [IP_ADDRESS].1 Clinical safet y and tolerability
Addition of results from preliminary  anal ysis of ongoing data regarding LDK378 and its 
possible effect on the QT interval.
Section [IP_ADDRESS].2 Clinical efficacy
Corrected some references to proper format
Section [IP_ADDRESS].4 Clinical Pharmacology
Additional data was added regarding the CLDK378X2101 first in human study  and 
CLDK378A2101 food effect study
Section 2.1 Study  rationale and purpose
Corrected some references to proper format
Section 2.2 Rationale for the study  design
Corrected some references to proper format
Section 5.2 I nclusion Criteria
Clarified the requirements of various genetic alterations of ALK tumors
Section 5.3 Exclusion Criteria
Addition of exclusion of patients with potassium, magnesium, calcium or phosphate 
abnormalities > CTCAE grade 1
Addition of exclusion of patients taking medications with a known risk of prolonging the 
QT interval or inducing Torsades de Pointes
Section 6.1.2 L DK378 Administration
Addition of instructions for patients able to swallow capsules to take 1 -2 tablespoons of an 
appropriate food, such as apple sauce or non -fat yogurt with each dose
Addition of instructions for patients not able to swallow capsules to mix with contents of 
capsules with an appropriate food such as apple sauce or non-fat yogurt and consume the 
mixture within 2 hours
Language added that as additional foods and/or liquids become available (through further 
testing) to mix with capsule contents for consumption, si tes will be informed
Table 6- 2 Criteria for defining dose -limiting toxicities
Table was changed to outline any adverse event of CTCAE grade 3 or higher is a DLT 
except for those events outlined in the new table
Section 6.4.3 Prohibited concomitant therap y
 

[COMPANY_001] Confidential Page 30
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Language added prohibiting the use of drugs known to have a high risk of increasing the 
QTc interval, and drugs known to increase the QTc interval that are also primarily 
metabolized by  [CONTACT_097]3A4/5
Table 7- 1 Visit evaluation schedule
Corrected table format Table 7 -4 Central ECG collection plan
Clarification that ECG does not need to be done within 30 minutes before PK sample but 
should be done an y time prior to PK sample
Section 7.3 Pharmacokinetics
Corrected h yperlink
Section 7.3.1 Pharmacokinetic blood sample collection and handling
Corrected h yperlink
Section 13 References
Corrected some references to proper format
Section 
14.2 Appendix 2: Guidance on concomitant therapi[INVESTIGATOR_111751]3A4/5, CYP2C9 
interactions and/or QTc prolongation potential
Language added prohibiting the use of drugs known to have a high risk of increasing the 
QTc interval, and drugs known to increase the QTc interval that are also primarily  
metabolized by  [CONTACT_097]3A4/5
Table14-8 Prohibited medications that are strong CYP3A4/5 inhibitors or inducers or 
sensitive CYP3A4/5 substrates with narrow therapeutic index or sensitive CYP2C9 substrates 
with narrow TI or causing QTc prolongation or sensitive CYP2C9 substrates with narrow TI
Updated table to expand list of drugs known to have a high risk of Q Tc prolongation
IRB/IEC/REB A pproval
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into account 
the changes described in this amended protocol.
 

[COMPANY_001] Confidential Page 31
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Protocol summary
Protocol 
numberLDK378X2103
Title A Phase I, open -label, dose escalation study of LDK378 in pediatric patients with 
malignancies that have a genetic alteration in anaplastic ly mphoma kinase (ALK)
Brief title Study of safety  and efficacy in pediatric patients with ALK -activated tumors
Sponsor and 
Clinical Phase[COMPANY_001];
Phase [ADDRESS_124487] range of ALK -activated 
tumor models, including models driven by [CONTACT_111810], and by [CONTACT_111811].
The primary  purpose of this study is to determine the maximum tolerated dose 
(MTD) and/or recommended dose for expansion (RDE) in both fe d and fasted 
pediatric patients, and to delineate a clinical dose to be used in any future 
pediatric studies. This study will also assess the safety, tolerability, PK and 
prelim inary evidence of antitumor activity of LDK378 in pediatric patients with 
neuro blastoma, and other ALK -activated tumors .
Primary 
ObjectiveEstimate the MTD and/or RDE of LDK378 as a single agent when administered 
orally to pediatric patients with ALK -activated tumors in the fasted and fed state
Secondary 
ObjectivesObjective 1: Characterize the safety and tolerability of LDK378 in pediatric 
patients in the fasted and fed state
Objective 2: Characterize single and multiple -dose PK of LDK378 in pediatric 
patients in the fasted and fed state
Objective 3: Assess the anti -tumor activity of LDK378 in the fasted and fed state
Study design This is a two -part, phase 1 study, with a dose escalation part in both the fasted 
and fed states, followed by [CONTACT_111812]. The expansion part will start after 
the fasted MTD/RDE has been determined. The expansion part will include 2 
diagnostic groups of patients, one restricted to patients with ALK -activated 
neuroblastoma and the second including patients with all other ALK -activated 
tumors. Enrollment will proceed in parallel. LDK378 will be adminis tered orally, 
once daily, continuously.
Population Patients, aged 12 months to <18 years, with malignancies carrying a genetic 
alteration of ALK.
 

[COMPANY_001] Confidential Page 32
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Inclusion 
criteria●Patients must be diagnosed with a locally advanced or metastatic malignancy 
that has progressed despi[INVESTIGATOR_14482], or for which no effective standard 
therapy exists
●Age ≥ 12 months and <18 years
●The tumor must carry  a genetic alteration of ALK, such as a mutation, 
translocation or amplification
●Patients must have evaluable or measurable disease as defined by [CONTACT_19565]: RECIST v1.1 for patients with non -hematologic malignancies; 
MIBG scan for patients with neuroblastoma; International W orking Group (I WG) 
criteria for patients with ly mphoma
●Performance statu s:
●Karnofsk y performance status score ≥ 60% for patients >12 years of age
● Lansk y score ≥ 50% for patients ≤ 12 years of age
Exclusion 
criteria●Patients with sy mptomatic central nervous system (CNS) metastases who are 
neurologically unstable or requi re increasing doses of steroids or local CNS-
directed therapy (such as radiotherapy, surger y or intrathecal chemotherapy) to 
control their CNS disease.
●Patients with clinically significant, uncontrolled heart disease or corrected QT 
(QTc) interval > 480 milliseconds, using the Fridericia correction (QTcF).
●Patients with the following laboratory values during screening:
● Creatinine > 1.[ADDRESS_124488] for age.
● Total bilirubin > 1.[ADDRESS_124489] for age, except for patients with Gilbert’s 
syndrome, who may be included if total bilirubin is ≤ 3.[ADDRESS_124490] 
bilirubin is ≤ 1.[ADDRESS_124491].
● Alanine aminotransferase (ALT) > [ADDRESS_124492] a value ≤ [ADDRESS_124493].
● Serum aspartate aminotransf erase (AST) > [ADDRESS_124494] a value ≤ [ADDRESS_124495].
● Absolute neutrophil count (ANC) < 0.75 x 109/L without use of granulocyte 
growth factor for ≥ 14 days.
● Platelet count < 50 x 1 09/L.
● Hemoglobin (Hgb) < 8 g/dL.
● Alkaline phosphatase (ALP) > 5.[ADDRESS_124496]
● Serum am ylase > [ADDRESS_124497]
● Serum lipase > ULN
● Fasting plasma glucose ≥175 mg/dL (≥9.8 mmol/L)
● Potassium, magnesium, calcium or phosphate abnormality > CTCAE 
grade 1.
●Body surface area (BSA) < 0.35 m2.
●Impairment of gastrointestinal (GI) function or GI disease that may  significantly 
alter the absorption of LDK378 (e.g., ulcerative diseases, uncontrolled nausea, 
vomiting, diarrhea, or malabsorption syndrome).
●Evidence of active viral hepatitis, including Hepatitis A, B or C (testing for viral 
hepatitis is not mandator y).
●Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing 
is not mandatory).
●Presence of ≥ CTCAE grade 2 toxicity (except alopecia, peripheral 
neuropathy, ototoxicity and ly mphopenia, which are not excluded if grade 3 or 
less) due to prior cancer therapy.
 

[COMPANY_001] Confidential Page 33
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
●Malignant disease, other than that being treated in this study. Exceptions to 
this exclusion include the following: malignancies that were treated curatively and 
have not recurred within 3 years prior to study entry; completely resected basal 
cell and squamous cell skin cancers; and completely resected carcinoma in situ of 
any type.
●History of known interstitial lung disease or in terstitial pneumonitis, including 
clinically significant radiation pneumonitis (i.e., affecting activities of daily living or 
requiring therapeutic intervention).
●Patients who have received sy stemic anticancer therapy within [ADDRESS_124498] dose of the ALK 
inhibitor.
●Radiotherapy to lungs ≤ [ADDRESS_124499] not recove red from radiotherapy -related toxicities. For all other 
anatomic sites, radiotherapy ≤ 2 weeks prior to starting the study treatment.
●Major surgery within [ADDRESS_124500] dose of LDK378. Insertion of a gastric 
feeding tube (G -tube), nasogastric feed ing tube (NG -tube), and central venous 
access are not considered major surgery.
●Patients receiving medications that are known to be strong inhibitors or 
inducers of CYP3A4/[ADDRESS_124501] 1 week prior to start of 
treatment with LDK 378 and for the duration of the study ( Appendix 2 ).
●Patients receiving medications that are mainly metabolized by [CONTACT_097]3A4/[ADDRESS_124502] 1 
week prior to start of treatment with LDK378 and for the duration of the study 
(Appendix 2 ).
●Medications with a known risk of prolonging the QT interval or inducing 
Torsades de Pointes ( Appendix 2 ).
●Pregnant or nursing (lactating) females.
●Females of child -bearing potential, defined as all females physiologically 
capable of becoming pregnant, unless they are using highly effective methods of 
contraception during dosing and for 3 months after stoppi[INVESTIGATOR_90524]. Highly 
effective contraception methods include:
● Total abstinence (when this is in line with the preferred and usual lifestyle 
of the patient) Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, 
post-ovulation methods) and withdrawal are not acceptable methods of 
contraception.
● Female sterilization (have had surgical bilateral oophorectom y with or 
without hysterectom y) total hysterectom y or tubal ligation at least six weeks 
before taking LDK378. In case of oophorectom y alone, only when the 
reproductive status of the female has been confirmed by [CONTACT_64062].
● Male sterilization (at least 6 months prior to screening). For female 
patients on the study the v asectomized male partner should be the sole 
partner for that patient.
● Use of oral, injected or implanted hormonal methods of contraception or 
placement of an intrauterine device (IUD) or intrauterine system (IUS), or other 
forms of hormonal contraception that have comparable efficacy  (failure rate 
<1%), for example hormone vaginal ring or transdermal hormone 
contraception.
In case of use of oral contraception females should have been stable on the same 
pi[INVESTIGATOR_6522] a minimum of 3 months before taking LDK378.
●Sexually active males, unless they use a condom during intercourse while 
 

[COMPANY_001] Confidential Page 34
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
taking LDK378 and for 3 months after stoppi[INVESTIGATOR_111752]378 treatment, and should not 
father a child in this period. A condom is required to be used also by 
[CONTACT_111813].
●Patient has other severe acute or chronic medical or psychiatric condition or 
laborator y abnormality that may interfere with the interpretation of study results, 
and in the judgment of the investigator would make the patient inappropriate for 
the study.
●Patient has a history of pancreatitis or history of increased am ylase or lipase 
that was due to pancreatic disease.
Investigational 
and reference 
therapyLDK378 (ceritinib)
Efficacy 
assessmentsOverall response rate (ORR) and duration of response (DOR), progression -free 
survival (PFS) as per RECIST 1.1 in patients with neuroblastoma and other solid 
tumors, and by [CONTACT_55578] (IW G) criteria in patients with 
lymphoma. MIBG response in patients with neuroblastoma. Resolution of bone 
marrow disease in patients with neuroblastoma.
Safety 
assessmentsIncidence rate of Dose Limiting Toxicities (DLT) during the first cy cle of LDK378 
treatment
Adverse events and serious adverse events, cha nges in laborator y values, 
assessments of phy sical examinations, vital signs and electrocardiograms
Other 
assessmentsPlasma concentration time profiles, PK parameters, including but not limited to 
AUCtau, Cmin, Cmax, Tmax, Racc, and T1/2,acc
 
 
Data analysis The primary  objective of the escalation part is to estimate the MTD/RDE of the 
single agent LDK378 when administered orally on a once daily sched ule to fed or 
fasted pediatric patients with ALK -activated tumors. The corresponding primary 
analysis method is an adaptive Bayesian logistic regression model (BLRM) 
guided by [CONTACT_111814] (EW OC) principle.
For all safety analyses, the safety set will be used. Unless otherwise specified, all 
listings and tables will be presented by [CONTACT_1570] (regimen [fasted versus 
fed] and dose level) in the clinical study report, with patients classified according 
to treatment received.
Pharmacokinetic parameters will be determined using either non -compartmental 
method(s) or fitting of the actual values to a population PK model.
Anti-tumor activity will be summarized in terms of overall response rate (ORR), 
duration of response (DOR), and progression -free survival (PFS).
 
 
Key words Phase I, pediatric, open -label, dose escalation, ALK -activat ed tumors
 

[COMPANY_001] Confidential Page 35
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
[ADDRESS_124503] described in anaplastic large cell lymphoma (ALCL); it was 
identified asthe gene on chromosome 2 fused to the NPM gene in the t(2;5)(p23;Q35) 
translocation, and is found in approximately  half of patients with ALCL, and a majorit y of 
pediatric ALCL cases ( Gasco yne 1999, McDermott 2008, Savage 2008 ). ALK activation by 
[CONTACT_111815], amplification, point mutations, or other genetic rearrangements has since been 
identifie d in other malignancies. About 
2-8% of non-small cell lung cancers (NSCLC) carry 
activating translocations of ALK, most commonly  an EML 4-ALK translocation created by [CONTACT_111816] 2 (Soda 2007, Scagliotti 2012, Takeuchi 2009). 
ALK activation is found in approximately  10% 
of neuroblastomas, but in contrast to ALC L 
and NSCLC, ALK activation in neuroblastoma occurs by [CONTACT_111817] (Chen 2008, Azarova 2011). Most pedigrees exhibiting the rare syndrome of 
familial neuroblastoma carry  somatic mutations that result in ALK activation, indicating that 
ALK is an important driver in this disease (Mosse 2008). Half of inflammatory 
myofibroblastic tumors (IMT), a rare soft tissue sarcoma most commonly  found in children, 
harbor genetic alterations of ALK, including translocations and changes in gene 
copy number 
(Coffin 2007, Griffin 1999 ). Increased ALK protein expression and increased AL K gene cop y 
number have also been described recentl y in 50%- 80% of rhabdom yosarcomas, more often in 
the alveolar subty pe than the emby[CONTACT_111818]. It is not yet known if ALK is an oncogenic 
driver in this disease (van Gaal 2012). Activating translocations of ALK, including both 
EML 4-ALK, commonl y found in NSCL C and NPM -ALK, commonl y found in ALCL, act as 
dominant oncogenes in murine models; however, the mechanism of oncogenesis is not well 
understood (Chiarle 2003 , Soda 
2007). Overexpression and activation of ALK mediate many 
downstream effects that may contribute to transformation, increased proliferation, and 
increased survival. For example, ALK activation in ALCL is associated with activation of 
various signal transduction intermediates and pathway s implicated in oncogenesis, including 
STAT3, Grb2, mTORC1, PI 3K/AKT, and MEK/ERK ( Tabbo 2012). Based on these findings, 
activation of ALK appears to be 
an important mechanism of oncogenesis in subsets of a 
variet y of malignancies, several of which t ypi[INVESTIGATOR_111753].
The role of ALK in healthy  mammals is not well understood. It is expressed throughout the 
nervous system during embry ogenesis in the mouse, most strongl y in the brain, and in the 
adult animal ALK expression is much reduced, but still detectable in the brain (Palmer 2009, 
Iwahara 1997). Despi[INVESTIGATOR_111754], available data suggest that inhibiting ALK in children is not a major safet y 
concern. Mice with the ALK gene knocked out develop normally  without any evident 
developmental abnormalities (Palmer 2009, Bilsland 2008). Behavioral testing suggests that 
ALK knock -out mice have 
an “anti -depressant” phenoty pe, but otherwise function and 
reproduce normal ly (Bilsland 2008). In humans, germline ALK mutations that constitutivel y 
activate the kinase domain are the likely cause of most cases of familial neuroblastoma, but 
the mutations are not associated wi
th other familial abnormalities ( Mosse 2008).
 

[COMPANY_001] Confidential Page 36
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
The ALK inhibitor crizotinib was approved by  [CONTACT_50741] 2011 “for the treatment 
of patients with locally  advanced or metastatic NSCL C that is ALK -positive as detected by  [CONTACT_108076] -approved test.” Clinical experience with crizotinib indicates that ALK inhibition has 
potent antitumor activity in several malignancies carrying genetic alterations of ALK. The 
response rate to crizotinib in ALK-translocated NSCL C was 50%- 60% in the phase 1 study 
(Kwak 2010, Kim 2012 ). Crizotinib is also active in several ALK -driven pediatric 
malignancies including neuro blastoma, ALCL, and IMT (Mosse 2012, Butry nski 2010). 
Crizotinib has been associated with a high frequency  of visual toxicities including changes in
dark-light accommodation and seeing trails of light (Kwak 2010), but these patient -reported 
events have not been associated with 
abnormalities on ophthalmology exams, or other 
neurological adverse even ts. The mechanism of these visual toxicities, and the degree that 
crizotinib distributes to the retina is not known; however, based on a single case report 
crizotinib achieves only very low concentrations in the CSF, approximately  0.26% of blood 
(Costa 2011).
It is anticipated that more potent and specific ALK inhibitors, such as LDK378, may be more 
active than crizotinib in ALK -driven diseases, and may also be active in the setting of 
crizotinib -resistant disease.
1.2 Introduction to investigational treatment(s) and other study  
treatment(s)
1.2.1 Overview  of LDK378
LDK378 is an orally  available ALK inhibitor [5-Chloro -N2-[2-isopropoxy -5-methy l-4-(4-
pi[INVESTIGATOR_111755] l)pheny l]-N4-[2(isopropy lsulfony l)phen yl]
-2,4- pyrimidinediamine].  
,  
In addition, LDK378 shows potent antitumor activity  in crizotinib -resistant models and the 
efficacy  seen in the ongoing Phase I clinical trial in patients (with and without previous 
crizotinib therapy ) led to the accelerated approval of LDK378 (ceritinib) by [CONTACT_4469] (FDA) under the trade name [CONTACT_111933]™ on 29- Apr- 2014 for the 
following indication:
ZYKADIA™ is indicated for the treatment of patients with AL K
-positive metastatic 
NSCL C who have progressed on or are intolerant to crizotinib.
This indication is approved under accelerated approval based on tumor response ra te and 
duration of response. An improvement in survival or disease -related s ymptoms has not 
been established. Continued approval for this indication may  be contingent upon 
verification and description of clinical benefit in confirmatory  trials.’
Furthermor e, the European Commission approved ZYKADIA on 06- May-2015 for the 
following indications:
ZYKADIA is indicated for the treatment of adult patients with anaplastic lymphoma 
kinase (ALK) positive advanced non -small cell lung cancer (NSCLC) previously  treated
with crizotinib.
 

[COMPANY_001] Confidential Page 37
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Submissions to other health authorities worldwide have been completed in some countries and 
are underway  in others. In this protocol we will refer to the investigational treatment as 
LDK378 only .
[IP_ADDRESS] Non- clinical experience
[IP_ADDRESS].[ADDRESS_124504] s in a dose -dependent manner. It 
inhibits autophosphory lation of ALK, ALK-mediated phosphory lation of downstream 
signaling proteins, and proliferation of ALK -dependent cancer cells both in vitro and in vivo. 
LDK378 is approximately 20-fold more potent than crizotinib in enzymatic inhibition assay s 
of the ALK kinase activity  (IC50of 0.15 nM for LDK378 and 3 nM for crizotinib). I n a kinase 
panel of 35 additional enzymes, LDK378 demonstrated a high degree of selectivity  for ALK 
inhibition since it inhibited only 2
 kinases (INSR and IGF1R) but with approximately  50-fold 
less potency  than inhibition for ALK.
Preclinical data showed inhibition of the kinase activity  of the NPM -ALK fusion protein (in 
Karpas299 human ALCL cells) and of the EML4
-ALK fusion protein (in H2228 human 
NSCL C cells) with LDK378 led to inhibition of cancer cell proliferation in vitro. The 
inhibition of the downstream signaling pathway  by [CONTACT_111819]378 correlated with the inhibition of 
proliferat ion. In addition, inhibition of NPM -ALK and EML4- ALK in mouse and rat 
xenograft models resulted in inhibition of tumor growth and tumor regression in vivo. 
LDK378 was also active in cell lines with ALK amplification or expression of activating point 
mutati ons. A single -dose pharmacod ynamic study  and multiple -daily dose efficacy  study 
performed in Karpas299 and H2228 tumor models indicated that a 70% to 80% reduction in 
the ALK signaling pathway  is required to achieve complete tumor regression in rodents.
[IP_ADDRESS].2 Antitumor activity in xenograft models
LDK378 is highl y active in mouse and rat xenograft models of lung cancer and ALCL that 
carry an ALK rearrangement. In murine xenograft models of H2228 NSCL C and Karpas299 
ALCL cells, LDK378 dosed at 25 mg/kg dail y, less than the MTD in these models, resulted in 
complete regression of established tumors. When dosed at 50 mg/kg daily for 14 days in the 
H2228 NSCL C model, LDK378 resulted in complete and prolonged (lasting for more than 4.5 
months, the observation period) tumor regressions. In the same experiments, crizotinib dosed 
at 100 mg/kg daily for [ADDRESS_124505] ant H2228 NSCL C cell 
lines, including resistant variants carrying I1171T or C1156Y mutations in the ALK kinase 
domain. These data support that LDK378 may be clinicall y active in ALK -rearranged 
malignancies that becomes resistant to crizotinib.
[IP_ADDRESS].3 Nonclinical pharmacokinetics (PK) and metabolism
LDK378 showed consistent PK characteristics following intravenous (IV) administration in 
mouse, rat, dog, and monkey . LDK378 showed low to moderate plasma clearance (CL) 
compared to hepatic blood flow (ranging from 9.2 to 27 mL/min/kg). The estimated plasma 
 

[COMPANY_001] Confidential Page 38
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
volume of distribution at steady  state (Vss) was high across all animal species (9.7 to 19.9 
L/kg). The elimination T1/2 of terminal phase in plasma was long in all species (6.2 to 29 
h).Good oral bioavailability  (48%- 100%) was observed in various animal species. LDK378 is 
highl y bound to plasma protein (> 94%) in all species. Following oral administration of 
[14C]LDK378 to LEH male rats, radioactivity  was widely  distributed. The highest tissue 
exposures were found in the intestine wall, uveal tract, pi[INVESTIGATOR_111756], bile, adrenal cortex, 
harderian gland, liver, spleen, lymph node, lung, kidney , thyroid, bone marrow, adrenal 
medulla and pancreas (25 to 710 -fold higher exposure relative to blood). Unchanged LDK378 
was the major component in feces and bile of intact and bile duct-cannulated rats. In the rat, 
LDK378 underwent oxidation, leading to the formation of five oxygenated metabolites 
(designated as M23.6, M30.6, M35.8, and M33.4). In addition, LDK378 underwent sulfa tion, 
leading to M36.8, and oxidation followed by [CONTACT_111820], resulting in the presence of M29.5. 
LDK378 also underwent glucuronidation, leading to M26.8 and M27.6. The major metabolite 
in feces was designated M33.4 (oxygenation) accounting for approximatel y 7% of the dose. 
All other metabolites in feces and bile were minor (< 5% of the dose). In rats dosed with 
[14C]-LDK378, LDK378 -derived radioactivit y was excreted predominantly  in the feces (> 
99%), and renal excretion was a minor pathway  for excretion (<1%). Fecal excretion was the 
result of biliary  excretion (69%) and gastrointestinal (GI) secretion (31%). Since parent drug 
was the major component in bile and feces after IV administration, enterohepatic circulation 
may occur.
LDK378 is a potent reversib le inhibitor of cytochrome CYP3A4/5, 2B6, 2C8, 2C9 and 2A6 
(half -maximal inhibitory  concentration (IC50) ranging from 0.162 to 0.0316 µM) and a weak 
inhibitor of 2C19, 2D6 and 2E1. Time -dependent inhibition of CYP3A4/[ADDRESS_124506] blood brain barrier at a low level, with concentrations of 
LDK378 in brain tissue about 10% of that in blood.
[IP_ADDRESS].4 Safety pharmacology and toxicology
LDK37 8 was evaluated for safety  in 2-and 4 -week studies in rats and monkey s. The principal 
toxicity  induced by [CONTACT_111819]378 was a systemic inflammation characterized by [CONTACT_111821]/neutrophilic inflammation of the 
biliopancreatic ducts, pancreas, and/or duodenum. Gastrointestinal toxicity  was observed in 
both species, characterized by [CONTACT_111822], decreased food consumption, emesis 
(monkey ), diarrhea, and at high doses, by [CONTACT_111823], mucosal 
inflammation and foamy  macrophages in the duodenal crypts and ampullae of rats and 
monkey s, respectivel y. Liver (bile duct) was also affected in both species only at the highest 
dose levels studied (100 mg/kg/day  in the 2-week studies for both species; 50 and 30 
mg/kg/day  in the 4-weeks studies in rat and monkey, respectivel y), and included increases in 
liver transaminases in a few animals at high doses, and mixed cell inflammation, erosion and 
cytoplasmic vacuolation of the bile duct epi[INVESTIGATOR_111647]. The pancreas was a target organ in the rat, 
but 
not the monkey , with acinar cell atroph y and mixed cell inflammation noted at mid-and 
 

[COMPANY_001] Confidential Page 39
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
high doses. Target organ effects showed partial to complete recovery  during the 4-week non -
dosing period. No effect s in the rat central nervous system or on the respi[INVESTIGATOR_111757], high doses (100 mg/kg).
LDK378 has potent activity  on the hERG channel with an IC50of 0.4 μM. However, there 
were no LDK378 -related effects in vivo in monkey s at doses as high as 100 mg/kg (human 
equivalent dose (HED) of 1950 mg) .
Please refer to the current L DK378 [Investigator’s Brochure] for further information.
[IP_ADDRESS] Clinical experience
[IP_ADDRESS].1 Clinical safety and tolerability
LDK378 is associated with a manageable safety  profile (Table 1-1). For the 255 patients 
treated at the recommended dose (RD) of 750 mg in the ongoing study 
[CLDK378X2101], 
the median duration of exposure as of the  was 26.9 we eks (range 0.4 
to 82.3 weeks). The most common adverse events (AE) regardless of study  drug relationship 
(incidence ≥25%) were diarrhea, nausea, vomiting, alanine aminotransferase (ALT) increased, 
fatigue, abdominal pain, decreased appetite, aspartate aminotransferase (AST) increased, and 
constipation.
The incidence of grade 3
-4 AEs, regardless of study  drug relationship was <10% for all AEs 
except ALT increased (26.7%) (Table 1-1). The incidence of grade 3-4 AEs, regardless of 
study  drug relationship was <5% for all AEs except AST increased (8.2%), diarrhea (5.9%), 
hypergly cemia (5.5%), lipase increased (5.1%), and blood alkaline phosphatase (ALP) 
increased (5.1%).
Table 1
-1 All grades (at least 10%) and associated grade 3 -4 adverse events, 
regardless of study  drug relationship, by  [CONTACT_111806] 750 mg dose group (Data cut -off date: )
Preferred termLDK378
750mg
N=255
All Grades Grade 3/4
n (%) n (%)
Total 255 (100.0) 184 (72.2)
Diarrhea 219 (85.9) 15 (5.9)
Nausea 205 (80.4) 11 (4.3)
Vomiting 153 (60.0) 10 (3.9)
Alanine Aminotransferase 
Increased110 (43.1) 68 (26.7)
Fatigue 102 (40.0) 10 (3.9)
Abdominal Pain 91 (35.7) 3 (1.2)
Decreased Appetite 87 (34.1) 2 (0.8)
Aspartate Aminotransferase 
Increased78(30.6) 21(8.2)
Constipation 73 (28.6) 0
 

[COMPANY_001] Confidential Page 40
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Preferred termLDK378
750mg
N=255
All Grades Grade 3/4
n (%) n (%)
Cough 62 (24.3) 0
Abdominal Pain Upper 58 (22.7) 2 (0.8)
Dyspnea 47 (18.4) 8 (3.1)
Asthenia 45 (17.6) 2 (0.8)
Blood Alkaline Phosphatase 
Increased45 (17.6) 13 (5.1)
Back Pain 43 (16.9) 1 (0.4)
Headache 41 (16.1) 3 (1.2)
Weight Decreased 39 (15.3) 4 (1.6)
Blood Creatinine Increased 39 (15.3) 0
Pyrexia 38 (14.9) 0
Rash 32 (12.5) 0
Insomnia 31 (12.2) 0
Dyspepsia 26 (10.2) 1 (0.4)
Hypokalemia 26 (10.2) 11 (4.3)
Dizziness 26 (10.2) 0
Dose reductions due to adverse events occurred in 58.4% of patients treated with LDK378 at 
the 750 mg dose; 38.8% of patients had only [ADDRESS_124507] frequent AEs 
requiring dose adjustments or interruptions reported in ≥5% of the patients were: ALT 
increased, nausea, AST increased, vomiting, diarrhea, fatigue, and abdominal pain. Adverse 
events (AEs) leading to study  drug discontinuations occurred in 10.2% of patients treated with 
LDK378 at the [ADDRESS_124508] frequent AEs leading to study drug discontinuations 
were decreased appetite, pneumonia, AL P increased, pneumonitis, and respi[INVESTIGATOR_33078].
Serious adverse events (SAEs) reported in 2% or more of the 255 patients treated at the 
recommended dose of 750 mg were convulsion, pneumonia, interstitial lung disease 
(ILD)/pneumonitis, dyspnea, hypergl ycemia, and nausea. Fatal adverse reactions occurred in 
5% of patients, consisting of: pneumonia (4 patients), respi[INVESTIGATOR_33078], ILD/pneumonitis, 
pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary 
tuberculosis, cardiac tamponade, and sepsis (1 patient each). Adverse events of special 
interest to be monitored for LDK378 have also been identified and include: hepatotoxicity , 
interstitial lung disease/pneumonitis, QTinterval prolongation, brady cardia, hypergl ycemia ,
gastrointestinal toxicity  (nausea, vomiting and diarrhea) and pancreatitis (including lipase and 
amylase elevations) .For additional details, refer to [Investigator’s Brochure].
[IP_ADDRESS].2 Clinical efficacy
 data from the ongoing Study  demonstrated a high rate 
of rapid and durable responses with LDK378 in 246 ALK-positive NSCLC patients treated in 
the 750mg dose group (RD). In these patients the ORR was 58.5% (95% CI: 52.1, 64.8) 
based on investigator assessment (Table 1-2). Among the 144ALK -positive NSCL C patients 
 

[COMPANY_001] Confidential Page 41
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
with a confirmed CR or PR based on investigator assessment, 86.1% of those patients 
achieved a response within 12 weeks, with a median time to response of 6.1 weeks (range: 3.0 
to 24.1) . The estimated median duration of response (DOR) based on investigato r assessment 
was long at 9.69 months (95% CI: 7.00, 11.40). Based on the investigator assessment, the 
median PFS was 8.21 months (95% CI : 6.70, 10.12) with 53.3% of the patients censored.
Importantly , LDK378 showed this level of high anti-cancer activity  regardless of prior ALK 
inhibitor status (i.e., whether or not the patient received previous treatment with an ALK 
inhibitor). A high ORR of 54.6% and 66.3% was observed in patients treated with a prior 
ALK inhibitor and inALK inhibitor naïve patients, respectivel y, by [CONTACT_3138] 
(Table 1-2). Rapid responses were observed in patients regardless of prior ALK inhibitor 
status, 6.1weeks (range: 4.6 to 24.1) in patients treated with a prior ALK inhibitor and 
6.1weeks (range: 3.0 to 24.1) in ALK inhibitor naïve patients. Further, the estimated median 
DOR was 7.39 months (95% CI: 5.42, 10.12) in patients 
treated with a prior ALK inhibitor 
and, the median DOR was not reached in ALK inhibitor naïve patients. However, the 12-
month DOR rate was 65.2% (95% CI: 46.4, 78.8) for the latter. The estimated median PFS 
was 6.90 months (95% CI: 5.39, 8.41) in patients treated with a prior ALK inhibitor, while the 
median PFS was not reached in ALK inhibitor naïve patients (95% CI: 8.31, NE). Finall y, 
LDK378 demonstrated activity  in 
patients with brain metastasis at baseline. Among the 98 
patients with brain metastasis who had received prior ALK -inhibitor treatment, the ORR was 
50.0% (95% CI: 39.7, 60.3), median DO R was 6.9 months (95% CI: 4.8, 8.5), and median 
PFS was 6.7 months (95% CI: 4.9, 8.4). For additional details, refer to the [Investigator’s 
Brochure] .
 

[COMPANY_001] Confidential Page 42
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Table 1-[ADDRESS_124509] overall response based on investigator assessment 
in NSCLC patients in the 750 mg dose group, by  [CONTACT_111824] A LK inhibitor 
status (Full A nalysis Set NSCLC 750 mg) (Cut -off date: )
NSCLC with prior 
ALK inhibitorNSCLC A LK 
inhibitor naïveAll NSCLC
N=163 N=83 N=246
n (%) n (%) n (%)
Best overall response
Complete response (CR) 2 (1.2) 1 (1.2) 3 (1.2)
Partial response (PR) 87 (53.4) 54 (65.1) 141 (57.3)
Stable disease (SD) 32 (19.6) 19 (22.9) 51 (20.7)
Progressive disease (PD) 16 (9.8) 0 16 (6.5)
Unknown 26 (16.0) 9 (10.8) 35 (14.2)
Overall response rate (ORR) (CR 
or PR), n (%)89 (54.6) 55 (66.3) 144 (58.5)
95% CI (46.6- 62.4) (55.1- 76.3) (52.1- 64.8)
This table presents data for all patients with ALK -positive NSCLC in the [ADDRESS_124510] overall response is based on investigator’s assessment of disease status using RECIST 1.[ADDRESS_124511] binomial 95% Confidence Interval
[IP_ADDRESS].3 Clinical pharmacodynamics
Data are not yet available from the ongoing clinical studies.
[IP_ADDRESS].4 Clinical pharmacokinetics
In adult patients with tumors characterized by [CONTACT_111825]
] and in healthy  v olunteers  
and  the single -dose pharmacokinetics of 
LDK378 in humans has the following features: (1) LDK378 was slowly  absorbed, with 
median peak plasma concentration occurring at approximately  4  to 6 h in patients, and 
approximately  6 to 8 h in healthy  subjects. Following Cmax, L DK378 concentrations declined 
in a mono -exponential manner. The geometric mean apparent terminal half-life ranged from 
31 to 41 h across the 400 to 750mg dose groups in patients and 36 to 48 h across the 450 to 
750 mg dose groups in healthy  subjects. (2) Cmax and AUClast increased dose -proportionally 
following singl e oral administration of LDK378 across the 50 to 750mg dose groups. (3) 
Moderate to high variability  in LDK378 PK parameters has been observed in both healthy  
subjects and patients. Following single oral doses of [ADDRESS_124512] variability  (geometric mean coefficient of 
variation; CV% range) was 42-74% and 35-72% for AUClast and Cmax, respectively. The 
corresponding 
values in patients were 93% and 87% following single oral doses of 50 to 
750mg based on a model developed for dose proportionality  anal ysis.
 

[COMPANY_001] Confidential Page 43
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
The multiple -dose PK of LDK378 following repeated daily oral dosing in patients has the 
following features: (1) AUCtau at the maximum tolerated dose and recommended dose of 
750mg increased from first dose with geometric mean accumulation ratios of 4.7 on Cycle1 
Day 8 after 1week of daily  dosing and 6.2 on Cycle2 Day 1 after 3weeks of daily dosing, 
respectivel y. Evaluation of trough concentration at 750mg that steady -state was achieved by 
[CONTACT_51199] 1 Day 15 following 2 weeks of daily  dosing. (2) LDK378 demonstrated nonlinear PK 
over time, as indicated by [CONTACT_111826] (CL/F) between 
single -dose (88.5 L/h at 750 mg) and stead y-state at Cycle2 Day 1 (33.2 L/h at750 mg). As 
LDK378 is a substrate as well as a time-dependent inhibitor of CYP3A, it is likely  that this 
PK nonlinearity  could be attributed to auto inhibition of L DK378 . In contrast with single dose 
data, Ctrough on Cycle2 Day 1 after repeated daily  dosing increased with dose in a greater 
than dose -proportional manner.
 
 
 
 
 
CYP3A was identified as the major CYP isozy me responsible for the metabolism of L DK378. 
An inhibition DDI study  conducted in healthy  volunteers indicated that ketoconazole (200 mg 
bid for 14days), a strong CYP3A inhibit or, increased the Cmax and AUCinf of a single 
450mg oral dose of LDK378 by 1.2-fold and 2.9-fold, respectivel y, compared with LDK378 
alone Therefore, concurrent use of strong CYP3A inhibitors should 
be avoided. An induction DDI study conducted in healthy  volunteers indicated that rifampin 
(600 mg daily  for 14days), a strong CYP3A inducer, decreased the Cmax and AUCinf of a 
single 750mg oral dose of LDK378 by44% and 70%, respectivel y, compared with LDK378 
alone Concurrent use of strong CYP3A inducers should be avoided.
A food effect study  was conducted in healthy  volunteers  Compared to the 
fasted state, a low-fat meal increased Cmax and AUCinf of a single oral dose of LDK378 
500mg in health y subje cts by 43% and 58%, respectivel y, whereas a high-fat meal increased 
Cmax and AUCinf by  41% and 73%, respectivel y.
[ADDRESS_124513] range of ALK -activated tumor models, including 
models driven by [CONTACT_111827], and by [CONTACT_111828].
As described in Section 1.1, genetic alterations of ALK are found in subsets of several 
pediatric cancers, including about 10% of neuroblastomas, the majorit y of pediatric ALCL, 
and about half of inflammatory  myofibroblastic tumors. Both in vitro and in vivo experiments 
have demonstrated that neuroblastoma, ALCL, and NSCL C models carry ing ALK alterations 
 

[COMPANY_001] Confidential Page 44
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
are frequently  dependent on ALK for their growth, and are responsive to treatment with ALK 
inhibitors (Chiarle 2003, Soda 2007 , Li 2011, Galkin 2007 ). Recent clinical data have also 
demonstrated that the ALK inhibitor crizotinib has antitumor activity in children with 
neuroblastoma and ALCL ( Mosse 2012).
In the ongoing phase 1 study , [CLDK378X2101] , LDK378 has demonstrated substantial 
antitumor activity  in adult patients with ALK -rearranged NSCL C. Together, these preclinical 
and clinical data support evaluation of LDK378 in pediatric patients with malignancies 
carrying genetic alterations of ALK.
Safety  data from studies in adult patients, as well as the pediatric patients alread y enrolled in 
this study  show a high incidence of GI adverse events (nausea, vomiting, diarrhea, abdominal 
pain). These AE’s seem to be generall y low-grade and manageable with prophy lactic 
medications. However, GI symptoms are uncomfo rtable and can affect patients’ general well-
being, as well as drug absorption and dosing compliance, with the latter potentially  limiting 
efficacy . Dosing with food has been shown to improve the GI tolerability  of other multi-
kinase inhibitors, such as im atinib ( Gleevec USPI ) and bosutinib ( Bosulif USPI ). Therefore, a 
separate dose-escalation arm under fed conditions will be explored once the fasting MTD 
and/or RDE is reached.
The primary  purpose of this study  is to estimate the maximum tolerated dose (MTD) and/or 
recommended dose for expansion (RDE) in pediatric patients, and to delineate a clinical dose 
to be used in any  future pediatric studies. Th e MTD will first be determined in the fasted state, 
then a second dose escalation to determine the MTD in the fed state (low-fat light snack) will 
be conducted. This study will also assess the safety , tolerability , PK and preliminary  evidence 
of antitumor activity  of LDK378 in children with neuroblastoma, and other ALK -activated 
tumors.
2.[ADDRESS_124514] a genetic alterat ion of ALK. The study  includes an expansion part 
at the MTD or RDE in order to better evaluate safety , tolerability , and preliminary evidence of 
antitumor activity  in neuroblastoma having a genetic alteration of ALK, and in other 
malignancies having a gene tic alteration of ALK.
The current open -label dose escalation study  design using a Bayesian logistic regression 
model (BLRM) is a well- established method to estimate the maximum tolerated dose (MTD) 
and/or recommended dose for expansion (RDE) in cancer patients. The adaptive BLRM will 
be guided by [CONTACT_111814] (EWOC) principle to control the risk of 
DLT in future patients on study . The use of Bayesian response adaptive models for small 
datasets has been accepted by [CONTACT_111829] (“Guideline on clinical trials in small populations”, 
February  1, 2007) and endorsed by [CONTACT_111830] (Babb 1998 , Neuenschwander 
2008, Neuenschwander 2010 ), and its development and appropriate use is one aspect of the 
FDA’s Critical Path Initiative.
The study  includes patients ranging from 12 months to <[ADDRESS_124515] be 
diagnosed with amalignancy  that has a genetic alteration of ALK (such as a mutation, 
translocation or amplification) and has progressed following standard therapy  or for which no 
 

[COMPANY_001] Confidential Page 45
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
standard treatment option exists. The study  is limited to malignancies with a genetic altera tion 
of ALK because LDK378 is only  expected to be active against ALK -activated malignancies.
In order to ensure experience with LDK378 across this age range, at least 3 patients will be 
treated in each of the following age categories: 12 months -< 7 years, 7 -< 12 years, and 12 -
<18 y ears.
2.3 Rationale for dose and regimen selection
The starting dose for the fasted dose escalation part is 66.7% of the MTD in adults, 
normalized to BSA. Based on the adult MTD of 750 mg qd, and a ty pi[INVESTIGATOR_111758] 1.7 m2, 
the pediatric starting dose of LDK378 is 300 mg/m2((750 mg x 0.667) /1.7 m2= 294 mg/m2, 
rounded to 300 mg/m2) dosed once daily  by [CONTACT_1966]. In adults, LDK378 is dosed once daily  by 
[CONTACT_1966], and the half -life of approximately  36 hours supports proceeding with once daily 
dosing in children.
The starting dose of 300 mg/m2corresponds to an adult dose of approximately  500 mg qd. In 
the ongoing phase 1 study  the combined response rate at the 400 mg qd and 500 mg qd dose 
levels was 63% (15/24), including unconfirmed responses only observed 
on a single 
evaluation as of the Aug 3, 2012 snapshot. In addition, considering that LDK378 is 20-fold 
more potent than crizotinib based on enzy matic inhibition assay s of ALK kinase activity  and 
at the clinical dose 500 mg qd, the median AUC of LDK378 is approximately  23.3 µM*hr 
(day 8
 of cycle 1), which exceeds the stead y state exposure of crizotinib of approximately  8.6 
µM*hr, at its MTD (FDA Clin Pharm, Biopharm review of crizotinib, NDA 202570), the 
selected starting dose in the current study  should produce anti-tumor activity . The probability 
of overdose at 500 mg qd is estimated to be <0.1% in the adult phase 1 study , based on the 
Bayesian logistic regression model. Thus, the starting dose of 300 mg/m2is expected to be 
active and well tolerated. The half-life of approximately  36 hours observed in adults supports 
once dail y dosing in children.
 
 
 
 
Rodent xenograft experiments in AL K-rearranged tumor models that are resistant to crizotinib 
require higher LDK378 exposures to achieve maximum tumor growth inhibition; therefore, it 
is likely  that higher doses of LDK378 will be more active in patients, and it is most 
appropriate to dose LDK378 at the MTD, not to target a minimal efficacious dose.
During the dose escalation parts of the study , dose escalation will be guided by [CONTACT_111831], 
but the maximum increase in dose for the fasted dose escalation part will be limited to 50% of 
the last prior dose level before reaching 450mg/m2, and to 25% after reaching 450 mg/m2, 
which is the MTD in adults, as shown in Table 6-1. Dose escalation for the fed dose 
escalation part will be limited to a 25% or smaller increase above the prior fed dose level. 
These restrictions are necessary  to prevent excessive escalation, since the starting dose is 
relativel y close to the adult MTD.
 

[COMPANY_001] Confidential Page 46
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
2.4 Rationale for choice of combination drugs
Not applicable.
2.5 Rationale for choice of comparators
Not applicable.
2.6 Risks and benefits
LDK378 dosed at 750 mg once daily  has remarkable anti-tumor activity and induces a high 
rate of rapid and durable responses and prolonged PFS in patients with advanced, ALK -
positive NSCL
C, regardless of whether they had been previousl y treated with an ALK 
inhibitor or were ALK inhibitor naïve. The substantial anti-tumor activity  and resulting 
clinical benefit combined with the clinically  manageable safet y profile of LDK378 strongl y 
support a positive benefit/risk balance for ALK -positive NSCL C patients.
Efficacy
Patients with prior ALK inhibitor treatment: AL K-positive NSCL C patients previously  treated 
with crizotinib who have progressed and patients intolerant to crizotinib have no effective 
treatment options, have a dismal prognosis, and represent a population with a high unmet 
medical need. In ALK -positive NSCL C patients failing treatment with crizotinib, independent 
from the resistance mechanism involved, ALK translocation is still present and is still the 
oncogenic driver in almost all of the cases. Chemotherap y is not expected to provide a 
meaningful clinical benefit in these patients, as was recentl y demonstrated in a Phase III study  
(PROFILE 1007) of crizotinib vs. chemo therap y in the second
-line setting ( Shaw et al 2013 ).
In ALK -positive NSCL C patients previously  treated with an ALK inhibitor and multiple prior 
lines of anti-neoplastic therap y, based on an independent review of tumor assessments, as of 
31-Oct- 2013, the response rate was 45.1% (95% CI: 37.1 - 53.3) and the median DOR was 
7.1 months (95% CI: 5.6 –NE). The median PFS was 6.7 months (95% CI : 5.5 -7.7) in Study  
[CLDK378X2101] . The median PFS is similar (overlappi[INVESTIGATOR_007] 95% CIs) to that reported for 
crizotinib in the second -line setting (7.7 months (95% CI : 6.0 - 8.8)) and similar or better than 
that reported for chemotherap y (4.2 months (95% CI: 2.8 
-5.7) with pemetrexed and 2.6 
months (95% CI : 1.6 -4.0) with docetaxel) in the PROFILE 1007 study  (Shaw et al 2013) for 
patients with locally  advanced or metastatic ALK-positive NSCL C who had received prior 
treatment with one platinum- containing chemotherap y regimen. Therefore, LDK378 fulfills 
an existing unmet medical need.
The efficacy  of LDK378 seen in Study  [CLDK378X2101] is highly  encouraging in heavil y 
pretreated patients with advanced disease, high tumor burden (including a high proportion of 
brain metastases at baseline), limited available therapeutic options, and dismal prognoses 
following prior ALK -targeted therapi[INVESTIGATOR_014], where the only options are chemotherap y andbest 
supportive care.
ALK inhibitor naïve patients: As of 31-Oct-2013, based on an independent review of tumor 
assessments, the response rate in ALK inhibitor naïve NSCL C patients was 61.0% (95% CI: 
49.2 - 72.0) in Study  [CLDK378X2101]. The median DOR wasnot evaluable for treatment -
naïve patients. The median PFS for LDK378 in ALK-inhibitor naïve patients was not 
 

[COMPANY_001] Confidential Page 47
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
evaluable (95% CI: 13.7 -NE) as the majorit y of patients were ongoing without an event at 
the time of the data cut -off.
Overall, these data sugg est that LDK378 as a first-line ALK inhibitor treatment has 
remarkable anti-tumor activity  and induces a consistently  high rate of durable responses in 
ALK inhibitor naïve patients.
Safety
The safet y profile of LDK378 is manageable ( Section [IP_ADDRESS] ), with a low rate of AEs leading 
to discontinuation. Furthermore, patients’ perception of their quality  of life was maintained or 
slightly  improved with LDK378 treatment. The most common AEs were gastrointestinal 
(diarrhea, nausea, vomiting); increases in transaminases, decreased appetite, fatigue; 
abdominal pain, and constipation were also seen in ≥ 25% of patients. These AEs can be 
managed with symptomatic treatment and/or dose reductions or interruptions; only 8.8% of 
patients 
discontinued study  drug due to an AE. No clinically  meaningful differences in the 
safet y profile were observed between ALK -positive NSCL C patients previously  treated with 
an ALK inhibitor and ALK inhibitor naïve patients.
The risks identifie d with LDK378 treatment include hepatotoxicity , interstitial lung disease 
(ILD)/pneumonitis, QT interval prolongation, brady cardia, hypergl ycemia, gastrointestinal 
toxicity  (nausea, vomiting and diarrhea) and pancreatitis (including lipase and amylase 
elevations) (Section 8.1.3). These risks can be managed and ameliorated by [CONTACT_111832]/interruption, or permanent discontinuation.
Risk management during study  conduct
In order to manage the risks associated with LDK378 treatment, specific dose modifications 
and stoppi[INVESTIGATOR_111759]. For patients who do not 
tolerate the initial protocol -specified dose, dose adjustments are provided in order to allow the 
patients to continue the study  treatment ( Section 6.3 . and Table 6 -
3). Patients whose treatment 
is temporaril y interrupted or permanently  discontinued due to a study  drug related AE or an 
abnormal laboratory  value must be followed until resolution or stabilization of the event, 
whichever comes first, including all stud y assessments appropriate to monitor the event.
In addition, a thorough post-treatment safet y follow -up is included (Section 
7.1.4). Patients 
may voluntarily  withdraw from study  treatment at any time or on the advice of the 
investigator if he/she believes that continuation 
would be detrimental to the patient’s well-
being. When the patient discontinues from study  treatment, an End of Treatment (EOT) visit 
must be performed as soon as possible and within [ADDRESS_124516] experienced an y new AEs and/or to follow resolution of ongoing AEs.
Detailed information on allowed and prohibited concomitant medications is provided in 
Section 6.4. In vitro drug metabolism studies show that the metabolism of LDK378 is 
mediated by [CONTACT_097]3A4/5. Appendix 2contains several tables listing medications that are
prohibited, permitted or to be used with caution during treatment with LDK378. Prohibited 
medications should be discontinued at least 1 week prior to the start of treatment with 
LDK378.
 

[COMPANY_001] Confidential Page 48
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Recommended guidelines for prophy lactic or supportive treatment for expe cted toxicities, 
including management of study -drug induced AEs, are extensivel y described in Section 6.3.
Furthermore, regarding adverse events of special interest (see Section 8.1.3 ):
Hepatotoxicity: Hepatotoxicity , as defined b y TB > 2xUL N and ALT and/or AST > 
3xULN and ALP < 2xULN, has been observed in <1% of patients treated with L DK378. 
to grade 3 or 4 ALT elevations were observed in 25% of patients r eceiving LDK378. 
Concurrent elevations in AL T >3xUL N and total bilirubin >2xUL N, with normal alkaline 
phosphatase, occurred in less than 1% of patients in clinical studies. The majority  of cases 
were manageable with dose interruption and/or dose reduction. Few events required 
discontinuation of L
DK378. Patients will be closely  monitored b y regular laboratory 
testing and related signs and sy mptoms. Risk to patients will also be minimized by  
[CONTACT_111833] y enrollment to subjects with laboratory values for AST, ALT, ALP and 
bilirubin below certain thresholds (see exclusion criteria #3).
Interstitial lung disease/pneumonitis: severe, life -threatening, or fatal interstitial lung 
disease (ILD)/pneumonitis have been observed in patients treated with LDK378 in cl inical 
studies. Most cases improved or resolved with interruption of LDK378. Patients will be 
monitored for s ymptoms such as shortness of breath, cough or fever. Risk to patients will 
be minimized by  [CONTACT_111834] a histo ry of interstitial 
lung disease or interstitial pneumonitis, including clinically  significant radiation 
pneumonitis (i.e., affecting activities of daily  living or requiring therapeutic intervention) 
(see exclusion criteria #10).
QT interval prolongation: QTc prolongation has been observed in clinical studies in 
patients treated with LDK378, which may  lead to an increased risk for ventricular 
tachyarrh ythmias (e.g., Torsade de pointes) or sudden death. A pharmacokinetic anal ysis 
suggested that LDK378 causes concentration -dependent increases in QTc. Repeated ECG 
tracings will be performed throughout the stud y to closely monitor cardiovascular safet y. 
Risk to patients will also be minimized by  [CONTACT_111835], uncontrolled heart disease and/or a recent cardiac event (within 
6 months), including a corrected QT (QTcF) > 480 ms using Fridericia’s correction on the 
screening ECG (see exclusion criteria #2).
Bradycardia: asymptomatic cases of brady cardia have been observed in patients treated 
with L DK378 in clinical studies. Repeated ECG tracings will be performed throughout the 
study  to closel y monitor cardiovascular safet y. Risk will also be minimized by [CONTACT_111836] (e.g., beta -blockers, non-
dihydropyridine calcium channel blockers, clonidine, and digoxin) to the extent possible. 
Heart rate and blood pressure will also be monitored regularly  during the study .
Hype rglycemia: events of hypergl ycemia (all grades) have been reported in less than 10% 
of patients treated with LDK378 in clinical studies; 5% of patients reported a grade 3/4 
event. The risk of h ypergly cemia was higher in patients with diabetes mellitus and/ or 
concurrent steroid use. Patients will be closely  monitored throughout the study  for any  
signs and s ymptoms related to elevated blood glucose levels. Risk will be minimized by  
[CONTACT_111837] < 175 mg/dL (< 9.8mmol/L ) at 
screening (see exclusion #3).
 

[COMPANY_001] Confidential Page 49
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Gastrointestinal toxicity: diarrhea, nausea, and vomiting have been very  commonly  
reported; 12.2% of patients reported a grade 3/4 event of diarrhea, nausea, or vomiting. 
Risk to patients will be minimized during the stud y by [CONTACT_111838], including anti -diarrheals, anti -emetics, or fluid 
replacement, as indicated.
Pancreatitis (including lipase and amylase elevations): in most cases, pancreatic 
enzy me elevations have been mild to moderate, and have t ypi[INVESTIGATOR_1306] y reversed with 
interruption of LDK378. Few patients have experienced pancreatitis with severe upper 
abdominal pain. Patients will be monitored closely for an y related signs and symptoms. In 
order to minimize t he risk to patients during the study , patients with a history  of 
pancreatitis or a history  of increased lipase or am ylase levels that was due to pancreatic 
disease will be excluded. I n addition, serum am ylase must be ≤[ADDRESS_124517] be withi n normal limits at screening.
Conclusion
The outstanding anti-tumor activity  and resulting clinical benefit combined with the 
manageable safet y profile of LDK378 strongl y support a positive benefit -risk balance for 
ALK -positive NSCL C patients, regardless of whether the patients had received prior ALK 
inhibitor treatment or not.
The risk to subjects in this trial will be minimized and managed by [CONTACT_111839], close clinical monitoring, dose modifications/interruptions and permanent 
discontinuation as required. There may be unforeseen risks with LDK378 which could be 
serious. Refer to the [Investigator’s Brochure] for additional information regarding the safet y 
profile of LDK378.
3 Objectives and endpoints
Objectives and related endpoints are described in Table 3-1 below.
 

[COMPANY_001] Confidential Page 50
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Table 3-1 Objectives and related endpoints
Objective Endpoint Analysis
Primary Refer to Section 10.4 .
Estimate the MTD and/or RDE of LDK378 as a 
single agent when administered orally to 
pediatric patients with ALK -activated tumors in 
fasting and fed statesIncidence rate of Dose Limiting Toxicities (DLT) during the first cy cle of 
LDK378 trea tment.
Secondary Refer to Section 10.7 .
(1) Characterize the safety and tolerability of 
LDK378 in the pediatric patients in fasting and 
fed states
(2) Characterize single and multiple -dose PK of 
LDK378 in pediatric patients in fasting and fed 
states
(3) Assess the anti -tumor activity of LDK378 in 
fasting and fed states(1) Adverse events and serious adverse events, changes in laborator y 
values, assessments of physical examinations, vital signs an d 
electrocardiograms.
(2) Plasma concentration time profiles, PK parameters, including but not 
limited to, AUCtau, Cmin, Cmax, Tmax, Racc, and T1/2,acc
(3) Overall response rate (ORR) and duration of response (DOR), 
progression -free survival (PFS) as per RECIST 1.1 in patients with 
neuroblastoma and other solid tumors, and by [CONTACT_19543] W orking Group 
(IWG) criteria in patients with ly mphoma. MIBG response in patients with 
neuroblastoma. 
 

[COMPANY_001] Confidential Page 51
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
 
 
 
 
  
 
 
 
 
 
 
 

[COMPANY_001] Confidential Page 52
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
[ADDRESS_124518], effective therap y exists. 
LDK378 will be administered orally , once dail y, continuously .
Because of the low incidence of cancers with abnormalities in ALK, the study  sites will pre-
screen patients for genetic alterations of ALK by [CONTACT_5583] a tumor sample to a central 
laboratory  designated by [CONTACT_5343]. The tumor sample may be a previously  obtained archival 
sample, or a sample obtained for the purpose of molecular pre-screening for this study . The 
ALK analysis results will be communicated to the study  center within approximately  2 weeks 
of the lab’s receipt of the sample. If the patient has alread y been identified to have a genetic 
alteration of ALK, he/she can be screened for the study  without assessment of ALK at a 
designated laboratory , if [COMPANY_001] reviews the local laboratory  assessment, and agrees that it is 
sufficient for eligibility . The patient/guardian must provide signed informed consent on the 
molecular pre-screening consent form before a pre-screening tumor sample is sent to the 
designated laboratory . Patients found to have a genetic alteration of ALK, such as a mutation, 
translocation or amplification, may be screened for the study , after the patient/guard ian 
provides signed informed consent. If the patient fulfills all other inclusion and exclusion 
criteria, the patient can begin treatment.
For the purpose of scheduling assessments, and establishing the MTD/RDE, a cy cle is defined 
as 21 days in length, butthere is no schedule break in dosing between cycles. It is anticipated 
that approximately  15-36 patients will be treated during the fasted escalation part (3- 6 patients 
in approximately  5-6 dose levels, and a minimum of 6 at the MTD dose level). It is 
anticipated that approximately  12-24 patients will be treated during the fed escalation part (3-
6 
patients in approximately  3-4 dose levels, and a minimum of 6 at the MTD dose level). 
Patients will be categorized according to one of the age ranges as they  enter the study .
The expansion part will start after the fasted MTD has been determined. During the expansion 
part patients will initially  be dosed at the fasted MTD, or at a lower RDE, if the available data 
suggest that the MTD is not appropriate for multiple cycles of therap y. Once the fed dose 
escalation part is opened, patients will be enrolled on the open cohort of the fed dose 
escalation part. At times when the fed dose escalation part is closed to enrollment, such as 
during the observation period betwee n cohorts, additional patients may continue to be 
enrolled in the expansion part at the fasted MTD/RDE. After the MTD/RDE is determined for 
the fed state and the available safety , PK and anti-tumor activity  data have been reviewed, a 
decision will be made as to whether dosing in the fasted or fed state is preferred. Once this 
decision is made all subsequent patients will be enrolled on that dosing strategy  to complete 
the planned expansion part. The expansion part will include 2 groups of patients, one 
restricted to patients with ALK -activated neuroblastoma and the second including all other 
ALK -activated tumors. Enrollment will proceed in parallel. The goals of the expansion part of 
 

[COMPANY_001] Confidential Page 53
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
the study  are to better characterize the safet y, tolerability  and PK profil e of LDK378, and to 
make a preliminary  assessment of antitumor activity . The neuroblastoma group will enroll 
approximately  25 patients on the preferred regimen (fed or fasted), and the mixed tumor 
group will enroll approximately  20 patients. See Section 10.10 for sample size rationale.
Figure 4-1 Overview of study  design
 

[COMPANY_001] Confidential Page 54
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
4.[ADDRESS_124519] occurrence of one of the following : 
1. A ll patients have discontinued study  treatment, and all required Study  evaluation 
completion (SEC) follow -up visit 
have been completed , or 
2.
Allpatie nts have died, have been lost to follow -up or have withdrawn consent to further 
participation in t he study , or the last patient on treatment has been enrolled into a separate 
rollover study or other option for continued treatment with L DK378, whichever comes 
first. 
Patients who are still receiving treatment with LDK378 and deriving clinical benefit will be 
offered enrollment into a separate study  or other option for continued treatment with LDK378 
that are considered acceptable at the country  level such as access to commerciall y available 
drug or managed access program. In the separate study , [COMPANY_001] will continue to supply 
LDK378 to patients who may benefit from continued treatment as per the Investigator’ s 
opi[INVESTIGATOR_1649]. Safety  will be monitored and reported to Health Authorities per regulatory 
requirements. Prior to the end of the current study  (CLDK378X2103), this separate protocol 
will be submitted to Health Authorities and I RBs involved in the current study . 
The final analy sis of study  data will be conducted at the end of the study  and all available 
safet y and efficacy  data from all patients will be analyzed. A final clinical study  report (CSR) 
will be produced reporting all available data collected.
4.4 Early study  termination
The study  can be ter minated at any time for any reason by  [CONTACT_5343]. This includes early  study 
termination if the investigators and [COMPANY_001] determine that patients are experiencing 
excessive toxicity  related to LDK378, and the available data indicate that continuation at a 
lower dose level is not appropriate. Should this be necessary , all patients should be seen as 
soon as possible and the same assessments should be performed as described in Section 7 for 
the EOT and SEC visits. The investigator may be informed of additional procedures to be 
followed in order to ensure that adequate consideration is given to the protection of the 
patient’s interests. The investigator will be responsible for informing IRBs and/or ECs of the 
early termination of the trial.
[ADDRESS_124520] neuroblastoma, ALCL, IMT, and rhabdom yosarcoma.
 

[COMPANY_001] Confidential Page 55
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
The investigator or designee must ensure that only patients who meet all the following 
inclusion and none of the exclusion criteria are offered treatment in the study.
5.[ADDRESS_124521] to meet all of the following criteria:
1.Patients must be diagnosed with a locall y advanced or metastatic malignancy that has 
progressed despi[INVESTIGATOR_111760] y, or for which no effective standard therapy  exists.
2.Age ≥ 12 months and <18y ears.
3.The tumor must carry  a genetic alteration of ALK including any  of the following:
A point mutation ,or any  other mutation (e.g. insertion or 
deletion), , which results in 
a change of  the amino acid sequence of the kinase domain of ALK.
An amplification of the ALK gene, defined as ≥ [ADDRESS_124522] be observed in 
focal clusters of tumor cells (not only  single cells) or in more than one -third of the 
tumor cells.
A rearrangement of the ALK gene (when rearrangement assessed by [CONTACT_111840] ≥ 15% of the tumor cells).
In patients with rhabdomyosarcoma or anaplastic large cell ly mphoma, expression of 
ALK protein based on immunohistochemistry is sufficient for eligibility .
4.Patients must have evaluable or measurable disease as defined by  [CONTACT_111841]: RECI ST v1.1 for patients with non-hematologic malignancies ( Appendix 5 ); 
MIB
G scan for patients with neuroblastoma, International Working Group (I WG) criteria 
for patients with ly mphoma ( Appendix 6 ).
5.Performance status:
Karnofsk y performance status score ≥ 60% for patients > 12 y ears of age.
Lansk y score ≥ 50% for patients ≤ 12 y ears of age.
Note : patients who are unable to walk because of paral ysis, but who are mob ile in a 
wheelchair, will be considered ambulatory  for the purpose of assessing the 
performance score.
6.Written informed consent/assent before an y study -specific molecular pre- screening and 
screening procedures. For pediatric patients (as defined by  [CONTACT_5737] s
tandards), consent will 
be obtained from parent(s) or legal guardian(s) and the signature [CONTACT_111934] [ADDRESS_124523] not meet anyof the following criteria:
1.Patients with sy mptomatic central nervous s ystem (CNS) metastases who are 
neurologicall y unstable or require increasing doses of steroids or local CNS -directed 
therap y (su ch as radiotherapy , surgery  or intrathecal chemotherapy ) to control their CNS 
disease.
 

[COMPANY_001] Confidential Page 56
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
2.Patients with clinically  significant, uncontrolled heart disease or corrected QT (QTc) 
interval > 480 milliseconds, using the Fridericia correction (QTcF).
3.Patients with the following laboratory  values during screening:
Creatinine > 1.[ADDRESS_124524] for age.
Total bilirubin > 1.[ADDRESS_124525] for age, except for patients with Gilbert’s sy ndrome, who 
may be included if total bilirubin is ≤ 3.[ADDRESS_124526] bilirubin is ≤ 1.[ADDRESS_124527].
Alanine aminotransferase (ALT) > [ADDRESS_124528] a value ≤ 5 x UL N.
Serum aspartate aminotransferase (AST) > [ADDRESS_124529] a value ≤ [ADDRESS_124530].
Absolute neutrophil count (ANC) < 0.75 x 109/L without use of granulocyte growth 
factor for ≥ 14 day s.
Platelet count < 50 x 109/L.
Hemoglobin (Hgb) < 8 g/dL .
Alkaline phosphatase (ALP) > 5.[ADDRESS_124531]
Serum amy lase > [ADDRESS_124532]
Serum lipase > ULN
Fasting plasma glucose ≥175 mg/dL (≥9.8 mmol/L)
Potassium, magnesium, calcium or phosphate abnormality  > CTCAE grade 1.
4.Body surface area (BSA) < 0.35 m2.
5.Impairment of gastrointestinal (GI) function or GI disease that may  significantly  alter the 
absorption of LDK378 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, 
or malabsorption sy ndrome).
6.
Evidence of active viral hepatitis, including Hepatitis A, B or C (testing for viral hepatitis 
is not mandatory ).
7.Known diagnosis of human immunodeficiency  virus (HIV) infection (HIV testing is not 
mandatory ).
8.Presence of ≥ CTCAE grade 2 toxicity  (except alopecia, peripheral neuropathy , 
ototoxicity  and l ymphopenia, which are not excluded if grade 3 or less) due to prior cancer 
therap y.
9.Malignant disease, other than that being treated in this study . Exceptions to this exclusion 
include the following: malignancies that were treated curativel y and have not recurred 
within 3 y ears prior to study  entry ; completel y resected basal cell and squamous cell skin 
cancers; and completel y resected carcinoma in situ of an y type.
10.History  of known interstitial lung disease or interstitial pneumonitis, including clinicall y 
significant radiation pneumonitis (i.e., affecting activities of 
daily  living or requiring 
therapeutic intervention) .
11.Patients who have received sy stemic anticancer therapy  within [ADDRESS_124533] dose of the ALK inhibitor.
 

[COMPANY_001] Confidential Page 57
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
12.Radiotherap y to lungs ≤ [ADDRESS_124534] 
not recovered from radiotherap y-related toxicities. For all other anatomic sites, 
radiotherap y ≤ [ADDRESS_124535] dose of LDK378. Insertion of a gastric feeding 
tube (G -tube), nasogastric feeding tube (NG- tube), and central venous access are not 
considered major surgery.
14. Patients receiving medications that are known to be strong inhibitors or inducers of 
CYP3A4/[ADDRESS_124536] 1 week prior to start of treatment with 
LDK378 and for the duration of the study  (Appendix 2 ).
15.Patients rece iving medications that are mainl y metabolized by [CONTACT_097]3A4/[ADDRESS_124537] 1 week prior to start of 
treatment with LDK378 and for the duration of the study  (Appendix 2 ).
16.Medications with a known risk of prolonging the QT interval or inducing Torsades de 
Pointes ( Appendix 2 ).
17.Pregnant or nursing (lactating) females.
18.Females of child -bearing pot ential, defined as all females ph ysiologically  capable of 
becoming pregnant, unless they  are using highly  effective methods of contraception 
during dosing and for 3 months after stoppi[INVESTIGATOR_90524]. Highly effective contraception 
methods include:
Total abstine nce (when this is in line with the preferred and usual lifest yle of the 
patient) Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post
-ovulation 
methods) and withdrawal are not acceptable methods of contraception.
Female sterilization (have h ad surgical bilateral oophorectom y with or without 
hysterectom y) total h ysterectom y or tubal ligation at least six weeks before taking 
LDK378. In case of oophorectom y alone, onl y when the reproductive status of the 
female has been confirmed by  [CONTACT_111842].
Male sterilization (at least 6 months prior to screening). For female patients on the 
study  the vasectomized male partner should be the sole partner for that patient.
Use of oral, injected or implanted hormonal methods of contracept ion or placement of 
an intrauterine device (IUD) or intrauterine s ystem (IUS), or other forms of hormonal 
contraception that have comparable efficacy  (failure rate <1%), for example hormone 
vaginal ring or transdermal hormone contraception.
In case of use of oral contraception females should have been stable on the same pi[INVESTIGATOR_6522] a 
minimum of 3 months before taking LDK378.
19.Sexually  active males, unless they  use a condom during intercourse while taking LDK378 
and for 3 months after stoppi[INVESTIGATOR_111752]378 treatment, and should not father a child in this 
period. A condom is required to be used also b y vasectomized men in order to prevent 
delivery  of the drug via seminal fluid.
20. Patient has other severe acute or chronic medical or psy chiatric condition or laboratory  
abno rmality  that may  interfere with the interpretation of study  results, and in the judgment 
of the investigator would make the patient inappropriate for the stud y.
21.Patient has a history  of pancreatitis or history  of increased am ylase or lipase that was due 
topancreatic disease.
 

[COMPANY_001] Confidential Page 58
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
[ADDRESS_124538] (DAR) eCRF.
6.1.[ADDRESS_124539] 50 mg, and the 
minimum dose will be 50 mg. LDK378 will be administered once daily  by [CONTACT_1966], or by [CONTACT_111843] G tube. For patients who are not able to swallow the capsules, or who will receive 
LDK378 through a NG tube or G tube, the capsules will be opened, and the contents mixed 
with an appropriate food or liquid. Further detailed instructions regarding capsule opening and 
administration will be provided to all study  sites separate from this protocol.
The study site staff will inform each patient of their actual daily  dose, and this will be 
recorded on the appropriate eCRF. The actual dose for each patient will be calculated using a 
body  surface area (BSA) conversion as follows:
Actual dose in mg = (planned dose level (mg/m2) x BSA) rounded to the nearest [ADDRESS_124540] 
site practice (e.g., if the BSA changes b y ± 10% from the previous dose calculation).
Individual doses will consist of the minimum number of capsules possible given based on the 
available ca psule sizes, and will be rounded to the nearest [ADDRESS_124541] be recorded on the appropriate eCRF. Patients/guardians will be asked to complete a 
paper dosing diary  starting Cycle 1 Day 1 and will return the paper dosing diary  to the study  
site at the beginning of each subsequent cy cle (cycle 2 and on). A new diary  will be dispe nsed 
to the patient at the beginning of each new cy cle.
6.1.2 LDK378 administration
LDK378 should be taken as follows:
Patients should take L DK378 once dail y at approximately  the same time each day . On 
days that PK samples are obtained, the patient will take LDK 378 during the clinic visit, 
when instructed b y the study  staff.
For patients enrolled in a fasted cohort each daily  dose of LDK378 (including day s which 
involve PK blood sampling) should be taken at least [ADDRESS_124542] meal and 
patients should not eat until 1 hour after LDK378 is taken.
Each dail y dose of LDK378 should be taken with 1- 2 tablespoons (15 -30 mL ) of an 
appropriate food (such as apple sauce or non -fat yogurt) and a glass of water, and 
consumed over as short a time as possible. Patients should be instructed to swallow 
capsules whole.
 

[COMPANY_001] Confidential Page 59
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
For patients enrolled in a fed cohort each daily  dose of LDK378 (including day s which 
involve PK blood sampling) should be taken with, or within 30 minutes after finishing a 
low-fat light snack containing 10 0-300 calories and 1.5 -2 grams of fat. Each daily  dose of 
LDK378 should be taken with a glass of water, and consumed over as short a time as 
possible. Patients should be instructed to swallow capsules whole.
For patients (including those in fasted cohorts and those in fed cohorts) who have 
difficulty  swallowing intact capsule(s), the capsule(s) may  be opened and the contents 
may be mixed with an appropriate food (such as apple sauce or non -fat yogurt) and eaten, 
or the contents may  be mixed with water and a dministered via a NG tube or G tube. Once 
LDK378 is mixed with the carrier food or water it should be consumed within 2 hours. 
Further detailed instructions regarding capsule opening and administration will be 
provided to all study  sites separate from this protocol. That document will also specify  
other foods and liquids that can be used as a carrier for LDK378, and updated as data 
become available.
If vomiting occurs during the course of treatment, re
-dosing is not allowed before the next 
scheduled dose.
Patients should be instructed not to make up missed doses. A missed dose will include 1) 
when a patient forgets to take LDK378 within 12 hours after the approximate time of the 
usual daily  dosing, or 2) a patient forgets to take his/her dose for that day . That day ’s dose 
should be omitted and the patient should continue treatment with the next scheduled dose.
Patients or guardians should inform the study  site staff of an y missed or delay ed doses.
The investigator should instruct the patient to take the L DK37 [ADDRESS_124543] eCRF. Patients/guardians will be 
asked to complete a paper dosing diary  starting C ycle 1 Day 1 and will return the paper 
dosing diary  to the study  site at the beginning of each subsequent cy cle (cycle 2 and on). 
A new diary  will be dispensed to the patient at the beginning of each new cy cle.
6.1.3 Treatment duration
Patients willcontinue treatment with the study  drug until unacceptable toxicity  that precludes 
any further treatment, disease progression, and/or treatment is discontinued at the discretion of 
the investigator or by [CONTACT_111844]. Patients who have disease progression but who, in the 
opi[INVESTIGATOR_689], have evidence of continued clinical benefit from LDK378 may 
continue to receive LDK378. A treatment cycle is defined as [ADDRESS_124544] be 
followed until resolution or stabilization of the event. Patients requiring interruptions greater 
than 2 cycles (42 days) will be discontinued from study  treatment. In certain cases, if the 
Investigator and the Sponsor conclude that a patient, who has experienced a treatment 
interruption greater than 2 cycles (42 days), could benefit from additional treatment, 
continuation may  be allowed.
6.2 Dose escalation guidelines
 

[COMPANY_001] Confidential Page 60
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
6.2.1 Starting dose rationale
The starting dose of LDK378 in this pediatric study  is based on the clinical safet y data, DLT 
and MTD data from the phase 1 study  ([CLDK378X2101] ) in adult NSCLC patients. In the 
adult phase 1 study  the MTD was 750 mg on a once daily  schedule. Based on the Bayesian 
logistic regression model (BLRM), at the 750 mg dose level the probability  of unacceptable 
toxicity  (DLT rate ≥ 33%) was 3.3% (satisfy ing the overdose criterion of < 25%), and the 
probability  of being within thetarget toxicity  interval (DLT rate ranging from 16% to < 33%) 
was 54%.
The starting dose for the fasted dose escalation, 300 mg/m2, is 66.7% of the adult MTD (0.677 
x 750 mg = 500 mg), scaled by [CONTACT_47735]. Assuming an average adult BSA of 1.7 m2, the starting 
dose is 300 mg/m2(rounded from 294 mg/m2). In the adult phase [ADDRESS_124545] antitumor 
responses 
occurred at doses ≥ 400 mg qd, with < 0.1% probability  of unacceptable toxicity  at 
the 500 mg qd dose level, as determined by [CONTACT_111845]. Thus, a starting dose of 300 mg/m2
offers a high probability of beginning at an active dose, but a low probability  of excessive 
toxicity . Additional information supporting the starting dose is provided in Section 2.3.
6.2.2 Provision al dose levels
Table 6-1describes the starting dose and the dose levels that may be evaluated for the fasted 
dose escalation part during this trial.
Table 6
-1 Provisional dose levels for fasted pediatric dose escalationa
Dose Level Provisional Daily DosebIncrement from previous dose
-1c200 mg/m233% reduction
1 (starting dose) 300 mg/m2Starting dose
2 450 mg/m250% increase
3 560 mg/m225% increase
4 700 mg/m225% increase
5 875 mg/m225% increase
6 1090 mg/m225% increase
a.This table is intended as an example for guidance for the dose escalation part only. Intermediate or 
higher dose levels may be used if the dose -escalation rules presented in this protocol are followed. 
Actual dose levels will be confirmed in writing by [CONTACT_111846] a new cohort.
b.All doses will be dosed on a mg/m2basis, rounded to the nearest 50 mg (refer to Section 6.1.1 for 
details).
c.Dose level - 1 may  be used if appropriate (e.g., if the starting dose level is not well tolerated).
The fasted dose escalation will continue until the MTD and/or the RDE dose is reached. 
Following completion of the dose escalation part of the study , a dose will be chosen for the 
expansion part of the study . The dose for the expansion part will be opened at either the fasted 
MTD, or a lower dose that is determined to be the RDE.
After the fasted dose escalation has reached the MTD and/or RDE, the fed dose escalation 
will begin. The starting dose for the fed dose escalation par t will be approximately  63% of the 
fasted MTD determined in this study . This is based on the data from adult healthy  volunteers 
 

[COMPANY_001] Confidential Page 61
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
taking LDK378 with a low-fat meal. It is estimated that the stead y state exposure of LDK378 
with a low-fat meal will be increase d 1.58 fold. Dose escalations during the fed dose 
escalation part of the study  will be limited to a 25% or smaller increase above the prior fed 
dose level.
Once the fed dose escalation begins, patients will be preferentially  enrolled on the opened fed -
dose escalation cohort; however, patients may continue to be enrolled into the expansion 
cohort at the fasted MTD/RDE if there is no availability  on a fed -cohort.
6.2.3 Guidelines for dose escalation and determination of (MTD/RDE)
For the purposes of dose escalation decisions, each cohort will consist of [ADDRESS_124546] fasted cohort will be 
treated with the starting dose of 300 mg/m2. The first fed cohort will be treated with a starting 
dose of approximately  63% of the fasted MTD determined in this study .
Patients must complete a minimum of [ADDRESS_124547] cycle of treatment to be 
considered evaluable for dose escalation decisions. Dose escalation decisions will occur when 
the cohort of patients has met these criteria.
Dose escalation decisions will be made by [CONTACT_111847]. 
Decisions will be based on a synthesis of all relev ant data available from all dose levels 
evaluated in the ongoing study , including safet y information, DLTs, all CTCAE Grade ≥ 2 
toxicity  data during C ycle 1 and available PK data from evaluable patients. The recommended 
dose for the next cohort of patients will be guided by [CONTACT_111848] 
(BLRM) with EWOC principle.
The adaptive Bayesian methodology  provides an estimate of all dose levels of LDK378 that 
do not exceed the MTD and incorporates all DLT information at all dose levels forthis 
estimation. I n general, the next dose will have the highest chance that the DL T rate will fall in 
the target interval (16- 33%) and will alway s satisfy  the EWOC principle. In all cases, the dose 
for the next cohort will not exceed a 50% (25% after reaching 450 mg/m2) increase from the 
previous dose. Smaller increases in dose may be recommended by [CONTACT_111849].
If the first 2 patients in a cohort experience a DLT, further enrollm ent to that cohort will stop 
and the BLRM will be updated with this new information. Re-evaluation of the available 
safet y and PK data will occur. By [CONTACT_111850], additional patients may  be enrolled at this dose level or a lower dose level as agreed by  
[CONTACT_111851] 25% (EWOC).
Dose escalation will continue until identification of the MTD or a suitable lower dose for 
expansion. This will occur when the following conditions are met:
1.at least [ADDRESS_124548] been treated at this dose.
2. the dose satisfies one of the following conditions:
a.the posterior probabilit y of targeted toxicity  at this dose exceeds 50% and is the 
highest among potential doses, or
 

[COMPANY_001] Confidential Page 62
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
b. minimum number of patients (15 for the fasted state dose escalation, 12 for the fed 
state dose escalation) have alread y been treated on the trial.
3. it is the dose recommended for patients, either per the model o r by [CONTACT_111852] b y [COMPANY_001] and Investigators in a dose -escalation teleconference, see Section [IP_ADDRESS].
Due to the rarity  of pediatric cancers with genetic alterations of ALK and the sm all number of 
patients evaluated at each dose level, and consistent with the typi[INVESTIGATOR_111761] 1 
pediatric oncology  studies, dose escalation decisions will not be based on age categories. 
However, if adequate data become available to indicate that the DLT rate is age-related, the 
protocol may  be amended to define different MTDs in different age categories.
To better understand the safet y, tolerability  and PK of LDK378, additional cohorts of patients 
may be enrolled at preceding dose levels, or to intermediate dose levels before or while 
proceeding with further dose escalation
.
If a decision is made to escalate to a higher dose level but one or more additional patient(s) 
treated at the preceding dose level experiences a DLT during the first cycle oftreatment, then 
the BLRM will be updated with this new information before any additional patients are 
treated at that higher dose level. Patients ongoing will continue treatment at their assigned 
dose levels.
[IP_ADDRESS] Implementation of dose escalation decisions
Toimplement dose escalation decisions, the available toxicity  information (including adverse 
events and laboratory  abnormalities that are not DL Ts), the recommendations from the BLRM, 
and the available PK information will all be evaluated by  [CONTACT_111853] (including the study  physician and statistician) during a dose decision meeting by 
[CONTACT_577]. Drug administration at the next higher dose level may not proceed until the 
investigator receives written confirmation from [COMPANY_001] indicating that the results of the 
previous dose level were evaluated and that it is permissible to proceed to a higher dose level.
[IP_ADDRESS] Intra -patient dose escalation
Intra -patient dose escalation is not permitted at any  time within the first [ADDRESS_124549] 4 cycles of therapy  without any LDK378 -related toxicity  ≥ CTCAE grade 2. The 
proposed higher dose must be a dose that has completed evaluation and has not exceeded the 
maximum tolerated dose (MTD). [COMPANY_001] must be consulted prior to an intra-patient dose 
escalation, and agree with the escalation decision. There is no limit to the number of times a 
patient may have his or her dose of LDK378 increased. The dose change must be recorded on 
the DAR eCRF.
Data from the first cycle of treatment at the new dose level will not be formally  included in 
the statistical model describing the relationship between dose and occurrence of DLT. 
However, these data will be incorporated into the clinical assessment of safety  when 
escalation to a new dose level is considered for the study .
 

[COMPANY_001] Confidential Page 63
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
[IP_ADDRESS] Changing from Fasted to Fed Dosing
Changing from fasted dosing to fed dosing is allowed after the patient has completed at least 
six cy cles of fasted dosing, provided the following:
The MTD/RDE in t he fed state has been determined, and dosing with food has been 
chosen for further expansion
The dose level of LDK378 must remain the same, or be reduced to the MTD/RDE in the 
fed state, if that is lower than the patient’s current dose
The patient must hav e tolerated the fasted dose without any  drug -related toxicity  ≥ Grade 
3, except for nausea, vomiting, diarrhea or abdominal pain
If a patient on the fasted dosing has had a drug
-related toxicity  of ≥ Grade [ADDRESS_124550] had a dose reduction 
and tolerated the reduced dose without a drug -related toxicity  of ≥ Grade [ADDRESS_124551] two 
cycles before changing from fasting dosing to fed dosing
6.2.4 Definitions of dose limiting toxicities (DLTs)
A DLT is defined as an adverse event or abnormal laboratory  value assessed as unrelated to 
disease, disease progression, inter-current illness, or concomitant therapi[INVESTIGATOR_111762] 21 day s (Cy cle 1) of treatment with LDK378 and meets any  of the c riteria included in 
Table 6-2. Any  adverse event is not considered a DL T if it does not happen within the first [ADDRESS_124552] notify  [COMPANY_001] immediately  of any unexpected CTCAE grade ≥ 3 
adverse events or laboratory  abnormalities. Prior to enrolling patients into a higher dose level, 
CTCAE grade 
≥ 2 adverse events will be reviewed for all patients at the current dose level
Table 6-
2 Criteria for defining dose -limiting toxicities
Any adverse event of CTCA E grade 3 or higher during cycle 1 is a DLT, with the following 
exceptions
Hematology ●Neutropenia is a DLT if it is CTCAE grade 4 lasting > 7 day s
●Thromobcy topenia is a DLT if it is CTCAE grade 3 lasting > 7 days 
or CTCAE grade 4 thrombocy topenia at any time 
●Anem ia is a DLT if it is CTCAE grade 4 lasting > 7 days
●Lymphopenia is a DLT if it is CTCAE grade 4
Renal ●Serum creatinine > [ADDRESS_124553] is a DLT Refer to Table 6 -5for 
additional follow up.
Hepatic ●AST or ALT increase is a DLT if CTCAE grade 3 or greater
●Total bilirubin is CTCAE grade [ADDRESS_124554] or ALT CTC AE grade 1 
in the absence of cholestasis or hemolysis. Refer to Table 6 -5for 
additional follow up.
Pulm onary ●Pneumonitis or ILD of any grade without infectious etiology is a 
DLT
 

[COMPANY_001] Confidential Page 64
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Any adverse event of CTCA E grade 3 or higher during cycle 1 is a DLT, with the following 
exceptions
Gastrointestinal ●Nausea and vomiting are DLTs if they are ≥ CTCAE grade 2 
despi[INVESTIGATOR_9025] -emetic therapy
●Amylase and/or lipase elevation ≥ grade 3 is a DLT. Refer to Table 
6-5for additional follow up.
●Diarrhea is a DLT if it is ≥ CTCAE grade 3 despi[INVESTIGATOR_9025] -
diarrhea treatment
Infection ●Infection or fever in the absence of neutropenia are DLTs if they 
are ≥ CTCAE grade [ADDRESS_124555] > 5 days
Electrolytes ●Hypophosphatemia is a DLT if it is ≥ CTCAE grade 3 and lasts > 7 
days
Fatigue ●Fatigue is a DLT if it is ≥ CTCAE grade 3 and lasts > 7 days
Other adverse events Other unacceptable toxicities may  be considered to be DLTs by [CONTACT_111854], even if not CTCAE grade 3 or higher
Any toxicity resulting in an 
excess of missed dosesInability to deliver ≥ 75% of the planned doses in a treatment cy cle 
(i.e. at least 16 doses in a 21 day cycle) because of toxicity at least 
possibly related to LDK378 is a DLT
CTCAE version 4.03 will be used for all grading.
Patients may receive supportive care as per local institutional guidelines.
Optimal therapy for vomiting or diarrhea will be based on institutional guidelines, with consideration of 
the prohibited medications listed in this protoco l.
Dose modification related to DLTs
If a patient experiences a DLT, treatment with LDK378 should be held. Following resolution 
of the toxicity  to grade 1 or to the patient’s baseline value the patient may resume treatment 
with LDK378. In general patients who resume therapy  following a DLT should resume at a 
lower dose level assessed to be safe with a minimum dose reduction of 50 mg. However, 
following recovery  of a DLT that was not considered clinically  important or can be managed 
if it recurs (e.g., replacement of an electrol yte), the patient may resume therap y without dose 
reduction, if the investigator considers that to be in the best interest of the patient. The dose 
should not be reduced below 150 mg/m2. Provisional dose levels for LDK378 are listed in 
Table 6-1.
6.[ADDRESS_124556] be 
followed until resolution or stabilizati on of the event. Patients requiring interruptions greater 
than 2 cycles (42 days) will be discontinued from study  treatment. In certain cases, if the 
Investigator and the Sponsor conclude that a patient, who has experienced a treatment 
 

[COMPANY_001] Confidential Page 65
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
interruption greater than 2 cycles (42 days), could benefit from additional treatment, 
continuation may  be allowed.
LDK378 dose reduction will follow the dose reduction steps described in Table 6-3. For each 
patient, a maxi mum of [ADDRESS_124557]-defined 
PD c onfirmed b y the investigator , the criteria for dose modification will also apply .
Table 6
-3 Dose reduction steps for LDK378 at RDE (fasted and fed states)
LDK378 dose levels Dose* and schedule
Starting dose level RDE: 500/510  mg/m2QD continuously
Dose level -1 400 mg/m2QD continuously
Dose level - 2 300 mg/m2 QD continuously
Dose level -3 200 mg/m2 QD continuously
*Dose reduction should be based on the worst preceding toxicity as per NCI -CTCAE version 4.03
**Dose reduction below 200 mg/m2/day is not allowed. If a dose reduction below 200 mg/m2/day is 
required, the patient should be permanently discontinued from LDK378
Guidelines for dose interruptions and re -initiation of LDK378 treatment (with or without dose 
reduction) are described in Table 6-4.
Patients, who discontinue from the study  for a study -related adverse event or an abnormal 
laboratory  value, must be follo wed as described in Section 7.1.3.
General guidelines for dose modifications for toxicities other than those listed in
Table 6 -
4:
For grade [ADDRESS_124558] be permanently  discontinued.
In the case of a DLT of QTc prolongation (QTc >500 ms) LDK378 must be withheld until 
resolution to grade [ADDRESS_124559] 50 mg. In the case of grade 4 QTc prolongation (QTc >500 ms 
complicated by [CONTACT_111809], polymorphic ventricular tachycardia, or signs/s ymptoms 
of serious arrhy thmia; or >60 ms change from baseline complicated by [CONTACT_111809], 
polymorphic ventricular tachycardia, or signs/sy mptoms of serious arrhy thmia) LDK378 
should be permanentl y discontinued.
Patients whose treatment is interrupted or permanently  discontinued due to an AE must be 
followed until resolution or stabil ization of the event. Patients requiring interruptions greater 
 

[COMPANY_001] Confidential Page 66
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
than 2 cycles (42 days) will be discontinued from study  treatment. In certain cases, if the 
Investigator and the Sponsor conclude that a patient, who has experienced a treatment 
interruption greater than 2 cycles (42 days), could benefit from additional treatment, 
continuation may  be allowed.
 

[COMPANY_001] Confidential Page 67
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Table 6-[ADDRESS_124560] toxicity (CTCA E 4.03 Grade)* Dose Modifications for LDK378
HEM ATOLOGICA L
Neutropenia ( ANC)
Grade 1 (ANC < LLN -1.5 x 109/L)
Grade 2 (ANC < 1.5 and ≥ 1.0 x 109/L)
Grade 3 (ANC < 1.0 and ≥0.5 x 109/L)Maintain dose level
Grade 4 (ANC < 0.5 x 109/L) Omit dose until resolved to ≤ Grade 2, then:
If resolved in ≤ 7 days, then maintain dose level
If resolved in > 7 days, then 1 dose level
Febrile neutropenia
(ANC < 1.0 x 109/L, with a single temperature of ≥ 38.3 °C or a 
sustained temperature of ≥ 38 °C for more than one hour )Omit dose until clinically resolved and neutropenia ≤ Grade 2, then 1 dose level
Thrombocytopenia
Grade 1 (PLT < LLN -75 x 109/L)
Grade 2 (PLT < 75 and ≥ 50 x 109/L)Maintain dose level
Grade 3 (PLT < 50 and ≥25 x 109/L) Omit dose until resolved to ≤ Grade 2, then:
If resolved in ≤ 7 days, then maintain dose level
If resolved in > 7 days, then 1 dose level
Grade 4 (PLT < 25 x 109/L) Omit dose until resolved to ≤ Grade 2, then 1 dose level
HEPA TIC
Alkaline phosphatase and/or Gamma -glutamyl transpeptidase (GGT)
Isolated elevations of any grade Maintain dose level
Total Bilirubin **
(for patients with Gilbert Syndrome these dose modifications apply 
to changes in direct [conjugated] bilirubin only)
Grade 1 (> ULN and ≤ 1.[ADDRESS_124561]) Maintain dose level with liver function test (LFTs)*** monitored as per protocol
 

[COMPANY_001] Confidential Page 68
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Worst toxicity (CTCA E 4.03 Grade)* Dose Modifications for LDK378
Grade 2 (> 1.5 and ≤ 3.[ADDRESS_124562]) with ALT or AST ≤ 3.[ADDRESS_124563] Omit dose until resolved to ≤ Grade 1, then:
If resolved in ≤ 7 days, then maintain dose level
If resolved in > 7 days, then 1 dose level
Grade 3 (> 3.0 and ≤ 10.[ADDRESS_124564]) with ALT or AST ≤ 3.[ADDRESS_124565] Omit dose until resolved to ≤ Grade 1, then:
If resolved in ≤ 7 days, 1 dose level
If resolved in 7 days, discontinue patient from LDK378
Grade 4 (> 10.[ADDRESS_124566]) Permanently discontinue patient from LDK378
AST or A LT
Grade 1 (> ULN and ≤ 3.[ADDRESS_124567]) Maintain dose level with LFTs*** monitored per protocol
Grade 2 (> 3.0 and ≤ 5.[ADDRESS_124568]) without total bilirubin elevation to > 
2.0 x ULNMaintain dose level with LFTs*** monitored per protocol
Grade 3 (> 5.0 and ≤ 20.[ADDRESS_124569]) without total bilirubin elevation 
to > 2.0 x ULNOmit dose until resolved to ≤ Grade 1, then 1 dose level
Grade 4 (> 20.[ADDRESS_124570]) without total bilirubin elevation to > 2.0 x 
ULNOmit dose until resolved to ≤ Grade 1, then [ADDRESS_124571] or ALT > 3.[ADDRESS_124572] with total bilirubin > 2.[ADDRESS_124573] in the 
absence of cholestasis or hemoly sisPermanently discontinue patient from LDK378. Refer to Section [IP_ADDRESS] for 
additional follow -up.
AST or ALT > 5.0 and ≤ 20.[ADDRESS_124574] with total bilirubin > 1.5 and ≤ 
3.0 x ULNPermanently discontinue patient from LDK378 if event reoccurs after dose 
reduction.
PANCREA TIC
Amylase and/or lipase evaluations (in absence of clinical sy mptoms)
Grade 1 (> ULN and ≤1.[ADDRESS_124575]) Maintain dose level
Grade 2 ( >1.[ADDRESS_124576]) Maintain dose level
Grade ≥3 (> 2.[ADDRESS_124577]) Omit dose until resolved to ≤ Grade 1, then 1 dose level
Note: W ithhold LDK378 for acute onset of new or progressive unexplained abdominal symptoms, such as severe pain or vomiting; perform diagnostic 
procedures (e.g., abdominal CT scan or ultrasound) to exclude pancreatic pathology.
REN AL
 

[COMPANY_001] Confidential Page 69
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Worst toxicity (CTCA E 4.03 Grade)* Dose Modifications for LDK378
Serum creatinine
Grade 1 (>1 and ≤1.5 x baseline; >ULN and ≤ 1.[ADDRESS_124578]) Maintain dose level
Grade 2 (>1.5 and ≤3.0 x baseline; > 1.5 and ≤ [ADDRESS_124579]) Omit dose until resolved to ≤ Grade 1, then:
If resolved in ≤ 7 days, then maintain dose level
If resolved in > 7 days, then 1 dose level
Grade 3 (>3.0 x baseline; > 3.0 and ≤ 6.[ADDRESS_124580]) Omit dose until r esolved to ≤ Grade 1, then 1 dose level
Grade 4 (> 6.[ADDRESS_124581]) Permanently discontinue patient from LDK378
GASTROINTESTINA L
Diarrhea****
Grade [ADDRESS_124582] anti -diarrhea treatment
Grade 2 (despi[INVESTIGATOR_76303] -diarrheal medication) Omit dose until resolved to ≤ Grade 1, then maintain dose level.
If diarrhea returns as ≥ Grade 2, then omit dose until resolved to ≤ Grade 1, then ↓ 
1 dose level
Grade 3 (despi[INVESTIGATOR_76303] -diarrheal medication) Omit dose until resolved to ≤ Grade 1, then ↓ 1 dose level
Grade 4 (despi[INVESTIGATOR_76303] -diarrheal medication) Omit dose until resolved to ≤ Grade 1, then ↓ 1 dose level
Nausea*****
Grade [ADDRESS_124583] anti -emetic treatment
Grade 3 (despi[INVESTIGATOR_111763]-emetics) Omit dose until resolved to ≤ Grade 1, then ↓ 1 dose level
Vomiting*****
Grade [ADDRESS_124584] anti -emetic treatment
Grade 2 (despi[INVESTIGATOR_111763] -emetics) Omit dose until resolved to ≤ Grade 1, then maintain dose level.
If vomiting returns as ≥ Grade 2, then suspend dose until resolved to ≤ Grade 1, 
then ↓ 1 dose level.
Grade 3 (despi[INVESTIGATOR_111763] -emetics) Omit dose until resolved to ≤ Grade 1, then ↓ 1 dose level
Grade 4 (despi[INVESTIGATOR_111763] -emetics) Omit dose until resolved to ≤ Grade 1, then ↓ 1 dose level
METABOLIC
Any Grade hy pophosphatemia Treatment with phosphate supplements as clinically indicated and maintain dose 
level
 

[COMPANY_001] Confidential Page 70
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Worst toxicity (CTCA E 4.03 Grade)* Dose Modifications for LDK378
Persistent hyperglycemia (glucose > 250 mg/dL) despi[INVESTIGATOR_111764]-hyperglycemic therapyOmit dose until hyperglycemia is adequately controlled then resume LDK378 at ↓ 1 
dose level
If adequate hyperglycemic control cannot be achieved with optimal medical 
managem ent perm anently d iscontinue patient from LDK378
GENER AL DISORDERS
Fatigue (asthenia)
Grade 1 or 2 Maintain dose level
Grade 3 If grade 3 fatigue resolves to Grade 2 in ≤ 7 day s, maintain dose level
If grade 3 fatigue lasts > 7 days, omit dose until resolved to ≤ Grade 2 and then 
dose level
PULMONA RY 
Notes:
●Withhold LDK378 for acute onset of new or progressive unexplained pulmonary sy mptoms, such as dy spnea, cough and fever and du ring diagnostic 
workup for pneumonitis/ILD. ● During evaluation of potential grade 2, 3, and 4 pneumonitis, if an infectious etiology is confi rmed (i.e., pneumonia) and 
pneum onitis is excluded, then consider resuming LDK378 at current dose level after the pneumo nia resolves.
●For pneumonitis not treatment related: If pneumonitis/ILD of grade [ADDRESS_124585] be permanently discontinued.
PNEUMONITIS 
Any Grade treatment- related ILD/pneumonitis Permanently discontinue patient from LDK378
CARDIA C
Electrocardiogram QT corrected (QTc) interval prolonged
Grade 1 (QTc 450 -480 ms)
Grade 2 (QTc 481 -500 ms)Maintain dose level
 

[COMPANY_001] Confidential Page 71
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Worst toxicity (CTCA E 4.03 Grade)* Dose Modifications for LDK378
Grade 3 (QTc ≥ [ADDRESS_124586] two separate ECGs) Omit dose until QTc is less than 481 ms , then 1 dose level
-Assess the quality of the ECG recording and the QT value and repeat if needed
Repeat ECG in 24 hours, or less, as clinically indicated; continue monitoring as 
clinically indicated until QTc < 481 ms.
In addition:- Determine the serum electrolyte levels (in particular hypokalemia, 
hypomagnesemia). If abnormal, correct abnormalities before resuming study drug 
treatment
-Review concomitant medication use for drugs with the potential to increase the 
risk of drug exposure related to QT prolongation
After resumption of dosing:
-Repeat ECGs 7 days after dose resumption for all patients who had therapy 
interrupted due to QTc ≥ 501 ms.
Grade 4 (QTc ≥ 501 or > 60 ms change from baseline and 
Torsades de pointes or poly morphic ventricular tachycardia or 
signs/sy mptoms of serious arrhythmia)Perm anently discontinue patient from LDK378
BRA DYCA RDIA
Grade 1 or Grade 2 Omit dose until recover y to asy mptomatic brady cardia or to a heart rate ≥ [ADDRESS_124587] the 
dose of LDK378
Grade 3 Omit dose until recover y to asy mptomatic brady cardia or to a heart rate ≥ 60 bpm
Patient may  resume LDK378 at ↓ 1 dose level with frequent monitoring
Grade 4 (in patients taking a concomitant medication also known to 
cause bradycardia or a medication known to cause hypotension)Omit dose until recover y to asy mptomatic brady cardia or to a heart rate ≥ 60 bpm
If the concomitant medication can be adjusted or discontinued, resume LDK378 at 
↓ 1 dose level with frequent monitoring
Grade 4 (in patients who are not taking a concomitant medication 
also known to cause bradycardia or known to cause hypotension)Permanently discontinue patient from LDK378
 

[COMPANY_001] Confidential Page 72
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Worst toxicity (CTCA E 4.03 Grade)* Dose Modifications for LDK378
* Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. All dose modifications should be based on the worst preceding toxicity.
**If Grade [ADDRESS_124588] (non -conjugated) component only, and hemoly sis as the etiology has been ruled out as per 
institutional guidelines (e.g., review of peripheral blood smear and hap toglobin determination), then ↓ 1 dose level and continue treatment at the 
discretion of the Investigator.
***LFTs include albumin, ALT, AST, total bilirubin (fractionated if total bilirubin > 2.[ADDRESS_124589]), alkaline phosphatase 
**** Dose modifications apply to patients who experience diarrhea despi[INVESTIGATOR_111765]. This medication should be started at the 
first sign of abdominal crampi[INVESTIGATOR_007], loose stools or overt diarrhea (see Section 6 .3.2.5 )
***** Dose modifications apply to patients who experience nausea and/or vomiting despi[INVESTIGATOR_111766]. T his medication should be 
started at the first sign of nausea and/or vomiting (see Section [IP_ADDRESS] )
 

[COMPANY_001] Confidential Page 73
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
6.3.2 Follow -up for toxicities
An unscheduled visit should be performed in all cases below where toxicity  monitoring is 
recommended more frequently  than defined by [CONTACT_111855] (Table 7-1). 
For details and frequency refer to Table 6
-5.
[IP_ADDRESS] Guidelines for the follow -up of laboratory  hematologic abnormalities
In case of any occurrence of febrile neutropenia, neutropenia ≥ grade 3, anemia grade 4, or 
thrombocytopenia ≥ grade 3, white blood cell count with differential (including neutrop hil 
count), platelet count and hemoglobin must be measured after [ADDRESS_124590] once a 
week (or more frequently  if clinically  indicated) until the event resolves to ≤ grade [ADDRESS_124591] be performed every  3 weeks (21 days).
Hematopoietic growth factors (e.g., erythropoietins, G-CSF, and GM-CSF) are not to be 
administered proph ylactically . Use of these drugs should be reserved to patients with severe 
neutropenia and anemia as per the labeling of these agents.
[IP_ADDRESS] Guidelines for the follow -up of liver laboratory abnormalities
In patients with any clinically  relevant liver laboratory  abnormality , as defined below, hepatic 
toxicity  monitoring must include ALL of the following LFTs: albumin, ALT, AST, total 
bilirubin (fractionat ed if total bilirubin > 1.5x ULN, and any additional evaluation suggested 
by [CONTACT_111856]), ALP. Note: for patients with 
Gilbert Syndrome, total and direct bilirubin must be monitored, but intensified monitoring
applies to changes in direct bilirubin only .
In case of any occurrence of ALT/AST/total bilirubin increase to grade 2, the LFTs must be 
monitored weekl y (or more frequentl y if clinically  indicated) until the event resolves to ≤ 
grade 1. Thereafter monitor ing must be continued every  2 weeks (or more frequentl y if 
clinically  indicated) for two additional cycles (e.g. 6 weeks). If there is no recurrence of ≥ 
grade 2 ALT/AST/total bilirubin elevations during this period, subsequent monitoring must be 
performed every  [ADDRESS_124592]/AL T at baseline, 
increased monitoring is required for grade 3/[ADDRESS_124593]/AL T; follow guidelines for grade [ADDRESS_124594]/AL T.
In case of any occurrence of ALT/AST/total bilirubin increase to grade 3or 4, LFTs must be 
monitored weekl y (or more frequentl y if clinically  indicated) until the event resolves to ≤ 
grade 1. Thereafter monitoring must be continued every  2 weeks (or more frequentl y if 
clinically  indicated) for four additional cycles (e.g., 12weeks). If there is no recurrence of ≥ 
grade 2 ALT/AST/total bilirubin elevations during this period, subsequent monitoring must be 
performed every  [ADDRESS_124595] be monitored weekl y (or 
more frequentl y if clinically  indicated) until the event resolves to ≤ grade 1 or stabilization 
occurs (no CTCAE grade change over 3 weeks). Refer to Table 6 -5.
Patients with transaminase increase combined with total bilirubin (TBIL) increase may be 
indicative of potential DILI, and should be considered as clinically  important events.
 

[COMPANY_001] Confidential Page 74
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
The threshold for potential DILI may depend on the patient’s baseline AST/AL T and TBIL 
value; patients meeting any of the follow ing criteria will require further follow -up as outlined 
below:
For patients with normal AL T andAST and TBIL value at baseline: AST or AL T > 3.[ADDRESS_124596] combined with TBIL > 2.0 x UL N
For patients with elevated AST or ALT or TBIL value at baseline: [AST or ALT > 2 x 
baseline AND > 3.[ADDRESS_124597]] OR [AST or ALT > 8.[ADDRESS_124598]], combined with [TBIL > 2 x 
baseline AND > 2.[ADDRESS_124599]]
Medical review needs to ensure that liver test elevations are not caused by  [CONTACT_15014], defined 
as: ALP elevation > 2.[ADDRESS_124600] with R value (ALT/ALP in x ULN) < 2 in patients without 
bone metastasis, or elevation of AL P liver fraction in patients with bone metastasis.
Note: (The R value is calculated by  [CONTACT_5358], using multiples of the ULN 
for both values. It denotes the relative pattern of ALT and/or ALP elevation is due to 
cholestatic or hepatocellular liver injury ).
In the absence of cholestasis, these patients should be immediately  discontinued from study 
drug treatment, and repeat LFT testing as soon as possible, prefer ably within 48 hours from 
the awareness of the abnormal results. The evaluation should include laboratory tests, detailed 
history , 
physical assessment and thepossibility of liver metastasis or new liver lesions, 
obstructions/compressions, etc:
Laboratory tests should include ALT, AST, albumin, creatin ine kinase, total bilirubin, 
direct and indirect bilirubin, GGT, prothrombin time (PT)/INR and alkaline phosphatase.
A detailed histo ry, including relevant information, such as review of ethanol, concomitant 
medications, herbal remedies, supplement consumption, history of any  pre-existing liver 
conditions or risk factors, should be collected.
Further testing for acute hepatitis A, B, C or E infection and liver imaging (e g, biliary  tract) 
may be warranted.
Additional testing for other hepatotropic viral infection (CMV, EBV or HSV), 
autoimmune hepatitis or liver biopsy  may  be considered as clinically  indicated or after 
consultation with specialist/hepatologist.
All cases confirmed after repeat testing and meeting the laboratory  criteria defined above, 
with no other alternative cause for LFT abnormalities identified should be considered as 
“medicall y significant”, these cases will meet the definition of SAE (Section 7.2.1) and 
reported as SAE using the term “potential drug-induced liver injury ”. All events should be 
followed up with the outcome clearl y documented.
[IP_ADDRESS] Guidelines for the follow -up of renal laboratory  abnormalities
In case of any occurrence of serum creatin ine grade 2, tests must be performed weekl y (or 
more frequently  if clinically  indicated) until the event resolves to ≤ grade 1. Subsequent 
monitoring must be performed every  3 weeks.
In case of an y occurrence of serum creatinine ≥ grade 3, tests must be pe rformed twice weekl y 
(or more frequently  if clinically  indicated) until the event resolves to ≤ grade 1. Subsequent 
monitoring must be performed every  3 weeks.
 

[COMPANY_001] Confidential Page 75
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
[IP_ADDRESS] Guidelines for monitoring pneumonitis
Monitor patients for pulmonary symptoms indicative of pneu monitis. In addition, withhold 
LDK378 for acute onset of new or progressive unexplained pulmonary  symptoms, such as 
dyspnea, cough and fever and during diagnostic workup for pneumonitis/ILD .Exclude other 
causes of pneumonitis, and follow dose modification guidelines as described in Table 6-4.
[IP_ADDRESS] Guidelines for the treatment of study  treatment -induced diarrhea
The investigator should consider/investigate potential concomitant medication -, food-, or 
comorbidi ty-driven causes of diarrhea (including infectious causes) and remedy  these causes 
if possible (e.g., discontinuation of concomitant medication, dietary  modification, treatment of 
comorbidity ).
The patient should be actively monitored for signs of dehydrat ion and instructed to take 
preventive measures against dehydration as soon as diarrhea occurs.
Antidiarrheal medication must be initiated at the first sign of abdominal crampi[INVESTIGATOR_007], loose 
stools or overt diarrhea. Concomitant medication for the treatment of diarrhea should follow 
local practices and the Investigator’s best judgment and may follow “the recommended 
guidelines for the treatment of cancer treatment -induced diarrhea” (Benson et 
al 2004). For 
example:
For uncomplicated diarrhea (grade 1 or 2 without complicating signs or s ymptoms), 
loperamide given at the usual pediatric dose as per local Label , along with oral hy dration, 
and dietetic measures should be considered. Note: complicating signs or s ymptoms 
include: moderate to severe crampi[INVESTIGATOR_007], decreased performance status, fever, neutropenia, 
frank bleeding or deh ydration.
For complicated diarrhea (all grade 3 or 4, grade 1 -
2 with complicating signs or 
symptoms), management should involve I V fluids, and consider treatment with antibiotics 
(e.g., fluoroquinolone) should be given.
Dose adaptation of LDK378 in case of treatment -related diarrhea must follow the guidelines 
presented above in Table 6 -4.
[IP_ADDRESS] Guidelines for the treatment of study  treatment -induced nausea and 
vomiting
Nausea and vomiting 
are among the most frequently  reported AEs following treatment with 
LDK378 and patients must therefore be closel y monitored for the appearance of these AEs.
The investigator should also consider/investigate potential concomitant medication-, food-, or 
comorbidity -driven causes of nausea and/or vomiting and remedy  these causes if possible 
(e.g., discontinuation of concomitant medication, dietary  modification, treatment of 
comorbidity ).
Individualized supportive and anti-emetic treatment should be initiated, as appropriate, at the 
first signs and/or symptoms of these AEs. In patients with vomiting, the patient should be 
monitored for signs of dehydration and instruct ed to take preventive measures against 
dehy dration.
 

[COMPANY_001] Confidential Page 76
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Concomitant medication for the treatment of nausea and/or vomiting should follow local 
practices and the Investigator’s best judgment. For moderatel y emetogenic drugs, such as 
LDK378 , International Guidel ines for anti-emetic treatment recommend early treatment with 
5-HT3-receptor antagonists (5 -HT3RAs).
Dose adaptation of LDK378 in case of treatment related nausea and/or vomiting must follow 
the guidelines presented above in Table 6 -4.
[IP_ADDRESS] Guidelines for the 
treatment of hypophosphatemia
In the phase I study  [CLDK378X2101] conducted in adult patients, as of 31-Oct- 2013, there 
were 9 cases of grade 3 hypophosphatemia observed in all dose groups, one of which was a 
DLT that contributed to the MTD determination –this patient was able to continue LDK378 
at the same dose. One patient in the 750 mg group had a grade 3 hypophosphatemia that 
resolved after dose adjustment or interruption; in the remaining 8 
cases, patients were able to 
continue therapy  without dose modification. Hypophosphatemia was not among the 
commonly  reported AE (6.3%), regardless of relationship to LDK378 treatment.
Therefore, phosphate levels will be checked during treatment. For any grade of 
hypophosphatemia during the study , treatment with phosphate supplements should be given as 
clinically  indicated, and t he LDK378 dose can be maintained.
[IP_ADDRESS] Guidelines for the follow -up of laboratory  pancreatic abnormalities
In case of any occurrence of lipase or amylase increase to grade [ADDRESS_124601] be monitored weekly  (or more frequently  if clinicall y indicated) until the event 
resolves to ≤ grade 1 (or to baseline).
After resumption of dosing, monitoring must be continued weekl y (or more frequently  if 
clinically  indicated) for one additional cy cle (i.e. 3 weeks). If there is no recurrence of ≥ grade 
[ADDRESS_124602] be monitored weekl y 
(or more frequently  if clinically  indicated) until the ev ent resolves to ≤ grade 1 or stabilization 
occurs (no CTCAE grade change over 3 weeks). Refer to Table 6 -5.
If amylase and/or lipase elevations are accompanied by [CONTACT_111857], withhold ceritininb, then perform 
diagnostic procedures (e.g., abdominal CT scan or ultrasound) to exclude pancreatic 
pathology .
See also dose modification guidelines described in Table 6-4.
 

[COMPANY_001] Confidential Page 77
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Table 6-5 Follo w up evaluations for selected toxicities
Toxicity Follow -up evaluation*
Investigations 
(hematologic)Febrile neutropenia or thrombocytopenia ≥ CTCA E Grade 3 or
Neutropenia or anemia ≥ CTCA E Grade 4
White blood cell count with differential (including neutrophil count), platelet count 
and hemoglobin must be measured after [ADDRESS_124603] once a week until 
resolution to ≤ CTCAE grade 2 or baseline.
Neutropenia ≥ CTCA E Grade [ADDRESS_124604] once a week until ≤ Grade [ADDRESS_124605] be performed ever y cycle (3 weeks)
Investigations 
(hepatic)Total bilirubin/A ST/A LT Grade 2 : (patients with liver metastasis and grade [ADDRESS_124606]/ALT at baseline, increased monitoring required for grade 3 ALT/AST. Follow 
guidelines for grade [ADDRESS_124607]/ALT
Test weekly (or more frequently) until ≤ Grade [ADDRESS_124608] ever y 2 weeks (or m ore frequently ) for 2 cycles (6 
weeks)
If no recurrence of ≥ Grade 2 event, continue monitoring every c ycle (3 weeks)
Total bilirubin/A LT/A ST ≥ Grade 3 :
Test weekly (or more frequent) until ≤ Grade [ADDRESS_124609] ever y 2 weeks (or more fre quently ) for 4 cycles (12 
weeks)
If no recurrence of ≥ grade 2 event, continue monitoring every c ycle (3 weeks)
Discontinuation due to liver toxicity :
Test weekly (or more frequent) until ≤ Grade 1 or stabilization
Investigations 
(renal)Serum creatinine Grade 2 :
Test weekly (or more frequent) until Grade [ADDRESS_124610] every c ycle (3 weeks)
Serum creatinine ≥ Grade 3 :
Test twice weekly (or more frequent) until ≤ Grade [ADDRESS_124611] every c ycle (3 weeks)
Investigations 
(pancreatic)Amylase/lipa se ≥ Grade 3:
Test weekly (or more frequently) until ≤ Grade 1. After resumption of dosing, 
continue to test weekly for one additional cycle (3 weeks). If no reoccurrence of ≥ 
Grade 2 event, continue monitoring ever y cycle (3 weeks) .
Investigations
(gastr ointestinal)Vomiting or diarrhea
Measure blood electrolytes at least once a week until the sy mptoms have resolved 
to ≤ CTCAE grade [ADDRESS_124612] be followed weekly  as deemed 
clinically appropriate until resolved to ≤ CTCAE grade 2 or baseline.
*Note: this table refers to the evaluation schedule only. Refer to Table 6 -4for dose modifications 
required for appli cable toxicities
 

[COMPANY_001] Confidential Page 78
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
6.4 Concomitant medications
6.4.1 Permitted concomitant therapy
[IP_ADDRESS] Corticosteroids
Chronic dosing of corticosteroids such as dexamethasone and prednisone is known to induce 
CYP3A enzymes, thereby  [CONTACT_111858]378 drug exposure to sub-
therapeutic levels.
If possible, sy stemic corticosteroid treatment should not be given during the study , except for:
Topi[INVESTIGATOR_14929] (e.g. ,rash), inhaled sprays (e.g., obstructive airway s diseases), 
eye drops or local injections (e.g.,intra-articular);
Stable doses of corticosteroid therap y such as dexamethasone and prednisone (e.g., for 
tumor associated s ymptoms) are permitted during the course of the study . The 
corticosteroid dose must have been stabilized (or decreasing) for at least 5 days before 
initiating study  therapy
[IP_ADDRESS] Bisphosphonates
The use of bisphosphonates is allowed regardless of indication provided patients have been on 
stable doses optimally  for at least 4 weeks prior to the start of treatment. Patients requiring 
initiation of bisphosphonate treatment during the course of the study  should be evaluated for 
progressive disease and the result of the evaluation should be clearl y documented in the 
patients’ source documentation.
No drug-drug interaction is expected betw een LDK378 and bisphosphonates as the two drugs 
are eliminated through different elimination pathway s. Bisphosphonates are not inhibitors of 
human CYP450 enzy mes involved in the metabolism of LDK378 and do not undergo 
metabolism in vivo.The same guidelines appl y to the use of denosumab for the treatment of 
bone metastatic disease.
[IP_ADDRESS] Drugs that are metabolized by  [CONTACT_097]450 enzymes
In vitro drug metabolism studies show that the metabolism of LDK378 is mediated by 
[CONTACT_097]3A4/5. LDK378 is a time-dependent CYP3A4/5 inhib itor and is also a potent reversible 
inhibitor of CYP2A6, 2E1, 2C9 and 3A4/[ADDRESS_124613] of LDK378 on substrate drugs metabolized 
by [CONTACT_111859]. The risk for CYP2A6 and CYP2E1 is largely  mitigated by [CONTACT_111860]- administered with LDK378 .
Concomitant treatment ofLDK378 with weak inhibitors or inducers of CYP3A4/5 is 
permitted. Caution is advised when LDK378 is co-administered with drugs that are moderate 
inhibitors or inducers of CYP3A4/5 (Appendix 2).Duration of concomitant treatment should 
be kept as short as possible (e.g., less than 1 week), or completel y avoided whenever possible. 
Patients receiving such medications must be monitored closely  for any potentiation of toxicity  
or decrease of clinical benefit due to an y individual concomitant medications, and may  require 
 

[COMPANY_001] Confidential Page 79
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
dose titration or adjustment. Note that co-administration of LDK378 with strong inhibitors or 
inducers of CYP3A4/5 is prohibited (refer to Section 6.4.2 ).
Concomitant treatment of LDK378 with medications known to be metabolized by [CONTACT_097]2C9 
and CYP3A4 is allowed with caution (Appendix 2), except for drugs which have narrow 
therapeutic 
index/sensitive substrates for these CYP isoforms (Appendix 2 ).
[IP_ADDRESS] Non- enzy me inducing anti -epi[INVESTIGATOR_111767]-enzy me inducing anti -epi[INVESTIGATOR_7377] (Non- EIAED) is allowed.
[IP_ADDRESS] Palliative radiotherapy and surgery
Local radiotherap y for analgesic purposes, or for lytic lesions at risk of fracture may be 
carried out if required. If palliative radiotherap y is initiated after start of study  treatment, the 
reason for its use must be clearl y documented and progression asper RECI ST 1.[ADDRESS_124614] be 
assessed and documented. 
Patients who develop progressive disease but are still deriving clinical benefit from ceritinib 
therap y, as determined by  [CONTACT_941] I nvestigator may  undergo radiotherapy  and/or surgical resection 
as palliative lo calized therapy  to treat metastatic lesions. Ceritinib should be held for at least [ADDRESS_124615] 1 day prior to any surgery . Ceritinib may be resumed 
≥3 day s after completing radiotherap y or minor surgery, and ≥2 weeks after maj or surgery .
[IP_ADDRESS] Gastric protection agents
The use of gastric protection agents including antacids, H2-antagonists, and proton pump 
inhibitors (PPIs) is allowed (Appendix 2). However, PPIs should be used with caution due to 
the theoretical effects of long-acting pH elevating agents 
(i.e., prolonged acid suppression) on 
reducing LDK378 absorption. When the concurrent use of a H2-
antagonist or an antacid with 
LDK378 is necessary , the H2 blocker must be administe red [ADDRESS_124616] be administered 2 hours before or 2 hours after the 
LDK378 dose. Time restrictions for the concurrent use of PPIs and LDK378 are not 
applicable due to the long-acting effects of PPIs on gastric pH (i.e., separation of doses will 
not likely  impact this interaction).
6.4.2 Prohibited concomitant therapy
[IP_ADDRESS] Other anticancer therapy
Anticancer therapy  (chemotherap y, targeted therapy , biologic therapy  or radiation therap y 
[except palliative radiot herap yand palliative surgery  as described in Section [IP_ADDRESS]], and 
anti-cancer surgery ), other than the study  treatment, must not be given to patients while they 
are enrolled in the treatment portion ofthe trial. If such agents are 
required then the patient 
must be permanentl y discontinued from the treatment portion of the study.
[IP_ADDRESS] Other investigational therapi[INVESTIGATOR_111768] .
 

[COMPANY_001] Confidential Page 80
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
[IP_ADDRESS] Warfarin and coumarin derivatives
Therapeutic doses of warfarin sodium or any  other coumarin -derivative anticoagulants are not 
permitted. LDK378 is an inhibitor of CYP2C9, the major metabolizing enzy me of warfarin. A 
clinically  relevant increase in warfarin exposur e is possible.
[IP_ADDRESS] Enzy me inducing anti -epi[INVESTIGATOR_111769]. Refer to Appendix [ADDRESS_124617] of prohibited EIAED.
If a patient is currentl y taking an EIAED, he/she must have disconti nued the EIAED therapy 
for at least 1 week prior to starting stud y drug.
If a patient was previously  on a non-EIAED and needs to permanentl y change anticonvulsant 
agent but cannot change to another non -EIAED, the patient will be taken off LDK378 .
[IP_ADDRESS] Strong CY P3A inhibitors and inducers
In vitro metabolism studies suggest that oxidative metabolism of LDK378 is predominantl y 
mediated b y CYP3A4/5.
Strong inhibitors or inducers of CYP3A4/5 are prohibited. Patients receiving concomitant 
medications known to strongl y inhibit and/or induce CYP3A4/[ADDRESS_124618] may  not be comprehensive
.
[IP_ADDRESS] Medications that are CYP2C9 and CYP3A 4/5 substrates with narrow  
therapeutic index
LDK378 is a potent inhibitor of drugs metabolized by [CONTACT_097]2C9 and CYP3A4/[ADDRESS_124619] may  not be comprehensive.
[IP_ADDRESS] Herbal medications
Herbal preparations/medications are not allowed throughout the study , as a potential drug-
drug interaction is always possible. These herbal medications include, but are not limited to: 
St. John’s wort, Kava, ephedra (ma huang), gingko biloba, dehy droepi[INVESTIGATOR_2119] (DHEA), 
yohimbe, saw palmetto, and ginseng.
Patients 
should stop using herbal medicat ions at least [ADDRESS_124620] dose of study 
treatment and may  be resumed 9 day s (5 ceritinib half life) after stud y drug discontinuation.
[IP_ADDRESS] Medications that may prolong the QT interval or have a known risk of 
inducing Torsades de Pointes
LDK378 has potent activity  on the hERG channel with an IC50of 0.4 μM. There were no 
LDK378 -
related effects in vivo in monkey s at doses as high as 100 mg/kg (human equivalent 
dose [HED] of 1950 mg).
 

[COMPANY_001] Confidential Page 81
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Serial ECGs were collected following a single dose and at stead y-state to evaluate the effect 
of LDK378 on the QT interval in an open -label, dose-escalation, and expansion [Study  
CLDK378X2101]. A total of 304 patients were treated with LDK378 doses ranging from 50 
to 750 mg with 255 patients treated with LDK378 750 mg. One of304 patients (<1%) was 
found to have a QTc >500 msec and 10 patients (3.3%) had an increase from baseline 
QTc >60 msec. A central tendency  analysis of the QTc data at average steady -state 
concentrations demonstrated that the upper bound of the 2-sided 90% CI for QTc was 16 
msec at LDK378 750 mg. A pharmacokinetic/pharmacod ynamic analysis suggested 
concentration -dependent QTc interval prolongation
Concomitant use of LDK378 and any medication included in Appendix 2, Table 14-11 titled 
“List of prohibited QT prolonging drugs” (i.e., drugs that are generally accepted by [CONTACT_111861].org Advisory  Board of the Arizona CERT 
to have a known risk of causing Torsa des 
de Pointes) is not permitted.
6.5 Patient numbering, treatment assignment or randomization
6.5.1 Patient numbering
Each patient is identified in the study  by a Patient Number (Patient No.), assigned when the 
patient is first pre-screened and is retained as the primary  identifier for the patient throughout 
his/her entire participation in the trial. The 
Patient No. consists of a 4-digit Center Number 
(Center No.) (as assigned by [CONTACT_111862]) with a sequential 5-digit patient 
number suffixed to it, sothat each patient is numbered uniquel y across the entire database. 
Upon signing the pre-screening informed consent/assent form (ICF), the patient is assigned to 
the next sequential Patient No. available to the investigator.
6.5.[ADDRESS_124621] the patient/guardian to 
take/dispense LDK378 as per protocol. LDK378 will be dispensed to the patient by  [CONTACT_111863]. All dosages prescribed to the patient and all dose changes during the 
study  must be recorded on the DAR eCRF.
Patients/guardians will be asked to complete a paper dosing diary  starting Cycle 1 Day 1
 and 
will return the paper dosing diary  to the study  site at the beginning of each subsequent cycle 
(cycle 2 and on). A new diary  will be dispensed to the patient at the beginning of each new 
cycle.
 
 
 
 
 

[COMPANY_001] Confidential Page 82
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
 
6.6.[ADDRESS_124622] access. Upon receipt, LDK378 should be stored according to the instructions 
specified on the drug labels.
6.6.3 Study drug compliance and accountability
[IP_ADDRESS] Study drug compliance
Compliance will be assessed by [CONTACT_1755]/or study  personnel at each patient visit 
and information provided by [CONTACT_5363]/or caregiver will be captured in the Drug 
Accountability  Form. This information must be captured in the source document at each 
patient visit. Patients/guardians will be asked to complete a paper dosing diary  starting Cycle 
1 Day 1 and will return the paper dosing diary to the study  site at the beginning of each 
subsequent cycle (cycle 2 and on). A new diary will be dispensed to the patient at the 
beginning of each new cycle.
On days when LDK378 is administered to the patient by [CONTACT_8887] (e.g. PK sampling 
days), compliance will be assured by [CONTACT_111864]378 under the supervision of 
investigator or his/her designee, and will be verified by  [CONTACT_111865]378 in plasma.
[IP_ADDRESS] Study drug accountability
The investigator or designee must maintain an accurate record of the shipment and dispensing 
of LDK378 in a drug accountability  log. Drug accountability  will be noted by [CONTACT_5364] . Patients will be asked to return 
all unused LDK378 and packaging on a regular basis, at the end of the study  or at the time of 
LDK378 discontinuation.
At study  close-out, and, as appropriate during the course of the study , the investigator will 
return all used and unused L DK378, packaging, drug labels, and a copy  of the completed drug 
accountability  logto the [COMPANY_001] monitor or to the [COMPANY_001] address provided in the 
investigator folder at each study site.
6.6.[ADDRESS_124623] party, 
as appropriate.
7 Visit schedule and assessments
7.1 Stud y flow and visit schedule
Table 7-1lists all of the assessments and indicates with an “X”, the visits when they are 
performed. All data obtained from these assessments must be sup
ported in the patient’s source 
 

[COMPANY_001] Confidential Page 83
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
documentation. No eCRF will be used as a source document. Visit windows can be found for 
procedures starting with Section 7.2.
 

[COMPANY_001] Confidential Page 84
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Table 7-1 Visit evaluation schedule
Category
Protocol Section
Pre-screening
Screening/ BaselineTreatment Period
End of study 
treatment (EoT)
Study Evaluation 
Completion (SEC)Cycle 1 Cycle 2 Cycles 3 -4 Cycles 5 -16Odd # 
Cycle ≥ 
17 
(teleph
one 
call)Even # Cycle 
≥ 18 (on site 
visit)
Visit Name 1 2 3 4 5 6 7 8 9 10 11 14+ 15+ 36
+37
+38+ 39+ [ADDRESS_124624] 30-
day 
follo
w-up
Obtain molecular pre -screening 
informed consentD7.1.1 . X
Obtain main informed consent D7.1.1 . X
Collection of tumor paraffin block or 
slides (archival tumor or tumor collected 
specifically for this study) for ALK 
assessment (only if ALK testing being 
performed at central lab)D7.1.1 . X
Patient history
Demography D7.1.1.3 . X X
Inclusion/exclusion criteria D5.2/5.3. X
Medical History D7.1.1.3 . X
Diagnosis and extent of cancer D [IP_ADDRESS] . X
Prior/concomitant therapi[INVESTIGATOR_014] (including 
prior antineoplastic therapi[INVESTIGATOR_014])D7.1.1.3 . Continuous
Antineoplastic therapi[INVESTIGATOR_111770]378D7.1.3 . X
 

[COMPANY_001] Confidential Page 85
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103Category
Protocol Section
Pre-screening
Screening/ BaselineTreatment Period
End of study 
treatment (EoT)
Study Evaluation 
Completion (SEC)Cycle 1 Cycle 2 Cycles 3 -4 Cycles 5 -16Odd # 
Cycle ≥ 
17 
(teleph
one 
call)Even # Cycle 
≥ 18 (on site 
visit)
Visit Name 1 2 3 4 5 6 7 8 9 10 11 14+ 15+ 36
+37
+38+ 39+ [ADDRESS_124625] 30-
day 
follo
w-up
Physical examination, including 
neurological examS7.2.2.1 . X X X X X X X X X
Performance status Karnofsky (> 12 
years old) OR Lansky (≤ 12 years old)D7.2.2.4 . X X X X X X X
Height D7.2.2.3 . X X X X X X
Weight D7.2.2.3 . X X X X X X
BSA D7.2.2.3 . X X X X X
Vital signs D7.2.2.2 . X X X X X X X X X
Laboratory  assessments
Hematology
** done at local laboratoryD7.[IP_ADDRESS] . X X X X X X X X X X*
*X X
Chemistry
** done at local laboratoryD7.[IP_ADDRESS] . X X X X X X X X X X*
*X X
Pregnancy test
** done at local laboratoryD7.[IP_ADDRESS] . X X X X X X*
*X X
 

[COMPANY_001] Confidential Page 86
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103Category
Protocol Section
Pre-screening
Screening/ BaselineTreatment Period
End of study 
treatment (EoT)
Study Evaluation 
Completion (SEC)Cycle 1 Cycle 2 Cycles 3 -4 Cycles 5 -16Odd # 
Cycle ≥ 
17 
(teleph
one 
call)Even # Cycle 
≥ 18 (on site 
visit)
Visit Name 1 2 3 4 5 6 7 8 9 10 11 14+ 15+ 36
+37
+38+ 39+ [ADDRESS_124626] 30-
day 
follo
w-up
Tumor evaluations
Radiological tumor evaluation (± 7 days) 
* post Cycle 14, collect on D15 every six 
cycles: Cycles 20, 26, 32, etc. until off 
studyD7.2.1 . X X C4 C6 
C10
C14X* X
MIBG imaging
(neuroblastoma patients only) (± 7 days) 
*post Cycle 14, collect on D15every six 
cycles: Cycles 20, 26, 32, etc. until off 
studyD7.2.1 . X If 
positive 
at 
BaselineIf 
positive 
at 
Baseline 
C4If posit -
ive at 
Base -
line 
C6, 
C10
C14If positive 
at 
Baseline*If 
posit -
ive at 
base-
line
Bone marrow bilateral aspi[INVESTIGATOR_26673] (neuroblastoma and lymphoma 
patients only) (±7 days)D7.2.1 . X Optional 
except in 
case of 
radiologi
cal CR Optional 
except in 
case of 
radiologi
cal CROptional 
except in 
case of 
radiologic
al CROptio
nal 
exce
pt in 
case 
of 
radiol
ogical 
CR 
ECG D7.[IP_ADDRESS] . X X X X X X X
 

[COMPANY_001] Confidential Page 87
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103Category
Protocol Section
Pre-screening
Screening/ BaselineTreatment Period
End of study 
treatment (EoT)
Study Evaluation 
Completion (SEC)Cycle 1 Cycle 2 Cycles 3 -4 Cycles 5 -16Odd # 
Cycle ≥ 
17 
(teleph
one 
call)Even # Cycle 
≥ 18 (on site 
visit)
Visit Name 1 2 3 4 5 6 7 8 9 10 11 14+ 15+ 36
+37
+38+ 39+ [ADDRESS_124627] 30-
day 
follo
w-up
Safety
Adverse events D8.1. Continuous
 
 
 
 
LDK378 administration D6.1. Continuous
PK sampling (* indicates during 
Escalation only)D7.3.1 . X
*X* X* X X X
Meal record (* indicates during 
Escalation only)D XX* X X X* X
 

[COMPANY_001] Confidential Page 88
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
7.1.1 Molecular pre -screening and screening examin ation
Only  patients with tumors carry ing a genetic alteration of ALK are eligible for this study . 
Patients will be considered potentiall y eligible if their tumor carries a mutation (including 
point mutations, insertions and deletions), rearrangement (including translocations and intra-
chromosomal rearrangements), or amplification involving the ALK gene, as long as the 
alteration does not clearly  result in inactivation of the kinase activity , such as deletion of the 
kinase domain, or a stop codon preventing translation of the kinase domain.
If the ALK tumor status is unknown when the patient is initially  considered for this study, 
patients/guardians will be asked to sign the molecular pre-screening ICF. The study  sites will 
pre-screen patients for genetic alterations of ALK by [CONTACT_5583] a tumor sample to a laboratory 
designated by [CONTACT_5343]. The tumor sample may  be a previously  obtained archival sample, or a 
sample obtained for the purpose of molecular pre-screening for this study  (tumor paraffin 
block or slides) . Additionally , a pathology  report should be submitted along with the patient’s 
archival tumor block/slides. The ALK analysis results will be communicated to the study 
center within approximately  [ADDRESS_124628] a genetic alteration of ALK at pre-screening, the laboratory  result may be used for 
eligibility  assessment, if [COMPANY_001] reviews the laboratory  assessment and agrees that it is 
sufficient for eligibility .
[IP_ADDRESS] Molecular pre -screening and screening period
 
 
 
 
 
 
 
 
 
 
 

[COMPANY_001] Confidential Page 89
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Patient re-screening is allowed and should be discu ssed with [COMPANY_001] on a case by [CONTACT_111866] -screening procedures are performed.
[IP_ADDRESS] Information to be collected on screening failures
Patients who sign the molecular pre-screening ICF but do not meet the pre-screening 
requirements will be considered ascreen failure. The reason will be entered on the Screening 
Log eCRF, and each patient’s demographic information will be added to the Demograph y 
eCRF. No other data will be entered into the clinical database for patients who are screen 
failures.
Patients who meet molecular pre-screening requirements and sign the main ICF but do not 
start treatment for any reason will be considered a screen failure. The reason for not being 
started on treatment will be entered on the Screening Log eCRF, and each patient’s 
demographic information will be added to the Demograph y eCRF. No other data will be 
entered into the clinical database for patients who are screen failures.
[IP_ADDRESS] Patient demographics and other baseline characteristics
The data that will be collected on patient characteristics at 
molecular pre-screening and 
baseline include general demographics, relevant medical history , the diagnosis and extent of 
their tumor/s and details regarding anti-neoplastic treatments that they have received in the 
past.
7.1.[ADDRESS_124629] cycle (C1D1) of LDK378 and 
ends after the last dose of L DK378.
Patients who enter the study  will be treated with continuous once daily  dosing of oral 
LDK378 until objective evidence of progression of disease, occurrence of unacceptable 
toxicities, or patient withdrawal.
During the study  treatment period, patients will be regularl y monitored to assess the safety 
and early  anti-tumor activity  of the treatment. For the purpose of scheduling and evalu ations, 
a treatment cy cle will consist of 21 day s.
For details of assessments during the treatment period, refer to Table 7 -1.
7.1.3 End of treatment visit
At any time, patients may voluntarily  withdraw from the study  or be removed from it at the 
discretion of the investigator. If withdrawal occurs, or if the patient fails to return for visits, 
effectivel y withdrawing, the investigator should make a reasonable effort (e,g. telephone, e
-
amil, letter) to understand the primary  reason for a patient’s premature withdrawal, record this 
information on the End of Treatment eCRF, and notify  [COMPANY_001]. Patients may be withdrawn 
from LDK378for one of the following reasons:
1.Adverse event(s).
2.Disease progression.
3.Protocol violation/deviation.
 

[COMPANY_001] Confidential Page 90
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
4. Patient withdrew consent.
5.Lost to follow -up.
6.Death.
Patients who discontinue LDK378 for any of the above reasons (except death) should be 
scheduled for an end of treatment (EOT) visit 14 days (up to 21 days) after discontinuing 
LDK378, at which time all of the assessments listed for the EOT visit will be performed. An 
EOT eCRF will be completed, giving the date and reason for stoppi[INVESTIGATOR_111771]378.
The EOT completion evaluations include the following:
A phy sical examination, including an a ssessment of any  tumor lesions; Karnofsky /Lansky  
performance status; height/weight and vital signs; hematology ; chemistry ; pregnancy  test 
for FCBP.
Radiological tumor evaluation of all tumor sites, if not evaluated ≤ 28 day s prior to the 
EOT visit, and if objective evidence of disease progression has not previously  been 
documented.
For neuroblastoma patients: MI BG imaging, if positive at baseline and not evaluated ≤ 28 
days prior to the EOT visit.
For neuroblastoma and ly mphoma patients: If bone marrow bila teral aspi[INVESTIGATOR_111772], it will be left to the investigator’s 
discretion to monitor the bone marrow aspi[INVESTIGATOR_111773]. In order to 
confirm a Complete disease Response (CR), bone marrow bi opsy or aspi[INVESTIGATOR_111774] a radiological CR has been achieved.
ECG.
Occurrence of new AEs and status of current AEs.
Collection of a fresh tumor biopsy , if medically  feasible, and the patient and/or guardian 
agrees.
All patients who discontinue LDK378 , including those who refuse to return for a final visit, 
should be contact[INVESTIGATOR_530] 30 days (up to 37 days) after discontinuing LDK378 for safet y 
evaluations and a list of concomitant medications, including antineoplastic therapi[INVESTIGATOR_111775] (Study  Evaluation Completion (SEC) visit). See Section 7.1.4. A SEC 
eCRF will then be completed, giving the date and reason for study  discontinuation.
For patients who refuse to return for visit
s or are unable to do so, every  effort should be made 
to contact [CONTACT_18622] a knowledgeable informant by [CONTACT_756]. Patients lost to follow up should 
be recorded as such on the Study  Evaluation Completion eCRF. A patient is considered “lost -
to-follow up” if the patient fails to show up for a scheduled follow -up visit and no response 
despi[INVESTIGATOR_111776] [ADDRESS_124630] the patient, such as via phone calls 
and / or registered letters. The investigator should show “due diligence” by [CONTACT_111867] (e.g., dates of telephone calls, 
registered letters, etc).
Patients whose treatment is interrupted or permanently  discontinued due to an AE must be 
followed until resolution or stabilization of the event. Patients requiring interruptions greater 
than 2 cycles (42 days) will be discontinued from study  treatment
. In certain cases, if the 
Investigator and the Sponsor conclude that a patient, who has experienced a treatment 
 

[COMPANY_001] Confidential Page 91
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
interruption greater than 2 cycles (42 days), could benefit from additional treatment, 
continuation may  be allowed.
Patients who discontinue from the study  for a study -
related adverse event will be followed for 
toxicity , as described above. All patients should be followed for adver se events and serious 
adverse events for 30 days (up to 37 days) following the last dose of LDK378 (Study  
Evaluation Completion (SEC) visit).
Patients who discontinue from LDK378 (e.g., due to disease progression) during Cycle [ADDRESS_124631] all the remaining evaluations for C ycle 1 performed prior to LDK378 completion.
The EOT visit is not considered the end of the study .
[IP_ADDRESS] Patient replacement
Escalation:
Patients will not be replaced on study . However, if a patient is considered as non-evaluable 
for the DDS (Dose Determining Set), enrollment of a new patient to the current cohort will be 
considered if there is less than the required number of evaluable patients. Enrollment of new 
patients may be considered until at least 
the minimum number (3) or at most the maximum 
number (6) of evaluable patients is achieved within the cohort. Minimum and maximum 
numbers of evaluable patients per cohort are defined in Section 6.2.3.
Expansion:
Patients will not be replace d.
[IP_ADDRESS] Withdrawal of Consent
Patients may voluntaril y withdraw consent to participate in the study  for any reason at any 
time. Withdrawal of consent occurs only when a patient does not want to participate in the 
study  any longer, and does not 
allow further collection of personal data.
In this situation, the investigator should make a reasonable effort (e.g. telephone, e-mail, 
letter) to understand the primary  reason for the subject’s decision to withdraw his/her consent 
and record this information.
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.
Further attempts to contact [CONTACT_111868] -up. 
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the subject’s study  withdrawal should be made as detailed in the 
assessment table. [COMPANY_001] will continue to keep and use collected study  information 
(including any data resulting from the analysis of a subject’s samples until their time of 
withdrawal) according to applicable law . 
 

[COMPANY_001] Confidential Page 92
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
All biological samples not yet analyzed at the time of withdrawal will no longer be used, 
unless permitted by [CONTACT_1289]. They  will be stored according to applicable legal 
requirements .
7.1.[ADDRESS_124632] a Study  Evaluation Completion (SEC) visit 30-days (up to 37 days) 
after the last dose of LDK378. At this time AE, SAE and concomitant 
medication (including 
subsequent antineoplastic therap y) information during the follow -up period will be recorded 
on the AE eCRF and [COMPANY_001] will be informed as necessary .
Patients lost to follow -up should have this documented on the appropriate eCRF and attempts 
made to contact [CONTACT_111869], as 
described in Section 7.1.[ADDRESS_124633] to follow -up
For patients whose status is unclear be cause they fail to appear for study  visits without stating 
an intention to withdraw consent, the investigator should show "due diligence" by [CONTACT_15027], family  or family  physician as agreed in the informed consent and by [CONTACT_15028], e.g. dates of telephone calls, 
registered letters, etc. A patient should not be considered lost to follow -up until due diligence 
has been completed. Patients lost to follow up should be recorded as such on the appropriate 
eCRF page.
7.[ADDRESS_124634] v1.1 ( Appendix 5) in patients with solid tumors, and 
per IWG criteria (Appendix 6) for patients with lymphoma. In addition, patients with 
neuroblastoma will be assessed by [CONTACT_111870][INVESTIGATOR_111777] . Disease response and progress ion will be determined by [CONTACT_111871]. When the revised International Neuroblastoma Response Criteria (INRC) 
currentl y in development are final they  will be incorporated into this protocol.
At screening (within 28 days of the start of LDK378), all patients will undergo CT with 
i.v. 
contrast or MRI of the brain, chest, 
abdomen and pelvis. If there is clinical evidence of 
disease in the neck, a CT or MRI of the neck will also be performed. If a patient is intolerant 
of iodine -based contrast agents, CTs may  be performed without contrast or MRI  may  be used. 
Visible skin lesions and easily  palpable subcutaneous tumors may be measured by [CONTACT_111872] a ruler or calipers. Ultrasound should not be used to measure sites of 
disease. Patients w ith neuroblastoma will undergo MIBG scanning, and bone marrow bilateral 
aspi[INVESTIGATOR_111778]. Patients with lymphoma will undergo bone marrow bilateral 
aspi[INVESTIGATOR_111779] y at screening. MIBG scans should be performed within 28 day s of the start
of treatment, and bone marrow bilateral aspi[INVESTIGATOR_111780] 42 
days of the start of treatment.
 

[COMPANY_001] Confidential Page 93
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Subsequent disease evaluations will be performed on Day 15 (±7 days) of cycles 2, 4 and 6. 
After cycle 6, disease evaluations will be performed on Day 15 (±7 days) of every  4thcycle 
(e.g., C10, C14), or sooner if there is clinical evidence of disease progression. Post Cycle 14, 
disease evaluations will be performed every  6  cycles (e.g., C20, C26, C32, etc.) and also 
performed at EOT. If the last prior disease evaluation was within 28 day s of EOT or objective 
evidence of progressive disease has already  been documented, then evaluations do not need to 
be repeated at EOT.
Disease evaluations after the screening assessment will include evaluation of all sites of 
disease identified at baseline, using the same technique that was used at screening. If there 
was no evidence of disease in a body  region at baseline, that region does not need to be 
imaged at subsequent assessments, unless there is clinical concern for a new lesion in that 
body  region. Bone marrow bilateral aspi[INVESTIGATOR_111781], and MIBG scans are not required 
after screening if they were negative at screening. If bone marrow bilateral aspi[INVESTIGATOR_111782], it will be left to the investigator’s 
discretion to monitor the bone marrow aspi[INVESTIGATOR_111773]. In order to confirm 
a Complete disease Response (CR), bone marrow biopsy  or aspi[INVESTIGATOR_111783] a 
radiologic al CR has been achieved.
MIBG scans if positive at screening will be required at each disease evaluation unless [ADDRESS_124635] screening were negative and tumor response is a confirmed 
Complete or partial response. MIBG scan will be required if radiological assessment 
demonstrates a progression of the disease.
7.2.2 Safety  and tolerability
Safety  and tolerability  assessments will include adverse event reporting and changes from 
baseline in laboratory  measures and vital signs. Tolerability  will be assessed by [CONTACT_111873]378 delay  or discontinuation.
After cycle 16, for odd numbered cycles, safet y assessments can be reduced to a phone call 
and local laboratory  tests (see Table 7-1) to assess patient safety . It is left to the investigator’s 
discretion to monitor patient’s safet y more closely  as suggested for even cycles if judged 
necessary . 
[IP_ADDRESS] Physical examination
A full physical examination (PE) that evaluates all major organ systems will be performed at 
baseline. This should include a brief neurological exam (examination by a
 neurologist is not 
required). A gynecological exam should be included if clinicall y indicated. Subsequent PEs 
should be focused on sites of disease, and c
linical signs and s ymptoms.
During the PE the patient’s history  related to their diagnosis and extent of cancer should be 
collected. Significant findings that were present prior to the signing of ICF must be included 
in the Relevant Medical History /Current Medical Conditions page on the patient’s eCRF. 
Significant new findings that begin or worsen after informed consent must be recorded on the 
Adverse Event page of the patient’s eCRF.
Note: PE may be performed within 4 days prior to the start of a cycle and±1 day for other 
visits.
 

[COMPANY_001] Confidential Page 94
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
PE to be performed:
Screening/baseline.
Cycle 1 Day  1.
Cycle 1 Day  8 and 15.
Cycle 2 and subsequent cy cles Day  1.
End of treatment.
[IP_ADDRESS] Vital signs
Vital signs (heart rate, blood pressure and temperature) will be obtained in the same position, 
as appropriate prior to any blood collection.
Note: Vital signs may be performed within 4 days prior to the start of a cycle and ±1 day for 
other visits.
Vital signs to be obtained:
Screening/baseline.
Cycle 1 Day  1 (pre -dose).
Cycle 1 Day  8 and 15.
Cycle 2 and subsequent cy cles Day  1.
End of treatment.
[IP_ADDRESS] Height, weight and body surface area
Height in centimeters (cm) and body  weight (to the nearest 0.1 kilogram (kg) in indoor 
clothing, but without shoes) will be measured. Body surface area (BSA) will be measured 
using the patient’s weight and height, in accordance with local site procedure. The baseline 
BSA will be used to determine the dose at C1D1.
Note: Height, weight and BSA may be performed within 4 days prior to the start of a cycle 
and ±1 day for other visits.
Assessments will be obtained on:
Screening/baseline.
Cycle 2 and subsequent cy cles Day  1.
End of treatment (except BSA).
[IP_ADDRESS] Performance status
Performance status will be scored using the Karnofsk y or Lansk y performance scales, 
depending on the patient’s age ( Appendix 3 and Appendix 4 ).
Note: Performance status may be performed within 4 days prior to the start of a cycle and ±1 
day for other visits.
Performance status to be obtained:
Screening/baseline.
Cycle 1 Day  1.
 

[COMPANY_001] Confidential Page 95
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Cycle 2 and subsequent cy cles Day  1.
End of treatment.
For patients that have their 13thbirthday  during the study , performance status will continue to 
be assessed by [CONTACT_111874] . This approach will 
preserve continuity for these patients.
[IP_ADDRESS] Laboratory  evaluations
Laboratory  tests will be collected and analyzed by [CONTACT_4145]’s local laboratory  even if 
study  medication is being held. More frequent examinations may be performed at the 
investigator’s discretion if medically  indicated; results should be recorded on the Unscheduled 
Visit eCRFs.
All efforts should be made to minimize the volume of blood drawn during the course of the 
study . For each test the smallest tube required by [CONTACT_111875], and all 
blood required at a time point, including that for routine safet y labs and PK samples should be 
drawn simultaneously  to minimize wastage and venipunctures. If a patient has an indwelling 
venous catheter appropriate for drawing blood, it should be used whenever possible to reduce 
venipunctures. The maximum volume of blood that may  be drawn over a 24 hour period is 0.8 
mL/kg, and the maximum volume of blood that may be drawn over a 4 week period is 2.4 
mL/kg. The maximum blood volumes required by [CONTACT_111876] [ADDRESS_124636] be skipped, PK samples should be 
prioritized as shown in Table 7
-5.
Table 7-2 Maximum blood volumes
Maximum Sample 
Volume24 hr (Cycle 1 Day 1) Cycle 1 (4 wk)
No. Samples Total Volume No. Samples Total Volume
Hematology [ADDRESS_124637] may  be performed at all time -points after screening/baseline, and samples are not 
required in females not of child -bearing potential.
b.PK sample volume may be reduced from 1 mL to.5 mL as necessary.
Maximum allowed blood volumes: 0.8 mL/kg over a 24 hr period, 2.4 mL/kg over a 4 week period.
At any time during the study , abnormal laboratory  parameters which are clinicall y relevant 
(e.g., require dose modification and/or interruption of LDK378, lead to clinical signs or 
symptoms, or require therapeutic intervention), whether specifically  requested in the protocol 
or not, must be recorded in th e AE eCRF.
 

[COMPANY_001] Confidential Page 96
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
[COMPANY_001] will be provided with a copy  of the laboratory  certification and tabulation of the 
normal ranges for each parameter required. In addition, if at any time a patient has laboratory  
parameters obtained from a different outside laboratory , [COMPANY_001] must be provided with a 
copy  of the certification and a tabulation of the normal ranges for that laboratory .
Note: Laboratory  tests may  be performed within 4 day s prior to the start of a cy cle and ±1 da y 
for other visits. In order to reduce the volume of blood drawn, tests performed during 
screening/baseline within 4 days of Cycle 1 Day 1 should not be repeated on Cycle 1 Day 1, 
unless repeat testing is considered medically  necessary .
For timing of assessments, refer to Table 7
-1.
[IP_ADDRESS].[ADDRESS_124638] of tests to be performed.
Hematology  to be performed:
Screening/baseline.
Cycle 1 Day  1, 8 and 15.
Cycles 2 – 4 Day  1and 15.
Cycle 5 and subsequent cy cles Day  1.
End of treatment.
[IP_ADDRESS].[ADDRESS_124639] of tests to be performed.
Clinical chemistry  to be performed:
Screening/baseline.
Cycle 1 Day  1, 8 and 15.
Cycles 2 – 4 Day  1 and 15.
Cycle 5 and subsequent cy cles Day  1.
End of treatment.
Table 7-[ADDRESS_124640] Name
[CONTACT_111935], W hite blood cells with differential (Basophils, Eosinophils, 
Lymphocytes, Monocytes, Neutrophils) and Platelets
Chemistry Albumin, ALT (SGPT), AST (SGOT), Bicarbonate, Calcium, Chloride, Creatinine, 
Blood Urea N itrogen (BUN) or Urea, LDH (only required in patients with 
lymphoma), Magnesium, Phosphate, Potassium, Sodium, Total Bilirubin (measure 
direct and indirect bilirubin if total bilirubin elevation ≥ grade 2 occurs), ALP, 
Serum am ylase, Serum lipase , plasma glucose
[IP_ADDRESS].[ADDRESS_124641].
Note: Pregnancy  testing should be performed within 1 day  prior to Cy cle 1 Day  1.
 

[COMPANY_001] Confidential Page 97
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Pregnancy  test to be performed:
Screening/baseline (serum).
Cycle 1 Day  1 (urine or serum).
Subsequent cy cles Day  1 (urine or serum).
End of treatment (urine or serum).
A positive pregnancy  test is cause for immediate withdrawal.
For females to be considered “of non-childbearing potential”, patient should meet one of the 
following:
Pre-menarchal.
Surgicall y sterile for at least 6 months (hysterectomy with bilateral oophorectomy or tubal 
ligation). Documentation of sterilization method must be provided. The date of 
sterilization will be recorded.
To ensure patient safet y, each pregnancy  in a patient receiving LDK378 must be reported to 
[COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy  should be followed up 
to and including the baby ’s date of birth to determine outcome, including spontaneou
s or 
voluntary  termination, details of the birth, and the presence or absence of any birth defects, 
congenital abnormalities, or maternal and/or newborn complications.
Pregnancy  should be recorded on a Clinical Trial Pregnancy  Form and reported by [CONTACT_50105] y and Epi[INVESTIGATOR_623]  (DS&E) follow -up should be 
recorded on the same form and should include an assessment of the possible relationship to 
LDK378 of any pregnancy  outcome. Any SAE experienced during pregnancy  must be 
reported on the SAE Report Form.
[IP_ADDRESS].4 Electrocardiogram (ECG)
A standard 12- lead ECG will be performed in accordance with Table 7-4.
Interpretation of the tracing will be made by a central ECG lab. Each ECG tracing should be 
labeled with the study  number, patient initials, patient number, date, and kept in the source 
documents at the study  site. Only  clinicall y significant abnormalities will be recorded in the 
AE eCRF page. Clinically  significant abnormalitie s at screening/baseline should be recorded 
on the Relevant Medical History /Current Medical Conditions eCRF page. Clinicall y 
significant findings must be discussed with the [COMPANY_001] Medical Monitor prior to enrolling 
the patient in the study . In the case of QTc >500 ms an ECG should be repeated dail y until the 
QTc prolongation has resolved to grade 1 or less.
 

[COMPANY_001] Confidential Page 98
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Table 7-4 Central ECG collection plan
Cycle Day Time ECG Type
Screening/
Baseline -[ADDRESS_124642]- dose 4 hours (ECG should be performed just prior to 
drawing PK sample if both are scheduled simultaneously12 Lead
[ADDRESS_124643]- dose 6 hours (ECG should be performed just prior to 
drawing PK sample if both are scheduled simultaneously12 Lead
[ADDRESS_124644]- dose 4 hours (ECG should be performed just prior to 
drawing PK sample if both are scheduled simultaneously12 Lead
[ADDRESS_124645]- dose 6 hours (ECG should be performed just prior to 
drawing PK sample if both a re scheduled simultaneously12 Lead
3 1 Pre-dose (ECG should be performed just prior to drawing PK 
sample if both are scheduled simultaneously12 Lead
4 1 Pre-dose (ECG should be performed just prior to drawing PK 
sample if both are scheduled simultaneously12 Lead
5-16 1 Pre- dose 12 Lead
Even # 
cycles≥181 Pre- dose 12 Lead
EOT 1 Within 14 days (up to 21 days) of last dose 12 Lead
7.3 Pharmacokinetics
Blood samples for PK analy sis of LDK378 will be collected during the study . Table 10 -1lists 
non-compartmental PK parameters for LDK378 which will be calculated from the individual 
plasma concentration versus time profiles using Phoenix®(Pharsight, Mountain View, CA). 
The indivi dual and mean plasma concentration versus time profiles of LDK378 will be 
display ed graphicall y. In addition, a population PK model may be developed to characterize 
inter-patient variability  and covariate effects on LDK378 by  [CONTACT_111877].
 
 
 
 
Blood sampling schedules for PK assessment during the escalation and expansion parts of the 
study  can be found in Table 7 -
5and Table 7 -6, respectively .
7.3.1 Pharmacokinetic blood sample collection and handling
PK blood samples will be collected in the escalation parts (Table 7-5) and the expansion part 
(Table 7-6). For the determination of LDK378 concentrations, 1 mL of whole blood will be 
drawn for each time point. For smaller patients where collection of PK samples may 
compromise local blood volume limits, 0.5 mL of whole blood may be drawn for each PK 
time point, in order to permit all samples to be collected without exceeding the maximum 
blood volume limits ( Section [IP_ADDRESS]). If the maximum blood volume limit will be exceeded in 
a particular patient, hematology , chemistry  and pregnancy  test 
samples should be drawn 
This document (090095a88d6def99 in docbase CREDI_BS) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 5/23/2018 3:24:29 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by [CONTACT_111878], May 23, 2018 11:27:[ADDRESS_124646] Hanover at Wed, 23 May 2018 11:24:08 AM EDT
Approved for report publication by [CONTACT_111879], May 23, 2018 10:23:[ADDRESS_124647]

[COMPANY_001] Confidential Page 99
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
preferentiall y over PK samples. If a PK sample needs to be omitted due to blood volume 
limits, the 4 hour samples on Cy cle 1 Day  1 and/or Cy cle [ADDRESS_124648] venipuncture or venous catheter or indwelling cannula inserted in a 
forearm vein. Samples should be processed and labeled as detailed in the [Laboratory  Manual] . 
Plasma fractions will be split in 2 aliquots and all samples should be stored frozen at ≤ -70°C 
within 90 minutes of venipuncture at the site until sample shipment.
Meal records, including start and stop times and amount of meal consumed, will be collected 
on PK collection days for patients taking LDK378 with food. Refer to below Table 7-5and 
Table 7-6. LDK378 administration method, including if the capsule was opened or swallowed 
whole, and t ype of vehicle, will also be collected on all PK collection day s for all patients.
Table 7
-5 Pharmacokinetic blood collection log –dose escalation (fasted and 
fed)
Cycle DayPK 
collection 
numberSample 
number Scheduled time points (hours)
Cycle 1 Day 1 1 1 pre-dose*
Cycle [ADDRESS_124649]-dose (± 15 min)
Cycle [ADDRESS_124650] -dose (± 15 min)
(If it is anticipated that the maximum allowed 
blood volume will be exceeded ( Section [IP_ADDRESS] ) 
sample should be skipped)
Cycle [ADDRESS_124651] -dose (± 15 min)
Cycle 1 Day 2 2 5 pre-dose* (i.e. 24h post- dose on Cycle 1 day 1)
Cycle 1 Day 15 3 6 pre-dose*
Cycle 2 Day 1 4 7 pre-dose*
Cycle [ADDRESS_124652] -dose (± 15 min)
Cycle [ADDRESS_124653] -dose (± 15 min)
(If it is anticipated that the maximum allowed 
blood volume will be exceeded ( Section [IP_ADDRESS] ) 
sample should be skipped)
Cycle [ADDRESS_124654] -dose (± 15 min)
Cycle 2 Day 2 5 11 pre-dose* (i.e. 24h post-dose on Cycle 2 day 1)
Cycle 3 Day 1 6 12 pre-dose*
Cycle 4 Day 1 7 13 pre-dose*
Unscheduled 1001+ Anytime
*Take sample immediately prior to LDK378 administration.
 

[COMPANY_001] Confidential Page 100
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Table 7-6 Pharmacokinetic blood collection log –dose expansion (fasted and 
fed)
Cycle DayPK collection 
numberSample 
number Scheduled time points (hours)
Cycle 2 Day 1 103 203 pre-dose*
Cycle [ADDRESS_124655]-dose (± 15 min)
Cycle [ADDRESS_124656] -dose (± 15 min)
Cycle [ADDRESS_124657] -dose (± 15 min)
Cycle 2 Day 2 106 209pre-dose* (i.e. [ADDRESS_124658] dose on 
Cycle 2 Day 1)
Cycle 3 Day 1 104 204 pre-dose*
Cycle 4 Day 1 105 205 pre-dose*
Unscheduled 2001+ Anytime
*Take sample immediately prior to LDK378 administration.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

[COMPANY_001] Confidential Page 101
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
 
 
  
 
 
 
 
 
 
 
 
 
8 Safety  monitoring and reporting
8.1 Adverse events
8.1.1 Definitions and reporting
An adverse event is defined as the appearance of (or worsening of any pre-existing) 
undesirable sign(s), symptom(s), or medical condition(s) that occur after patient/guardian 
signed ICF has been obtained.
For patients whose ALK status is unknown and who sign the molecular pre-screening ICF, 
AEs which occur after signature [CONTACT_111936] 8.2 and are reported to be causally  related with 
study  procedures (e.g. an invasive procedure such as biopsy ). Once the main I CF is signed, all 
AEs per the descriptions below will be captured in the Adverse Event eCRF.
Patients whose ALK s tatus is known will sign the main I CF.
Abnormal laboratory  values or test results occurring after informed consent constitute adverse 
events only if they induce clinical signs or symptoms, are considered clinically  significant, 
require therapy  (e.g., hemat ologic abnormalit y that requires transfusion or hematological stem 
cell support), or require changes in study  medication(s).
Except for screening failures, adverse events that begin or worsen after informed consent 
should be recorded in the Adverse Events eCRF. Conditions that were alread y present at the 
time of informed consent should be recorded in the 
Relevant Medical History /Current 
 

[COMPANY_001] Confidential Page 102
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Medical Conditions of the patient’s eCRF. Adverse event monitoring should be continued for 
at least [ADDRESS_124659] dose of LDK378. Adverse events (including lab 
abnormalities that constitute AEs) should be described using a diagnosis whenever possible, 
rather than individual underly ing signs and symptoms. When a clear diagnosis cannot be 
identified, each sign or s ymptom should be reported as a separate Adverse Event.
Adverse events will be assessed according to the Common Terminology  Criteria for Adverse 
Events (CTCAE) version 4.03.
If CTCAE grading does not exist for an adverse event, the severit y of mild, moderat e, severe, 
and life -threatening, corresponding to Grades 1 -4, will be used. CTCAE Grade 5 (death) will 
not be used in this study ; rather, information about deaths will be collected on the EOT or the 
SEC eCRF.
The occurrence of adverse events should be sought by [CONTACT_105]-directive questioning of the 
patient/guardian during the screening process after informed 
consent and at each visit during 
the study . Adverse events also may be detected when they are volunteered by [CONTACT_111880], or through physical examination, laboratory 
test, or other assessments. As far as possible, each adverse event should be evaluated to 
determine:
1.The severit y grade (CTCAE Grade 1 -4).
2.Its duration (Start and end dates) or Ongoing at End of Study .
3.Its relationship to L DK378 (Reasonable possibility  that AE is related: No, Yes).
4.Action taken with respect to study  or investigational treatment (none, dose adjusted, 
temporaril y interrupted, permanentl y discontinued, unknown, not applicable).
5.Wheth er medication or therap y was given (no concomitant medication/non -drug therap y, 
concomitant medication/non -drug therap y).
6.Whether it is serious, where a serious adverse event (SAE) is defined as in Section 8.2.1.
If the event worsens the event should be reported a second time in the CRF noting the start 
date when the event worsens in toxicity . For grade 3 and 4 adverse events only, if 
improvement to a lower grade is determined a new entry  for this event should be reported in 
the CRF noting the start date when the event improved from h aving been Grade 3 or Grade 4.
Any AE that constitutes a DLT should be reported like a grade 3 and 4 adverse event. 
All adverse events should be treated appropriately . If a concom itant therap y is given, this 
action should be recorded on the Adverse Event eCRF.
Once an adverse event is detected, it should be followed until its resolution or until it is 
judged to be permanent, and assessment should be made at each visit (or more frequently , if 
necessary ) of any  changes in severity , the suspected relationship to L DK378, the interventions 
required to treat it, and the outcome.
Progression of malignancy  (including fatal outcomes), if documented by [CONTACT_15039] (for example, as per RECIST 1.1 criteria for solid tumors or as per IWG guidelines 
for hematological malignancies), should not be reported as a serious adverse event.
Adverse events separate from the progression of malignancy  (example, deep vein thrombosis 
at the time of progression or hemopty sis concurrent with finding of disease progression) will 
 

[COMPANY_001] Confidential Page 103
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
be reported as per usual guidelines used for such events with proper attribution regarding 
relatedness to the drug.
Adverse events of a special interest to be monitored for LDK378 have also been identified 
and include: hepatotoxicity , interstitial lung disease/pneumonitis, QT interval prolongation, 
bradycardia, hypergl ycemia, gastrointestinal toxicity  (nausea, vomiting and diarrhea) and 
pancreatitis (including lipase and amylas e elevations). For additional details, refer to the 
Investigator’s Brochure.
8.1.[ADDRESS_124660] abnormalities
[IP_ADDRESS] Definitions and reporting
Laboratory  abnormalities that constitute an Adverse event in their own right (are considered 
clinically  significant, induce clinical signs or symptoms, require concomitant therapy  or 
require changes in LDK378), should be recorded on the Adverse Events eCRF. Whenever 
possible, a diagnosis, rather than a symptom should be provided (e.g. anemia instead of low 
hemoglobin). Laborat ory abnormalities that meet the criteria for Adverse Events should be 
followed until they have returned to normal or an adequate explanation of the abnormality  is 
found. When an abnormal laboratory  or test result corresponds to a sign/sy mptom of an 
alread yreported adverse event, it is not necessary  to separately  record the lab/test result as an 
additional event.
Laboratory  abnormalities, that do not meet the definition of an adverse event, should not be 
reported as adverse events. A Grade 3 or 4 event (severe) as per CTCAE 4.03 does not 
automatically  indicate a SAE unless it meets the definition of serious as defined below and/or 
as per investigator’s discretion. A dose hold or medication for the lab abnormality  may be 
required by [CONTACT_64103], by [CONTACT_108], be an 
adverse event and must be reported as such.
8.1.[ADDRESS_124661]
 
 
 
Details regarding these adverse events are provided in the [Investigator’s Brochure] for 
LDK378. Potential emergent new AEs will be monitored during the course of the study .
8.2 Serious adverse events
8.2.1 Definitions
Serious adverse event (SAE) is defined as one of the following:
Is fatal or life -threatening.
Results in persistent or significant disability /incapacity .
Constitutes a congenital anomaly /birth defect.
 

[COMPANY_001] Confidential Page 104
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Is medicall y significant, i.e., defined as an event that jeopardizes the patient or may 
require medical or surgical intervention to prevent one of th e outcomes listed above.
Requires inpatient hospi[INVESTIGATOR_1081].
Note that hospi[INVESTIGATOR_14944]:
Routine treatment or monitoring of the studied i ndication, not associated with any  
deterioration in condition.
Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent.
Social reasons and respit e care in the absence of any  deterioration in the patient’s 
general condition.
Note that treatment on an emergency outpatient basis that does not result in hospi[INVESTIGATOR_5317] y of the definitions of a SAE given above 
is not a serious adverse event.
For patients with unknown ALK status and who sign the molecular pre-screening ICF, SAE 
collection will start upon signing the molecular pre -screening ICF. SAEs will only  be reported 
if the event is suspected to be causally  related to a study  procedure as assessed by [CONTACT_1275] (e.g. an invasive procedure such as biopsy ). SAEs will be followed until 
resolution or until clinically relevant improvement or stabilization. If the main ICF is not 
signed (molecular screen failure), SAE collection ends [ADDRESS_124662] be reported as follow -up to the original epi[INVESTIGATOR_5319] 24 
hours of the investigator receiving the follow -up information. An SAE occurring at a different 
time interval or otherwise considered completely  unrelated to a previously  reported one 
should be reported separately as a new event.
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess and record the relationship of each SAE to 
LDK378, complete the SAE Report Form in English, and send the completed, signed form by 
[CONTACT_87109] 24 hours to the oncology  [COMPANY_001] Drug Safet y and Epi[INVESTIGATOR_623]  (DS&E) 
department.
The telephone and telefax number of the contact [CONTACT_111881][INVESTIGATOR_623]  (DS&E), specific to the site, are listed in the investigator folder 
provided to each site. The original copy of the SAE Report Form and the fax confirmation 
sheet must be kept with the case report form documentation at the study  site.
 

[COMPANY_001] Confidential Page 105
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Follow -up information is sent to the same contact(s) to whom the original SAE Report Form 
was sent, using a new SAE Report Form stating that this is a follow -up to the previously  
reported SAE and giving the date of the original report. Each re-occurrence, complication, or 
progression of the original event should be reported as a follow -up to that event regardless of 
when it occurs. The follow -up information should describe whether the event has resolved or 
continues, if and how it was treated, and whether the patient continued or withdrew from 
study  participation.
If the SAE is not previously  documented in the Investigator’s Brochure or Package Insert 
(new occurrence) and is thought to be related to LDK378 , an oncology  [COMPANY_001] Drug Safet y 
and Epi[INVESTIGATOR_623]  (DS&E) department associate may urgentl y require further information 
from the investigator for Health Authorit y reporting. [COMPANY_001] may need to issue an 
Investigator Notification (IN), to inform all investigators involved in any study with the same 
drug that this SAE has been reported. Suspected Unexpected Serious Adverse Reactions 
(S[LOCATION_003]Rs) will be collected and reported to the competent authorities and relevant ethics 
committees in accordance with Directive 2001/20/EC or as per national regulatory 
requirements in participating countries.
To ensure patient safet y, each pregnancy  occurring while the patient is on LDK378 must be 
reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy  should be 
followed up from the estimated date of delivery plus 3 months to determine outcome, 
including spontaneous or voluntary  termination, details of the birth, and the presence or 
absence of any birth defects, congenital abnormalities, or maternal and/or newborn 
complications.
Pregnancy  should be recorde d on a Clinical Trial Pregnancy  Form and reported by [CONTACT_5373][INVESTIGATOR_18540] (DS&E). 
Pregnancy  follow -up should be recorded on the same form and should include an assessment 
of the possible relationship to the LDK378. An y SAE experienced during pregnancy  must be 
reported on the SAE Report Form.
Pregnancy  outcomes must be collected for the female partners of any males who took 
LDK378 in this study  up to and including the baby’s date of birth. Consent to report 
information regarding these pregnancy  outcomes should be obtained from the mother.
No evidence available at the time of the approval of this study  protocol indicated that special 
warnings or precautions were appropriate, other than those noted inthe provided Investigator 
Brochure. Additional safety  information collected between [Investigator’s Brochure] updates 
will be communicated in the form of Investigator Notifications. This information will be 
included in the patient ICF and should be discus sed with the patient during the study  as 
needed.
8.3 Data Monitoring Committee
Not applicable.
8.4 Steering Committee
Not applicable.
 

[COMPANY_001] Confidential Page 106
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
9 Data collection and management
 
 
 
 
 
 
 
 
 
 
9.2 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, [COMPANY_001] 
personnel (or designated CRO) will review the protocol and eCRFs with the investigators and 
their staff. During the study , the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy  of entries on the eCRFs, the adherence to the 
protocol to Good Clinical Practice, the progress of enrollment, and to ensure that LDK378 is 
being stored, dispensed, and accounted for accor ding to specifications. Key study personnel 
must be available to assist the field monitor during these visits.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information recorded on eCRFs must be traceable to source documents in the 
patient's file. The investigator must also keep all original signed ICFs (a signed copy is given 
to the patient/guardian).
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the CRF entries. [COMPANY_001] monitoring standards require full verification 
for the presence of informed consent/assent, adherence to the inclusion/exclusion criteria and 
documentation of SAEs. Additional checks of the consistency  of the source data with the 
CRFs are performed according to the stud y-specific moni toring plan.
 

[COMPANY_001] Confidential Page 107
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
9.3 Data collection
For studies using Electronic Data Capture (EDC), the designated investigator staff will enter 
the data required by [CONTACT_5374] (eCRF). The eCRFs 
have been built using fully  validated secur e web-enabled software that conforms to [ADDRESS_124663] been trained. Automatic validation programs check for data discrepancies in the 
eCRFs and, allow modific ation or verification of the entered data b y the investigator staff.
The Principal Investigator [INVESTIGATOR_111784], accurate, and that entry  and updates are performed in a timely  manner.
 
Patient drug diary  data will be entered into a paper diary  by [CONTACT_102]/guardian. Patient 
diaries will be part of the study  source doc umentation and be kept at the study  site.
9.4 Database management and quality  control
For studies using eCRFs, [COMPANY_001] personnel (or designated CRO) will review the data entered 
by [CONTACT_5375] . Electronic data queries stating the 
nature of the problem and requesting clarification will be created for discrepancies and 
missing values and sent to the study  site via the EDC system. Designated study  site staff are 
required to respond promptly  to queries and to make any  necess ary changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using 
the WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemical 
classification system. Relevant medical history /current medic al conditions and adverse events 
will be coded using the Medical dictionary  for regulatory  activities (MedDRA) terminology .
Samples and/or data will be processed centrall y and the results will be sent electronically to 
[COMPANY_001] (or a designated CRO).
For EDC studies, after database lock, the investigator will receive a CD -ROM or paper copi[INVESTIGATOR_111785] y site.
[ADDRESS_124664] to demographic and baseline characteristics, efficacy observations and 
measurements, safet y observations and measurements, and all relevant PK measurements 
using descriptive stat istics (quantitative data) and contingency  tables (qualitative data).
The study  data will be analyzed and reported based on all patients’ data of both dose 
escalation and safety  expansion parts at the end of study , and a final CSR will be written. 
 

[COMPANY_001] Confidential Page 108
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Patients treated with the MTD, or RDE if different, on the regimen (fasted or fed) during the 
dose escalation part, will be pooled with those receiving both the same dose and the same 
regimen during the expansion part. For patients undergoing intra-patient dose escalation to 
doses other than their initially  received dose level, their post-escalation data will be listed 
separately . However, only data before the first intra-patient escalation will be used in 
summary  statistics. A treatment group is defined by  [CONTACT_111882] (fasted versus fed).
10.1 Analysis sets
10.1.1 Full analy sis set
The full analy sis set (FAS) (Full Analy sis Set) includes all patients who received at least one 
dose of LDK378. Patients will be classified according to the planned treatment. The FAS will 
be used for all listings of raw data. Unless otherwise specified, the FAS will be the default 
analysis set used for all analy ses.
10.1.[ADDRESS_124665] one dose of LDK378.
On the specified regimen, patients will be classified according to dose level received, where 
dose level received is defined as:
1.The dose level assigned if it was received at least once, or
2.The first dose level received in the study , if the assigned dose level was never received.
10.1.3 Per-protocol set
Not applicable.
10.1.4 Dose -determining analy sis set
The dose determining set (DDS) consists of all patients from the safet y set who either meet 
the following minimum exposure criterion and have sufficient safety  evaluations or 
discontinue earlier due to DLT. A patient is considered to have met the minimum exposure 
criterion if having received at least [ADDRESS_124666] 
sufficient safety  data to conclude that a DLT did not occur.
Patients who do not meet these minimum safet y evaluation requirements will be regarded as 
ineligible for the DDS.
10.1.5 Pharmacokinetic analy sis set
The pharmacokinetic analy sis set (PAS) consists of all patients who have receive 
at least one 
dose of LDK378 and have at least oneevaluable PK sample. Additional criteria for the PAS 
will be defined in the RAP. The PAS will be used for summaries of PK data (tables and 
figures) as well as for listings of derived parameters. The definition of an evaluable PK blood 
sample will be furth er specified in the SAP.
 

[COMPANY_001] Confidential Page 109
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
10.2 Patient demographics/other baseline characteristics
Demographic and other baseline will be summarized descriptively  for all patients in the FAS. 
Categorical data will be presented as frequencies and percentages. For continuous data, mean, 
standard deviation, median, 25th and 75th percentiles, minimum, and maximum will be 
presented.
10.3 Treatments (study  treatment, concomitant therapi[INVESTIGATOR_014], compliance)
10.3.1 Study treatment
The actual dose and duration in days of LDK378 treatment, as well as the dose intensity  
(computed as the ratio of actual dose received and actual duration) and the relative dose 
intensity  (computed as the ratio of dose intensity  and planned dose received/planned duration), 
will be listed and summarized by [CONTACT_111883]. 
The summary  data will be presented for each treatment cycle individually , as well as for all 
study  days as a single category . The FAS will be used.
10.3.2 Concomitant therapi[INVESTIGATOR_111786]-drug therapi[INVESTIGATOR_111787]378 will be listed by [CONTACT_4676], and summarized by [CONTACT_111884]. The FAS will be used.
 
 
10.4 Primary  objective
The primary  objective of the escalation part is to estimate theMTD/RDE respectivel y on 
fasted regimen and on fed regimen of the single agent LDK378 when administered orall y on a 
once daily schedule to pediatric patients with ALK -activated tumors. The corresponding 
primary  analy sis method is an adaptive Bay esian logis
tic regression model (BLRM) guided by 
[CONTACT_111814] (EWOC) principle ( Neuenschwander et al 2008).
10.4.1 Variable
The primary  endpoint is the incidence of dose limiting toxicities (DLTs) in Cycle 1. 
Estimation of the MTD of the treatment will be based upon the estimation of the probability 
of DLT in Cycle 1 for patients in the DDS. This probability  is estimated by [CONTACT_111885] 10.4.2.
 

[COMPANY_001] Confidential Page 110
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
10.4.2 Statistical hy pothesis, model, and method of analy sis
Dose escalation
The BLRM with 2 parameters, guided by [CONTACT_111886], will be used to make dose 
recommendations and estimate the MTD/ RDE during both the fasted escalation part and the 
fed e scalation part of the study .
The DLT relationship in the escalation part of the study  will be described by [CONTACT_111887]:
logit(π (d)) = log(α) + β log(d/d*), α>0, β>0 [1]
where logit(π (d))= ln ((d)/(1-(d))), and π(d)is the probability  of a DLT at dose d. Doses are 
rescaled as d/d* with reference dose of d*= 400 mg/m2. As a consequence α is equal to the 
odds of toxicity  at d*. Note that for a dose equal to zero, the probability  of toxicity  is zero.
The same 2-paramet er form of the BLRM described in equation [1] will be used to estimate 
the dose-DLT relationships separatel y for fasted and fed patients. The Bayesian approach 
requires the specification of prior distributions for the model parameters. Dose escalation in 
fed patients will begin once the MTD/RDE is determined in fasted patients. Data from fasted 
patients will be utilized to formulate a prior distribution for the BLRM parameters for fed 
patients. The prior distributions and the process of their derivation areprovided in the 
statistical appendix ( Appendix 1 ).
Dose recommendation
After each cohort is completed the posterior distributions for the probabilities of DLT at 
different dose levels are obtained. Theresults of this analy sis are summarized in terms of the 
estimated probabilities that the true rate of DLT at each dose-level will lie within each of the 
following intervals:
(0, 0.16) under -dosing.
(0.16, 0.33) targeted toxicity .
(0.33, 1.00) excessive to xicity .
Following the principle of EWOC, after each cohort of patients the recommended dose is the 
one with the highest posterior probability  of the DLT rate falling in the target interval (16%, 
33%) among the doses fulfilling EWOC, i.e. it is unlikely  (< 25% posterior probabilit y) that 
the DLT rate at the dose falls in the excessive toxicity  interval. In addition, the maximum dose 
escalation for the fasted regimen is limited to 50% before reaching 450 mg/m2, and to 25% 
after reaching 450 mg/m2, which corre spond to the adult MTD. Dose escalations for the fed 
dose escalation part will be limited to a 25% or smaller increase above the prior fed dose level.
Note that the dose that maximizes the posterior probability  of targeted toxicity  is the best 
estimate of the MTD, but it may  not be an admissible dose according to the overdose criterion 
if the amount of data is insufficient. If vague prior information is used for the probabilities of 
DLT, in the earl y stages of the study  this escalation procedure will reflec t a cautious strategy .
 

[COMPANY_001] Confidential Page 111
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
The dose recommended by [CONTACT_111888] a clinical assessment of the toxicity  profiles observed at 
the time of the anal ysis in determining the nex t dose level to be investigated.
Details of the criteria for dose escalation and the determination of the MTD are provided in 
Section 6.2.3.
Listing/summary
 of DLTs
DLTs will be listed and their inciden ce summarized by [CONTACT_64205], worst 
grade based on the CTCAE version 4.03, type of adverse event, and by [CONTACT_3148]. The DDS 
will be used for these summaries.
Dose expansion
Upon completion ofthe first cycle of treatment for at least 10 patients within the dose 
expansion part, if the observed DLT rate exceeds 33%, the BLRM will be re-run to confirm 
that the estimated MTD/RDE on either regimen still satisfies the overdose criteria of the 
model. If the dose fails to satisfy  the criteria a chang e to the dose under study  may be made 
according to the Bay esian model recommendation , after review of the clinical data.
10.5 Handling of missing values/censoring/discontinuations
Patients in the dose-escalation part who are ineligible for the dose-determining set may be 
replaced if necessary . Patients in the safet y expansion part will not be replaced.
As of the date of data -cutoff for the final CSR for the purposes of reporting:
Time to event data (i.e. PFS) will be censored if no event is observed before the cut-off 
date or before the start date of a new anti-neoplastic therap y, whichever occurs earlier. 
The censoring date will be the date of last adequate tumor assessment before either of 
these two dates. If a PFS event is documented after two or more missing or non-adequate 
tumor assessments, then the date of PFS will be censored at the date of the last adequate 
tumor assessment. If a PFS event is observed after a single missing or non -adequate tumor 
assessment, the actual date of event will be used .
Continuin g events (e.g. adverse events, concomitant therapi[INVESTIGATOR_014], etc.) will be summarized 
using the data cut
-off date as the date of completion, with an indication within listings that 
the event is continuing.
For patients who discontinue the study  with ongoing event s, the discontinuation date will be 
used as the completion date of the event with the appropriate censoring as described in the 
above paragraph.
The reason for discontinuation from study  will be summarized and listed, along with dates of 
first and last LDK 378, duration of exposure to LDK378 and date of discontinuation for each 
patient.
Other missing data will simply  be noted as missing in appropriate tables/listings. The FAS 
will be used.
 

[COMPANY_001] Confidential Page 112
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
10.6 Supportive analy ses
10.7 Secondary  objectives
Refer to Section 3 for secondary  objectives.
10.7.1 Safety  objectives
[IP_ADDRESS] Analysis set and groupi[INVESTIGATOR_111788], the safety set will be used. Unless otherwise specified, all listings and 
tables will be presented by [CONTACT_1570] (regimen (fasted versus fed) and dose level) in the 
clinical study  report, with patients classified according to treatment received as described in 
Section 10.1.
Data from patients of the expansion part will be pooled with the patients of the escalation part 
receiving the same dose.
[IP_ADDRESS] Adverse events (A Es)
All AEs recorded during the study  will be summarized. The incidence of treatment -emergent 
AEs (new or worsening from baseline) will be summarized by [CONTACT_64205], 
severit y based on CTCAE version 4.03, type of adverse event, and relationship to LDK378, 
by [CONTACT_1570]. Deaths repor table as SAEs and non-fatal SAEs will be listed by [CONTACT_111889] b y primary sy stem organ class, t ype of adverse event, and treatment group.
Any other information collected (e.g. start/end dates and duration of adverse event, severit y or 
relatedness to study  medication) will be listed as appropriate.
[IP_ADDRESS] Laboratory  abnormalities
All laboratory  values will be converted into SI units, as appropriate, and the severity  grade 
calculated using CTCAE, version 4.03. Parameters for which a grading does not exist will be 
classified into low/normal/high group by  [CONTACT_111890].
For each laboratory  test (e.g. hematology , biochemistry  etc.) a listing of laboratory  values will 
be provided by [CONTACT_90715], patient and treatment group. The frequency  of notable 
lab abnormalities (i.e. newly  occurring CTCAE grade 3 or 4 
laboratory toxicities), will be 
reported by [CONTACT_46642], cycle and treatment group. Similarly , the frequency  of all laborator y 
abnormalities will be tabulated by [CONTACT_46642], worst CTC AE v4.03 grade experienced, and 
treatment group. Laboratory  data will be summarized by [CONTACT_111891] 4.03. All remaining data will be 
summarized by  [CONTACT_111892] d on normal ranges.
Laboratory  data will be also be display ed by [CONTACT_111893] (means, medians, standard deviations, ranges).
 

[COMPANY_001] Confidential Page 113
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
[IP_ADDRESS] Other safety  data
ECG
shift table baseline to worst on- treatment result for overall assessments.
listing of ECG evaluations for all patients with at least one abnormality .
Vital signs
Definitions of notably  abnormal results will be included in the anal ysis plans.
shift table baseline to worst on- treatment result.
table with descriptive statistics at baseline, one or several post -baseline time points and 
change from baseline to the post- baseline time points.
Data from other tests will be listed, notable values will be flagged, and any other information 
collected will be listed as appropriate. Any statistical tests performed to explore the data will 
be used onl y to highlight any interesting comparisons that may warrant further consideration.
[IP_ADDRESS] Supportive analy ses for secondary  objectives
[IP_ADDRESS] Tolerability
Tolerability  of LDK378 will be assessed by [CONTACT_111894]. Reasons for dose interruption and dose reductions will be listed by 
[CONTACT_111895]. Cumulative dose, dose intensity  and relative dose intensity  of 
LDK378 will be listed by [CONTACT_111895]. Categories for relative dose intensity  of 
LDK378 will be specified as < 0.5, ≥ 0.5 -< 0.75, ≥ 0.75 
-< 0.9, ≥ 0.9 -< 1.1 and ≥ 1.1. The 
number and proportion of patients within each category  will be presented.
10.7.2 Pharmacokinetics
All PK analy ses will be performed based on the PAS unless otherwise specified.
Pharmacokinetic variables:
Pharmacokinetic parameters will be determined using non-compartme ntal method(s), using 
Phoenix WinNonlin (Pharsight, Mountain View, CA ). The PK parameters listed in Table 10 -
1
will be estimate d and reported, as appropriate. PK data generated from this study  may  be us ed 
in conjunction with PK data from other adult clinical studies in future meta -analyses for 
population PK assessment. These data will be reported separatel y.
 

[COMPANY_001] Confidential Page 114
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Table 10-1 Nonc ompartmental pharmacokinetic parameters
AUCtau The AUC calculated to the end of the dosing interval, tau.
Cmin Observed concentration at the end of a dosing interval (taken directly before next 
administration).
Cmax The maximum observed plasma, blood, serum, or other body fluid drug concentration.
Tmax The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug 
concentration.
T1/2,acc Effective half -life can be calculated from Racc.
CLss/F Apparent oral total body clearance of drug from the plasma calculated from steady -state 
exposure.
Racc Accumulation ratio calculated using AUCtau values obtained from a dosing interval at 
steady -state divided by [CONTACT_111896] 1.
[IP_ADDRESS] Data handling principles
Any missing PK parameters will not be imputed. All concentrations of LDK378 below their 
respective LLOQs (lower limits of quantification) or missing data will be labeled as such in 
the concentration data listings. Concentrations below the LLOQ will be treated as zero in 
summary  statistics and for the calculation of PK parameters.
[IP_ADDRESS] Data analy sis principles
Basic tables, figures and listings
Summary  statistics, including n, mean, SD, coefficient of variation CV (%) for mean, 
geometric mean, geometric CV (%), median, minimum and maximum, will be tabulated for 
evaluable PK plasma concentration of LDK378 by [CONTACT_111897]. Graphical representation of individual plasma 
concentration -time profiles will be generated too.
Descriptive statistics will also be provided for all PK parameters by [CONTACT_111898]. Summaries by [CONTACT_111899].
Advanced analy sis methods
Dose linearity  will be assessed by [CONTACT_111900] -based method with respect 
to AUCtau and Cmax at steady  state. To assess the attainment of steady  state, median Cmin 
will be plotted by  [CONTACT_111901].
 
 
10.7.[ADDRESS_124667] 1.1 for patients with neuroblastoma and other solid tumors, and IWG 
 

[COMPANY_001] Confidential Page 115
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
criteria for patients with lymphoma, and summarized in terms of overall response rate (ORR), 
duration of response (DOR), and progression- free survival (PFS). In patients with 
neuroblastoma, disease assessable only by [CONTACT_111902]-target lesions. When the revised International Neuroblastoma 
Response Criteria (INRC) currently  in devel opment are final they will be incorporated into 
this protocol.
For analysis by [CONTACT_1570], patients from the expansion part and patients from the 
escalation treated at the MTD/RDE 
on the same regimen (either fasted or fed) will be 
combined to be included in the same dose level.
For analysis of patients at the MTD/RDE on one regimen (either fasted or fed), patients from 
the dose escalation part treated at the MTD/RDE on the same regimen will be classified into 
one of the expansion groups.
For patients w ith neuroblastoma, resolution of disease assessable by [CONTACT_111903] y from the response assessment b y RECI ST 1.1.
ORR will be summarized by [CONTACT_111904], and exact 95% 
confidence intervals will be presented . To assess anti-tumor activity  in pediatric patients 
previously  treated with an ALK inhibitor, BOR and ORR will be tabulated for this subset of 
patients.
Kaplan Meier analyses of PFS and DOR will be provided overall and by [CONTACT_3227], if 
sufficient number of patients allow. For MTD/RDE patients, Kaplan Meier analyses of PFS 
and DOR will be done by  [CONTACT_111905], if appropriate .
In addition, for the expansion group patients with ALK activated neuroblastoma , a Bayesian 
approa ch will be used to estimate the ORR along with a 95% credible intervals based on the 
posterior distributions, using minimally  informative unimodal Beta prior distributions. The 
prior clinical assumption for LDK378 in this selected patient population will be used in order 
to derive a minimally  informative unimodal Beta prior distribution that reflects the level of 
uncertaint y around the ORR before starting the current trial. 
At completion of the study , this 
prior distribution will be updated with all data available from the expansion group patients 
with ALK activated neuroblastoma (including those treated at the MTD in the dose escalation 
part) in the FAS. Once updated, the posterior probability  that the true ORR at the MTD/ RDE
for these patients lies in the following categories will be presented:
(0, 10%) insufficient antitumor activity .
(10%, 20%) limited antitumor activity .
(20%, 30%) moderate antitumor activity .
(30%, 100%) substantial antitumor activity .
If the observed ORR is equal to or greater than 30%, then this will be considered as 
preliminary  evidence of substantial antitumor activity  of LDK378 in ALK activated 
neuroblastoma. If the observed ORR is between 20% and 30% then this will be considered as 
evidence of moderate antitumor activity , and as li mited antitumor activity  if it is between 10% 
and 20%. If the observed ORR is less than 10% (i.e. ≤ 2 CR or PR out of 25), then insufficient 
antitumor activity  will be declared.
 

[COMPANY_001] Confidential Page 116
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Note that for a sample size of n = 25 (see Section 10.8 ), if the observed ORR is greater than or 
equal to 20% (i.e. ≥ 5 CR or PR), then the true ORR has a posterior risk of less than 10% of 
being in the insufficient antitumor activity  category .
A minimally  informative unimodal Beta prior distribution of the true ORR is derived as 
follows. A priori it is assumed that the true mean of the ORR equals 20%. A true ORR of 20% 
is the midpoint between limited and 
moderate antitumor activity  and serves as a compromise 
between a skeptical view assuming the treatment has only limited antitumor activity  and an 
optimistic view assuming the treatment has moderate antitumor activity . The parameters of 
the minimally  informative Beta prior distribution of the ORR are then derived as a=1/4 and 
b=1.
 
 
 
 
 
 
 
 
 
 
 
 
 

[COMPANY_001] Confidential Page 117
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
 
 
 
10.[ADDRESS_124668] 6 
patients at the MTD/RD E level separatel y on each regimen, as described in Section 6.2.3. 
Multiple cohorts may be sequentially  enrolled to the same dose level. Additional cohorts of 1 
to 6 
patients may be enrolled at any doselevel below the estimated MTD/RDE for further 
elaboration of safet y and pharmacokinetic parameters as required. At least [ADDRESS_124669] reasonable operating characteristics relating to its 
MTD recommendation ( Appendix 1 ).
10.10.2 Dose Expansion
During the expansion part, approximately  45 patients will be treated on the preferred regimen 
(including all patients treated at the MTD on that regimen during the dose escalation who are 
eligible for the safet y set), approximately  25 patients in group 1 on the preferred regimen, and 
approximately  20 patients in group 2.
Group 1: ALK-activ ated neuroblastoma
Based on the ORR (per RECI ST 1.1) intervals described inSection 10.4.[ADDRESS_124670] “modera te 
antitumor activity ” (i.e. seeing at least 5 responses out of 25 patients) given the true ORR = 
10%, and how likely  it is to correctl y declare activity  given the true ORR = 30% when 25 
patients are evaluated.
If the true ORR = 10%, the probability  to wro ngly declare activit y is 9.8%.
If the true ORR = 30%, the probability  to correctly  declare activit y is 91.0%.
Given a sample size of 25 in group 1, if 5 responses are seen, the observed ORR is 20% with 
an 80% credible interval of (10.7%, 30.3%). This will be considered as preliminary evidence 
of antitumor activity  of LDK378 at the MTD/RDE within this group.
 

[COMPANY_001] Confidential Page 118
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Group 2: other A LK-activ ated tumors, such as IMT and A LCL
For group 2, sample size estimation is based on safet y. A sample size of 20 will result in an 
87.8% probability  of detecting an AE with an incidence rate of ≥ 10%.
10.11 Power for analy sis of key secondary  variables
Not applicable.
11 Ethical considerations and administrative procedures
11.1 Regulatory  and ethical compliance
This clinical study  was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical principles laid down in the Declaration of Helsinki.
11.2 Responsibilities of the investigator and IRB/IEC/REB
The protocol and the proposed molecular pre-screening and main ICFs must be reviewed and 
approved by a properly  constituted Institutional Revi ew Board/Independent Ethics 
Committee/Research Ethics Board (IRB/IEC/REB) before study  start. A signed and dated 
statement that the protocol and ICFs have been approved by [CONTACT_1201]/IEC/REB must be given 
to [COMPANY_001] before study initiation. Prior to study start, the investigator is required to sign a 
protocol signature [CONTACT_5389]/her agreement to conduct the study in accordance with 
these documents and all of the instructions and procedures found in this protocol and to give 
access to all relevant data and records to [COMPANY_001] monitors, auditors, [COMPANY_001] Clinical 
Quality  Assurance representatives, designated agents of [COMPANY_001], IRBs/IECs/REBs and 
regulatory  authorities as required.
11.3 Informed consent procedures
Patients may only be included in the study after providing written (witnessed, where required 
by [CONTACT_6617]), IRB/IEC/REB -approved informed consent or, if incapable of doing so, 
after such consent has been provided by a legally  acceptable representative of the patient. In 
cases where the patient’s representative gives consent, the patient should be informed about 
the study  to the extent possible given his/her understanding. If the patient is capable of doing 
so, he/she should indicate assent by [CONTACT_111906] a 
separate assent form.
Informed consent must be obtained before conducting any study -specific procedures (i.e. all 
of the procedures described in the 
protocol). The process of obtaining informed consent 
should be documented in the patient source documents. The date when a patient’s informed 
consent was actuall y obtained will be captured in their eCRFs.
[COMPANY_001] will provide to investigators, in separate documents, proposed molecular pre-
screening and main ICFs that is considered appropriate for this study and complies with the 
ICH GCP guideline and regulatory  requirements. Any changes to these ICFs suggested by  [CONTACT_111907] 119
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
investigator must be agreed to by  [CONTACT_111908] I RB/IEC/REB, and copi[INVESTIGATOR_111789]/IEC/REB 
approval.
Females of child bearing potential should be informed that taking the study  medication may 
involve unknown risks to the fetus if pregnancy  were to occur during the study  and agree that 
in order to participate in the study  they must adhere to the contraception requirement for the 
duration of the study  and for 3 months after stoppi[INVESTIGATOR_90524]. If there is any question that the 
patient will not reliably  comply , they  should not be entered in the study .
11.4 Discontinuation o f the study
[COMPANY_001] reserves the right to discontinue this study  under the conditions specified in the 
clinical study  agreement. Specific conditions for terminating the study  are outlined in Section 
4.4.
11.5 Publication of study  protocol and results
[COMPANY_001] assures that the key design elements of this protocol will be posted in a publicl y 
accessible database such as clinicaltrials.gov. In addition, upon study  completion and 
finalization of the study  report the results of this study  will be either submitted for publication 
and/or posted in a publicly  accessible database of clinical study  results.
11.[ADDRESS_124671] keepi[INVESTIGATOR_5324], in 
compliance with Section 
4.9 of the ICH E6 GCP, and regulatory and institutional 
requirements for the protection of confidentiality of patients. As part of participating in a 
[COMPANY_001] -sponsored study , each site will permit authorized representatives of the sponsor(s) 
and regulatory  agencies to examine (and when required by [CONTACT_1289], to copy) clinical 
records for the purposes of qualit y assurance reviews, audits and evaluation of the study 
safet y and progr ess.
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary  for the reconstruction and evaluation of the trial. 
Examples of these original documents and data records include, but are not limited to, hospi[INVESTIGATOR_2553], clinical and office charts, laboratory notes, memoranda, patients’ diaries or 
evaluation checklists, pharmacy  dispensing records, recorded data from automated 
instruments, copi[INVESTIGATOR_10379], 
microfiches, photographic negatives, microfilm or magnetic media, x-rays, and patient files 
and records kept at the pharmacy , at the laboratories, and medico- technical departments 
involved in the clinical trial.
Data collection is the responsibility  of the study  staff at the site under the supervision of the 
site Principal Investigator. The electronic case report form (eCRF) is the primary  data 
collection instrument for the study . The investigator should ensure th e accuracy , completeness, 
legibility , and timeliness of the data reported in the eCRFs and all other required reports. Data 
reported on the eCRF, that are derived from source documents, should be consistent with the 
 

[COMPANY_001] Confidential Page 120
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
source documents or the discrepancies should be explained. All data requested on the eCRF 
must be recorded. Any missing data must be explained. Any change or correction to a paper 
eCRF should be dated, initialed, and explained (if necessary ) and should not obscure the 
original entry . For electro nic eCRFs an audit trail will be maintained by  [CONTACT_5382].
The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by 
[CONTACT_64122]/or guidelines. The investigator/institution should take measures to 
prevent accidental or premature destruction of these documents.
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completion of the Clinical Trial unless Sponsor provides written 
permission to dispose of them or, requires their retention for an additional period of time 
because of applicable laws, regulations and/or guidelines.
11.[ADDRESS_124672] ensure anon ymity of the patients; patients must not be identified by 
[CONTACT_64123]. Signed ICFs and patient screening logs must 
be kept strictly confidential to enable patient identific ation at the site.
11.8 Audits and inspections
Source data/documents must be available to inspections by [CONTACT_5385].
11.[ADDRESS_124673] 
be considered a protocol amendment, and unless such an amendment is agreed upon by 
[CONTACT_6669]/IEC/REB it cannot be implemented. All significant 
protocol deviations will be recorded and reported in the CSR.
12.[ADDRESS_124674] be approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC/REB. 
Only  amendments that are required for patient safety  may be implemented prior to 
IRB/IEC/REB approval. Notwithstanding the need for approval of formal protocol 
amendments, the investigator is expected to take any immediate action required for the safet y 
of any patient included in this study , even if this action represents a deviation from the 
 

[COMPANY_001] Confidential Page 121
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
protocol. In such cases, Novart is should be notified of this action and the IRB/IEC at the study 
site should be informed according to local regulations (e.g. [LOCATION_006] requires the notification of 
urgent safet y measures within 3 days) but not later than 10 working day s.
 

[COMPANY_001] Confidential Page 122
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
13 References (available u pon request)
Azaravoa AM, Gautam G, George RE (2011) Emerging importance of ALK in neuroblastoma. 
Sem Cancer Biol, 21: 267-275.
Babb J, Rogatko A, Zacks S (1998) Cancer phase I clinical trials: efficient dose escalation 
with overdose control. Stat Med; 17 (10):1103- 1120.
Bilsland JG, Wheeldon A, Mead A, et al (2008) Behavioral and Neurochemical Alterations in 
Mice Deficient in Anaplastic Ly mphoma Kinase Suggest Therapeutic Potential for Psy chiatric 
Indications. Neurops ychopharmacology ; 33: 685 -700.
Bosulif [LOCATION_002] Package Insert.
Butry nski JE, D’Adamo DR, Hornick JL, et al (2010) Crizotinib in ALK-rearranged 
inflammatory  myofibroblastic tumor. N Engl J Med; 363:1727 -33.
Center for Drug Evaluation and Research (2011) Pharmacometric Review of Crizotinib, NDA 
202570. Clinical Pharmacology  and BioPharmaceutics Review.
Chen Y, Takita J, Choi YL, et al (2008) Oncogenic mutations of ALK kinase in 
neuroblastoma. Nature 455:971 -74.
Chiarle R, Gong JZ, Guasparri I, et al (2003) NPM -ALK transgenic mice spontaneous ly 
develop T -cell ly mphomas and plasma cell tumors. Blood; 101: 1919 -27.
Chiarle R, Voena C, Ambrogio C, et al (2008) The anaplastic lymphoma kinase in the 
pathogenesis of cancer. Nat Rev Cancer, 8:11- 23.
Coffin CM, Hornick JL, Fletcher CDM (2007) Inflamma tory myofibroblastic tumor -
Comparison of clinicopathologic, histologic, and immunohistochemical features including 
ALK expression in atypi[INVESTIGATOR_111790]. American Journal of Surgical Pathology ; 
31:509 -520.
Costa DB, Kobay ashi S, Pandy a S, et al(2011) CSF Concentration of the Anaplastic 
Lym phoma Kinase Inhibitor Crizotinib. J Clin Oncol; 29 (15): 443 -445.
Fischer M. et al(2016) Phase 1 study  of ceritinib in pediatric patients with malignancies 
harboring activated anaplastic lymphoma kinase (ALK ): Safet y, pharmacokinetics and 
efficacy  results from the fed population European Journal of Cancer , Volume 69 , S49 - S50.
Galkin AV, Melnick JS, Kim S, et al (2007) Identification of NVP -TAE684, a potent, 
selective, and efficacious inhibitor of NPM -ALK.PNAS; 104 (1): 270-275.
Gasco yne RD, Aoun P, Wu D, et al (1999) Prognostic Significance of Anaplastic Lymphoma 
Kinase (ALK) Protein Expression in Adults With Anaplastic Large Cell Lym phoma. Blood; 
93(11): 3913-3921.
Geoerger B. et al (2015) Phase I study  of ceritinib in pediatric patients (Pts) with malignancies 
harboring a genetic alteration in AL K (ALK+): Safety , pharmacokinetic (PK), and efficacy  
results. Journal of Clinical Oncology  2015 33:15_suppl, [ZIP_CODE] -
[ZIP_CODE] .
Gleevec [LOCATION_002] Package Insert.
Griffin CA, Hawkins AL, Dvorak C, et al (1999) Recurrent Involvement of 2p23 in 
Inflammatory  Myofibroblastic Tumors. Cancer Research; 59: 2776 -80.
 

[COMPANY_001] Confidential Page 123
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Iwahara T, Fujimoto J, Wen D, et al (1997) Molecular characterization of ALK, a receptor 
tyrosine kinase expre ssed specificall y in the nervous sy stem. Oncogene; 14: 439-449.
Kim DW, Ahn MJ, Shi Y, et al (2012) Results of a global phase II study  with crizotinib in 
advanced ALK -positive non-small cell lung cancer (NSCL C). J Clin Oncol; 30 (suppl); 
abstract 7533.
Kwa k EL, Bang YJ, Camidge DR, et al (2010) Anaplastic l ymphoma kinase inhibition in non
-
small -cell lung cancer. N Engl J Med; 363(18):1693 -703.
Li N, Michell ys PY, Kim S, et al (2011) Activity  of a potent and selective phase I ALK 
inhibitor LDK378 in naive and crizotinib -resistant preclinical tumor models. Molecular 
Cancer Therapeutics; 10 ([ADDRESS_124675] ); abstract B232.
McDermott U, Iafrate AJ, Gray  NS, et al (2008) Genomic alterations of anaplastic lymphoma 
kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer 
Res;68(9):[ADDRESS_124676], Sharma S, et al (2012) First-in-human phase I study  of the ALK 
inhibitor L DK378 in advanced solid tumors. J Clin Oncol.30 (suppl): abstract 3007.
Mosse YP, Balis FM, Lim MS (2012) Efficacy  of crizotinib in children with 
relapsed/refractory  ALK-driven tumors including anaplastic large cell lymphoma and 
neuroblastoma: a Children’s Oncology  Group phase I consortium study. J Clin Oncol 30 
(suppl: abstract 9500.
Mosse YP, Laudenslager M, Long L, et al (2008) Identification of ALK as a major familial 
neuroblastoma predisposition gene. Nature; 455 (7261): 930-5.
Neuenschwander B, Branson M, Gsponer T (2008) Critical aspects of the Bayesian approach 
to phase I cancer trials. Stat Med; 27 (13):2420 -39.
Neuenschwander B, Capkun -Niggli G, Branson M, et al (2010) Summarizing historical 
information on controls in clinical trials. Clinical Trials; 7:5 -18.
Palmer RH, Vernersson E, Grabbe C, et al (2009) Anaplastic lymphoma kinase: signaling in 
development and d isease. Biochem J; 420: 345-361.
Savage KJ, Harris NL, Vose JM, et al (2008) ALK -anaplastic large -cell lymphoma is 
clinically  and immunophenoty pi[INVESTIGATOR_111791]+ ALCL and peripheral T-cell 
lymphoma, not otherwise specified: report from the International Peripheral T- Cell 
Lym phoma Project. Blood; 111(12):5496 -504.
Scagliotti G, Stahel RA, Rosell R, et al (2012) ALK translocation and crizotinib in non-small 
cell lung cancer: An evolving paradigm in oncology  drug development. Eur J Cancer; 
48(7) :961-
73.
Shaw AT, Mehra R, Kim D -W, et al (2013) Clinical activity  of the ALK inhibitor LDK378 in 
advanced, ALK -positive NSCL C; J Clin Oncol; 31 (Suppl; abstr 8010).
Soda M, Choi YL, Enomoto M (2007) Identification of the transforming EML 4-ALK fusion 
gene in non -small -cell lung cancer. Nature; 448(7153):561 -6.
Tabbo F, Barreca A, Pi[INVESTIGATOR_100214] G, et al (2012) ALK signaling and target therapy  in anaplastic large 
cell ly mphoma. Frontiers in Oncology ; 2: 1 -12.
 

[COMPANY_001] Confidential Page 124
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Takeuchi K, Choi YL, Togashi Y, et al (2009) KIF5B-ALK, a novel fusion oncokinase 
identified by [CONTACT_111909] -based diagnostic system for ALK -positive lung 
cancer. Clin Cancer Res; 15(9):3143 -
9.
van Gaal JC, Flucke UE, Roeffen MHS (2012) Anaplastic lymphoma kinase aberrations in 
rhabdom yosarcoma: clinica l and prognostic implications. J Clin Oncol; 30:308-15.
 

[COMPANY_001] Confidential Page 125
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
14 Appendices
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

[COMPANY_001] Confidential Page 126
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.
 

[COMPANY_001] Confidential Page 127
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
 
  
 
 
 
 
 
 
 
 

[COMPANY_001] Confidential Page 128
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

[COMPANY_001] Confidential Page 129
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
 
 
 

[COMPANY_001] Confidential Page 130
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
 
 
 
   
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

[COMPANY_001] Confidential Page 131
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
 
 
 
 
 
 
 
 
 
  
  
 

[COMPANY_001] Confidential Page 132
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
 
 
 
 
 
 
 
 
 
 
 
 

[COMPANY_001] Confidential Page 133
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
  
 

[COMPANY_001] Confidential Page 134
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
  
 
 

[COMPANY_001] Confidential Page 135
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
 
 
 
 
 
 
 
 
 

[COMPANY_001] Confidential Page 136
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
 
 
 

[COMPANY_001] Confidential Page 137
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
 
 

[COMPANY_001] Confidential Page 138
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
14.3 Appendix 3: Karnofsky  Performance Status Scale (for patients 
greater than 12 years old)
Able to carry on normal 
activity and to work; no 
special care needed100% Normal no complaints
90% Able to carry on normal activity; minor signs or sy mptoms of 
disease.
80% Normal activity with effort; some signs or sy mptoms of disease.
Unable to work; able to 
live at home and care 
for most personal 
needs; var ying amount 
of assistance needed.70% Cares for self; unable to carry  on normal activity or to do active 
work.
60% Requires occasional assistance, but is able to care for most of his 
personal needs.
50% Requires considerable assistance and frequent medical care.
Unable to care for self; 
requires equivalent of 
institutional or hospi[INVESTIGATOR_3113]; disease may  be 
progressing rapi[INVESTIGATOR_375].40% Disabled; requires special care and assistance
30% Severely disabled; hospi[INVESTIGATOR_111792].
20% Very sick; hospi[INVESTIGATOR_20545]; active supportive treatment 
necessary.
10% Moribund; fatal processes progressing rapi[INVESTIGATOR_375].
0 Dead
 

[COMPANY_001] Confidential Page 139
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
14.4 Appendix 4: Lansky score (for patients less than or equal to 12 
years old)
100 Fully active, normal
90 Minor restrictions in physically strenuous activity
80 Active, but tires more quickly
70 Both greater restriction of play and less tim e spent in play activity
60 Up and around, but minimal active play; keeps busy with quieter activities
50 Gets dressed but lies around much of the day; no active play but able to participate in all quiet 
play and activities
40 Mainly in bed; participates in quiet activities
30 Bed-bound; needs assistance even for quiet play
20 Often Sleepi[INVESTIGATOR_007]; play entirely limited to ver y passive activities
10 No play; does not get out of bed
0 Unresponsive
 

[COMPANY_001] Confidential Page 140
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
14.5 Appendix 5: Response Evaluation Criteria in Solid Tumors
(RECIST 1.1) Harmonization of Efficacy  Analysis of Solid Tumor 
Studies
Harmonization of Efficacy  Analysis of Solid Tumor Studies
Guidelines for Response, Duration of Overall Response,
TTF, TTP, Progression -Free Survival and Overall Survival
(based on RECI ST 1.1)
Document type: TA Specific Guideline
Document status: Version 3.1: 29-Nov-2011
Version 3:0: 19-Oct-2009
Version 2:0: 18-Jan-2007
Version 1:0: 13-Dec-2002
Release date: 29-Nov-[ADDRESS_124677] of contributors
Authors (Version 3.1):  
Authors (Version 3):  
Authors (Version 2):  
Authors (Version 1):
 

[COMPANY_001] Confidential Page 141
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Glossary
CR Complete response
CRF Case Report Form
CSR Clinical Study Report
CT Computed tomography
DFS Disease -free survival
eCRF Electronic Case Report Form
FPFV First patient first visit
LPLV Last patient last visit
MRI Magnetic resonance imaging
OS Overall survival
PD Progressive disease
PFS Progression -free survival
PR Partial response
RAP Reporting and Analysis Plan
RECIST Response Evaluation Criteria in Solid Tumors
SD Stable disease
SOD Sum of Diameter
TTF Time to treatment failure
TTP Time to progression
UNK Unknown
 

[COMPANY_001] Confidential Page 142
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
[ADDRESS_124678] criteria for tumor responses (Therasse et al 2000) and the 
revised RECI
ST 1.1 guidelines ( Eisenhauer et al 2009 ).
The efficacy  assessments described in Section [ADDRESS_124679] response. Section 3.2 is summarizing the “time to event” variables and 
rules which are mainl y derived from internal discussions and regulatory  consultations, as the 
RECI ST criteria do not define these variables in detail. Section 
4of this guideline describes 
data handling and programming rules. This section is to be referred to in the RAP (Reporting 
and Anal ysis Plan) to provide further details needed for programming.
[ADDRESS_124680] criteria ( Therasse et al 2000 ), New Guidelines 
to Evaluate the Response to Treatment in Solid Tumors, Journal of National Cancer Institute, 
Vol. 92; 205-[ADDRESS_124681] guidelines (version 1.1) (Eisenhauer et al 2009) 
European Journal of Cancer; 45:228 -
247.
2.1 Definitions
2.1.1 Disease measurability
In order to evaluate tumors throughout a study, definitions of measurability  are required in 
order to classify  lesions appropriatel y at baseline. In defining measurability , a distinction also 
needs to be made between nodal lesions (pathological ly mph nodes) and non-nodal lesions.
Measurable disease - the presence of at least one measurable nodal or non-nodal lesion. 
If the measurable disease is restricted to a solitary  lesion, its neoplastic nature should be 
confirmed b y cytology /histology .
For patients without measurable disease see Section 3.2.8 .
Measurable lesions (both nodal and non -nodal)
Measurable non- nodal - As a rule of thumb, the minimum size of a measurable non -nodal 
target lesion at baseline should be no less than double the slice thickn ess or 10mm 
whichever is greater -e.g. the minimum non -nodal lesion size for CT/MRI  with 5mm cuts 
will be 10 mm, for 8 mm contiguous cuts the minimum size will be 16 mm.
Lytic bone lesions or mixed ly tic-blastic lesions with identifiable soft tissue components, 
that can be evaluated b y CT/MRI , can be considered as measurable lesions, if the soft 
tissue component meets the definition of measurability .
Measurable nodal lesions (i.e. ly mph nodes) - Lymph nodes 15 mm in short axis can be 
considered for selection as target lesions. Ly mph nodes measuring  10 mm and <15 mm 
are considered non -measurable. Lymph nodes smaller than 10 mm in short axis at baseline, 
regardless of the slice thickness, are normal and not considered indicative of disease.
 

[COMPANY_001] Confidential Page 143
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Cystic lesions :
Lesions that meet the criteria for radiographicall y defined simple cy sts (i.e., spherical 
structure with a thin, non -irregular, non -nodular and non-enhancing wall, no 
septations, and low CT density  (water -like) content) should not be considered as 
malignan t lesions (neither measurable nor non- measurable) since they  are, by  
[CONTACT_108], simple cy sts.
‘Cystic lesions’ thought to represent cy stic metastases can be considered as 
measurable lesions, if they meet the definition of measurability  described above. 
However, if noncy stic lesions are present in the same patient, these are preferred for 
selection as target lesions.
Non-measurable lesions - all other lesions are considered non -measurable, including small 
lesions (e.g. longest diameter <[ADDRESS_124682]/MRI  orpathological ly mph nodes with 
10 to < 15 mm short axis), as well as trul y non -measurable lesions e.g., blastic bone 
lesions, leptomeningeal disease, ascites, pleural/pericardial effusion, inflammatory  breast 
disease, l ymphangitis cutis/pulmonis, abdomin al masses/abdominal organomegaly 
identified by  [CONTACT_15072].
2.1.2 Eligibility  based on measurable disease
If no measurable lesions are identified at baseline, the patient may be allowed to enter the 
study  in some situations (e.g. in Phase III studies where PFS is the primary  endpoint). 
However, it is recommended that patients be excluded from trials where the main focus is on 
the Overall Response Rate (ORR). Guidance on how patients with just non-m easurable 
disease at baseline will be evaluated for response and also handled in the statistical anal yses is 
given in Section 3.2.8.
2.2 Methods of tumor measurement -general guidelines
In this documen
t, the term “contrast” refers to intravenous (i.v) contrast.
The following considerations are to be made when evaluating the tumor:
All measurements should be taken and recorded in metric notation (mm), using a ruler or 
calipers. All baseline evaluations s hould be performed as closel y as possible to the 
beginning of treatment and never more than 4 weeks before the beginning of the treatment.
Imaging- based evaluation is preferred to evaluation by [CONTACT_111910] a treatment.
For optimal evaluation of patients, the same methods of assessment and technique should 
be used to characterize each identified and reported lesion at baseline and during follow-
up. Contrast
-enhanced CT of chest, abdomen and pelvis should preferably  be performed 
using a [ADDRESS_124683]/MRI  scan 
slice thickness should not exceed [ADDRESS_124684] or 
develops a contraindication during the trial, the following change in imaging modalit y will 
be accepted for follow up: a non- contrast CT of chest (MRI  not recommended due to 
respi[INVESTIGATOR_14943]) p lus contrast -enhanced MRI of abdomen and pelvis.
 

[COMPANY_001] Confidential Page 144
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
A change in methodology  can be defined as either a change in contrast use (e.g. keepi[INVESTIGATOR_111793], like CT, but switching from with to without contrast use or vice -versa,
regardless of the justifica tion for the change) or a change in technique (e.g. from CT to
MRI , or vice -versa), or a change in an y other imaging modality . A c hange in methodology
will r esult by [CONTACT_15074] a UNK overall lesion response assessment . However, another
response assessment than the [COMPANY_001] calculated UNK response may  be accepted from
the investigator or the central blinded reviewer if a definitive response assessment can be
justified, based on the available information.
FDG -PET : can complement CT scans in assessing progress ion (particularly  possible for
‘new’ disease). New lesions on the basis of FDG- PET imaging can be identified according
to the following algorithm:
Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of PD
based on a new lesion.
No FDG -PET at baseline with a positive FDG- PET at follow -up:
If the positive FDG -PET at follow -up corresponds to a new site of disease confirmed by
[CONTACT_4654], this is PD.
If the positive FDG -PET at follow -up is not confirmed as a new site of disease on CT,
additiona l follow -up CT are needed to determine if there is trul y progression occurring at
that Site (if so, the date of PD will be the date of the initial abnormal CT scan).
If the positive FDG -PET at follow -up corresponds to a pre -existing site of disease on CT
that is not progressing on the basis of the anatomic images, this is not PD.
Chest x -ray: Lesions on chest x -ray are acceptable as measurable lesions when they  are
clearl y defined and surrounded by [CONTACT_6776]. However, CT is preferable.
Ultrasound : When t he primary  endpoint of the study  is objective response evaluation,
ultrasound (US) should not be used to measure tumor lesions. I t is, however, a possible
alternative to clinical measurements of superficial palpable l ymph nodes, subcutaneous
lesions and th yroid nodules. US might also be useful to confirm the complete
disappearance of superficial lesions usually  assessed by  [CONTACT_12148].
Endoscopy and laparoscopy : The utilization of endoscopy  and laparoscopy  for objective
tumor evaluation has not y etbeen full y and widely validated. Their uses in this specific
context require sophisticated equipment and a high level of expertise that may  only be
available in some centers. Therefore, the utilization of such techniques for objective tumor
response shoul d be restricted to validation purposes in specialized centers. However, such
techniques can be useful in confirming complete pathological response when biopsies are
obtained.
Tumor markers : Tumor markers alone cannot be used to assess response. However,
some disease specific and more validated tumor markers (e.g. CA -125 for ovarian cancer,
PSA for prostate cancer, alpha -FP, LDH and Beta- hCG for testicular cancer) can be
integrated as non -target disease. If markers are initially  above the upper normal limi t they
must normalize for a patient to be considered in complete clinical response when all
lesions have disappeared.
Cytology and histology: Cy tology  and histology  can be used to differentiate between PR
and CR in rare cases (i.e., after treatment to diff erentiate between residual benign lesions
 

[COMPANY_001] Confidential Page 145
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
and residual malignant lesions in tumor ty pes such as germ cell tumors). Cytologic 
confirmation of neoplastic nature of an y effusion that appears or worsens during treatment 
is required when the measurable tumor ha s met the criteria for response or stable disease. 
Under such circumstances, the cy tologic examination of the fluid collected will permit 
differentiation between response and stable disease (an effusion may  be a side effect of the 
treatment) or progressive disease (if the neoplastic origin of the fluid is confirmed).
Clinical examination : Clinical lesions will only  be considered measurable when they  are
superficial (i.e., skin nodules and palpable l ymph nodes). For the case of skin lesions,
documentation by [CONTACT_6775] , including a ruler to estimate the size of the lesion, is
recommended.
2.3 Baseline documentation of target and non -target lesions
For the evaluation of lesions at baseline and throughout the study , the lesions are classified at 
baseline as either target or non- target lesions:
Target lesions
: All measurable lesions (nodal and non-nodal) up to a maximum of five
lesions in total (and a maximum of two lesions per organ), representative of all involved
organs should be identified as target le sions and recorded and measured at baseline. Target
lesions should be selected on the basis of their size (lesions with the longest diameter) and
their suitability  for accurate repeated measurements (either by  [CONTACT_111911] ). Each target lesion must be uniquely  and sequentially  numbered on the CRF
(even if it resides in the same organ).
Minimum target lesion size at baseline
Non-nodal target : Non- nodal target lesions identified by  [CONTACT_111912] (e.g. clinical examination, photography ) should be at least [ADDRESS_124685] diameter. See Section 2.1.1.
Nodal target : See 
Section 2.1.1 .
A sum of diameters (long axis for non -nodal lesions, short axis for nodal) for all target lesions 
will be calculated and reported as the baseline sum of diameters (SOD). The baseline sum of 
diameters will be used as reference by [CONTACT_14218]. 
Each target lesion identified at baseline must be followed at each subsequent evaluation and 
documented on eCRF.
Non-target lesions : All other lesions are considered non- target lesions, i.e. lesions not
fulfilling the criteria for target le sions at baseline. Presence or absence or worsening of
non-target lesions should be assessed throughout the study ; measurements of these lesions
are not required. Multiple non -target lesions involved in the same organ can be assessed as
a group and recorde d as a single item (i.e. multiple liver metastases). Each non- target
lesion identified at baseline must be followed at each subsequent evaluation and
documented on eCRF.
2.4 Follow -up evaluation of target and non -target lesions
To assess tumor response, the sum of diameters for all target lesions will be calculated (at 
baseline and throughout the study ). At each assessment response is evaluated first separately 
 

[COMPANY_001] Confidential Page 146
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
for the target (Table 2-1) and non-target lesions ( Table 2-2) identified at baseline. These 
evaluations are then used to calculate the overall lesion response considering both the target 
and non
-target lesions together ( Table 2 -3) as well as the presence or absence of new lesions.
2.4.1 Follow -up and recording of lesions
At each visit and for each lesion the actual date of the scan or procedure which was used for 
the 
evaluation of each specifi c lesion should be recorded. This applies to target and non- target 
lesions as well as new lesions that are detected. At the assessment visit all of the separate 
lesion evaluation data are examined by [CONTACT_111913]. Therefore all such data applicable to a particular visit should be associated with the 
same assessment number.
[IP_ADDRESS] Non- nodal lesions
Following treatment, lesions may  have longest diameter measurements smaller than the image 
reconstruction interval. Lesions smaller than twice the reconstruction interval are subject to 
substantial “partial volume” effects (i.e., size may be underestimated because of the distance 
of the cut from the longest diameter; such lesions may appear to have responded or pro gressed 
on subsequent examinations, when, in fact, they  remain the same size).
If the lesion has completely disappeared, the lesion size should be reported as [ADDRESS_124686] slice 
thickness (but should not be changed with varying CT slice thickness). Actual measurement 
should be given for all lesions larger than [ADDRESS_124687] diameter irrespective of slice 
thickness/reconstruction interval.
In other cases where the lesion cannot be reliably  measured for reasons other than its size (e.g., 
borders of the lesion are confounded by [CONTACT_15081]), no measurement 
should be entered and the lesion cannot be evaluated.
[IP_ADDRESS] Nodal lesions
A nodal lesion less than 10 mm in size by [CONTACT_15082]. Lymph nodes are 
not expected to disappear completely , so a “non- zero size” will alway s persist.
Measurements of nodal target lesions that become [ADDRESS_124688] slice thickness 
(but 
should not be changed with varying CT slice thickness).Actual measurement should be given 
for all lesions larger than 5 mm in short axis irrespective of slice thickness/reconstruction 
interval.
However, once a target nodal lesion shrinks to less than 10 mm in its short axis, it will be 
considered normal for response purpose determination. The lymph node measurements will 
continue to be recorded to allow the values to beincluded in the sum of diameters for target 
lesions, which may  be required subsequentl y for response determination.
 

[COMPANY_001] Confidential Page 147
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
2.4.2 Determination of target lesion response
Table 2 -1 Response criteria for target lesions
Response Criteria Evaluation of target lesions
Complete Response (CR): Disappearance of all non -nodal target lesions. In addition, any 
pathological ly mph nodes assigned as target lesions must have a 
reduction in short axis to < 10 mm 1
Partial Response (PR): At least a 30% decrease in the sum of diam eter of all target lesions, 
taking as reference the baseline sum of diameters.
Progressive Disease (PD): At least a 20% increase in the sum of diameter of all measured target 
lesions, taking as reference the smallest sum of diameter of all target 
lesions recorded at or after baseline. In addition to the relative increase 
of 20%, the sum must also demonstrate an absolute increase of at least 
5 mm2.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in 
lesions whic h would qualify for PD.
Unknown (UNK) Progression has not been documented and one or more target lesions 
have not been assessed or have been assessed using a different 
method than baseline.3
1.SOD for CR may  not be zero when nodal lesions are part of target lesions
2.Following an initial CR, a PD cannot be assigned if all non- nodal target lesions are still not present 
and all nodal lesions are <10 mm in size. In this case, the target lesion response is CR
3.Methodology change See Section 2.2 .
Notes on target lesion response
Reappearance of lesions : If the lesion appears at the same anatomical location where a target 
lesion had previously  disappeared, it is advised that the time point of lesion disappearance 
(i.e., the “0 mm” recording) be re-evaluated to make sure that the lesion was not actuall y 
present and/or not visualized for technical reasons in this previous assessment. If it is not 
possible to change the 0 value, then the investigator/rad iologist has to decide between the 
following three possibilities:
The lesion is a new lesion, in which case the overall tumor assessment will be considered 
as progressive disease.
The lesion is clearl y a reappearance of a previously  disappeared lesion, in which case the 
size of the lesion has to be entered in the CRF and the tumor assessment will remain based 
on the sum of tumor measurements as presented in Table 2-1 above (i.e., a PD will be 
determined if there is at least 20% increase in the sum of diameters of allmeasured target 
lesions, taking as reference the smallest sum of diameters of all target lesions recorded at 
or after baseline with at least 5 mm increase in the absolute sum of the diameters). Proper 
documentation should be available to support this decision. This applies to patients who 
have not achieved target response of CR. For patients who have achieved CR, please refer 
to last bullet in this section.
For those patients who have onl y one target lesion at baseline, the reappearance of the 
target lesion which disappeared previousl y, even if still small, is considered a PD.
 

[COMPANY_001] Confidential Page 148
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Missing measurements : In cases where measurements are missing for one or more target 
lesions it is sometimes still poss ible to assign PD based on the measurements of the 
remaining lesions. For example, if the sum of diameters for [ADDRESS_124689] -baseline visit 
is 140 mm (with data for 2 other lesions missing) then a PD should be assigned. However, 
in other cases where a PD cannot definitel y be attributed, the target lesion response would 
be UNK.
Nodal lesion decrease to normal size : When nodal disease is included in the sum of 
targe t lesions and the nodes decrease to “normal” size they  should still have a 
measurement recorded on scans. This measurement should be reported even when the 
nodes are normal in order not to overstate progression should it be based on increase in the 
size of nodes.
Lesions split : In some circumstances, disease that is measurable as a target lesion at 
baseline and appears to be one mass can split to become two or more smaller sub -lesions. 
When this occurs, the diameters (long axis -
non-nodal lesion, short axi s -nodal lesions) 
of the two split lesions should be added together and the sum recorded in the diameter 
field on the case report form under the original lesion number. This value will be included 
in the sum of diameters when deriving target lesion respon se. The individual split lesions 
will not be considered as new lesions, and will not automatically  trigger a PD designation.
Lesions coalesced : Conversel y, it is also possible that two or more lesions which were 
distinctly  separate at baseline become confluent at subsequent visits. When this occurs a 
plane between the original lesions may  be maintained that would aid in obtaining diameter 
measurements of each individual lesion. I f the lesions have trul y coalesced such that they 
are no longer separable, the maximal diameters (long axis - non- nodal lesion, short axis -
nodal lesions) of the “merged lesion” should be used when calculating the sum of 
diameters for target lesions. On the case report form, the diameter of the “merged lesion” 
should be recorded for
the size of one of the original lesions while a size of “0”mm should 
be entered for the remaining lesion numbers which have coalesced.
The measurements for nodal lesions , even if less than [ADDRESS_124690]  with slight modifications.
Since lesions less than [ADDRESS_124691] disa ppeared.
Once a CR target lesion response has been assigned a CR will continue to be appropriate 
(in the absence of missing data) until progression of target lesions.
Following a CR, a PD can subsequently  only be assigned for target lesion response if 
either a non -nodal target lesion “reappears” or if any  single nodal lesion is at least [ADDRESS_124692] 20% increase in sum of the diameters of all nodal target lesions 
relative to nadir with at least 5 mm increase in the absolute sum of the diamete rs.
 

[COMPANY_001] Confidential Page 149
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
2.4.3 Determination of non -target lesion response
Table 2 -2 Response criteria for non -target lesions
Response Criteria Evaluation of non -target lesions
Complete Response (CR): Disappearance of all non -target lesions. In addition, all ly mph nodes 
assigned a non -target lesions must be non -pathological in size (< 10 mm 
short axis)
Progressive Disease (PD): Unequivocal progression of existing non -target lesions.1
Non-CR/Non -PD: Neither CR nor PD
Unknown (UNK) Progression has not been documented and one or more non -target 
lesions have not been assessed or have been assessed using a 
different method than baseline.
1.Although a clear progression of non -target lesions only is exceptional, in such circumstances, the 
opi[INVESTIGATOR_111794] (or study chair).
Notes on non -target lesion response
The response for non- target lesions is CRonly if all non- target non- nodal lesions which 
were evaluated at baseline are now all absent and with all non -target nodal lesions 
returned to normal size (i.e. < 10 mm). If an y of the non -target lesions are still present, or 
there are an y abnormal nodal lesions (i.e. 10 mm) the response can onl y be ‘ Non-
CR/Non -PD’ unless an y of the lesions was not assessed (in which case response is UNK ) 
or there is unequivocal progression of the non -target lesions (in which case response is 
PD).
Unequivocal progression : To achieve “unequivocal progression” on the basis of non -
target disease there must be an overall level of substantial worsening in non -target disease 
such that, even in presence of CR, PR or SD in target disease, the overall tumor burden 
has increased sufficiently to merit discontinuation of therap y. A modest “increase” in the 
size of one or more non- target lesions is usually  not sufficient to qualify  for unequivocal 
progression status. The designation of overall progression solely  on the basis of change in 
non-target disease in the face of CR, PR or SD of target disease is therefore expected to be 
rare. In order for a PD to be assigned on the basis of non -
target lesions, the increase in the 
extent of the disease must be substantial even in cases where the re is no measurable 
disease at baseline. If there is unequivocal progression of non- target lesion(s), then at least 
one of the non -target lesions must be assigned a status of “Worsened”. Where possible, 
similar rules to those described in Section 2.4.[ADDRESS_124693] s associat ed with Progressive Disease (PD) and has to 
be recorded as a new lesion in the New Lesion CRF page.
If a new lesion is 
equivocal , for example because of its small size, continued therap y and 
follow -up evaluation will clarify  if it represents truly  new dise ase. If repeat scans confirm 
 

[COMPANY_001] Confidential Page 150
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
there is definitel y a new lesion, then progression should be declared using the date of the 
first observation of the lesion.
If new disease is observed in a region which was not scanned at baseline or where the 
particular basel ine scan is not available for some reason, then this should be considered as 
a PD. The one exception to this is when there are no baseline scans at all available for a 
patient in which case the response should be UNK, as for an y of this patient's assessmen t 
(see Section 2.5).
A lymph node is considered as a “new lesion” and, therefore, indicative of progressive 
disease if the short axis increases in size to [ADDRESS_124694] time in the study  plus 5 
mm absolute increase.
FDG -PET : can complement CT scans in assessing progression (particularly  possible for 
‘new’ disease). See 
Section 2.2 .
2.5 Evaluation of overall lesion response
The evaluation of overall lesion response at each assessment is a composite of the target 
lesion response, non-target lesion response and presence of new lesions as shown below in 
Table 2
-3.
Table 2 -3 Overall lesion respon se at each assessment
Target lesions Non-target lesions New Lesions Overall
lesion response
CR CR No CR1
CR Non-CR/Non -PD3No PR
CR, PR, SD UNK No UNK
PR Non-PD and not UNK No PR1
SD Non-PD and not UNK No SD1, 2
UNK Non-PD or UNK No UNK1
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
1.This overall lesion response also applies when there are no non- target lesions identified at 
baseline.
2.Once confirmed PR was achieved, all these assessments are considered PR.
3.As defined in Section 2.4 .
If there are no baseline scans available at all, then the overall lesion response at each 
assessment should be considered Unknown (UNK).
If the evaluation of any of the target or non-target lesions identified at baseline could not be 
made during follow -up, the overall status must be ‘unknown’ unless progression was seen.
In some circumstances it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of comple te response depends on this determination, it is recommended 
that the residual lesion be investigated (fine needle aspi[INVESTIGATOR_337]/biopsy ) to confirm the CR.
 

[COMPANY_001] Confidential Page 151
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
[ADDRESS_124695] response recorded from the start of the treatment until 
disease progression/recurrence (taking as reference for PD the smallest measurements 
recorded since the treatment started). In general, the patient's best respons e assignment will 
depend on the achievement of both measurement and confirmation criteria.
The best overall response will usually  be determined from response assessments undertaken 
while on treatment. However, if any assessments occur after treatment withd rawal the 
protocol should specifically  describe if these will be included in the determination of best 
overall response and/or whether these additional assessments will be required for sensitivity  
or supportive analyses. As a default, any assessments taken more than [ADDRESS_124696] overall response determination. If response assessments 
taken after withdrawal from study  treatment and/or alternative therapy  are to be included in 
the main endpoint determination, then this should be described and justified in the protocol.
Where a study  require s confirmation of response (PR or CR), changes in tumor measurements 
must be confirmed by  [CONTACT_15085] [ADDRESS_124697] be clearl y stated in the protocol. 
The main goal of confirmation of objective response is to avoid overestimating the response 
rate observed. In cases where confirmation of response is not feasible, it should be made clear 
when reporting the outcom e of such studies that the responses are not confirmed.
For non -randomized trials where response is the primary  endpoint, confirmation is needed.
For trials intended to support accelerated approval, confirmation is needed.
For all other trials, confirmation of response may  be considered optional.
The best overall response for each patient is determined from the 
sequence of overall (lesion) 
responses according to the following rules:
CR = at least two determinations of CR at least 4 weeks apart before progre ssion where 
confirmation required or one determination of CR prior to progression where confirmation 
not required.
PR = at least two determinations of PR or better at least 4 weeks apart before progression 
(and not qualify ing for a CR) where confirmation r equired or one determination of PR 
prior to progression where confirmation not required.
SD = at least one SD assessment (or better) > 6 weeks after randomization/start of 
treatment (and not qualifying for CR or PR).
PD = progression  12 weeks after randomization/ start of treatment (and not qualify ing 
for CR, PR or SD).
 

[COMPANY_001] Confidential Page 152
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
UNK = all other cases (i.e. not qualify ing for confirmed CR or PR and without SD after
more than [ADDRESS_124698] 12 weeks).
Overall lesion responses of CR must stay the same until progression sets in, with the 
exception of a UNK status. A patient who had a CR cannot subsequentl y have a lower status 
other than a PD, e.g. PR or SD, as this would imply  a  progression based on one or more 
lesions reappearing, in whi ch case the status would become a PD.
Once an overall lesion response of PR is observed (which may have to be a confirmed PR 
depending on the study) this assignment must stay the same or improve over time until 
progression sets in, with the exception of anUNK status. However, in studies where 
confirmation of response is required, if a patient has a single PR (30% reduction of tumor 
burden compared to baseline) at one assessment, followed by  a <30% reduction from baseline 
at the next assessment (but not 20% increase from previous smallest sum), the objective 
status at that assessment should be SD. Once a confirmed PR was seen, the overall lesion 
response should be considered PR (or UNK) until progression is documented or the lesions 
totally  disappear in which case a CR assignment is applicable. In studies where confirmation 
of response is not required after a single PR the overall lesion response should still be 
considered PR (or UNK) until progression is documented or the lesion totally  disappears in 
which case a CR assignment is applicable.
Example: In a
 case where confirmation of response is required the sum of lesion diameters is 
200 mm at baseline and then 140 mm - 150 mm - 140 mm - 160 mm - 160 mm at the 
subsequent visits. Assuming that non-target lesions did not progress, the overall lesion 
response would be PR 
-SD - PR -PR -PR. The second assessment with 140 mm confirms the 
PR for this patient. All subsequent assessments are considered PR even if tumor 
measurements decrease only by 20% compared to baseline (200 mm to 160 mm) at the 
following assessments.
If the patient progressed but continues study  treatment, further assessments are not considered 
for the determination of best overall response.
Note: these cases may be described as a separate findi ng in the CSR but not included in the 
overall response or disease control rates.
The best overall response for a patient is alway s calculated, based on the sequence of overall 
lesion responses. However, the overall lesion response at a given assessment may be provided 
from different sources:
Investigator overall lesion response.
Central Blinded Review overall lesion response.
[COMPANY_001] calculated overall lesion response (based on measurements from either
Investigator or Central Review).
The primary  analysis of the best overall response will be based on the sequence of 
investigator/central blinded review/calculated (investigator)/calculated (central) overall lesion 
responses.
Based on the patients’ best overall response during the study , the following rates are then 
calculated:
 

[COMPANY_001] Confidential Page 153
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Overall response rate (ORR) is the proportion of patients with a best overall response of CR 
or PR. This is also referred to as ‘Objective response rate’ in some protocols or publications.
Disease control rate (DCR) is the proportion of patients with a best overall response of CR 
or PR or SD.
Another approach is to summarize the progression rate at a certain time point after baseline. In 
this case, the following definition is used:
Early progression rate (EPR) is the proportion of patients with progressive disease within 8 
weeks of the start of treatment.
The protocol should define populations for which these will be calculated. The timepoint for 
EPR is study  specific. EPR is used for the multinomial designs ofDent and Zee (2001) and 
counts all patients who at the specified assessment (in this example the assessment would be 
at 8 weeks ± window) do not have an overall lesion response of SD, PR or CR. Patient s with 
an unknown (UNK) assessment at that time point and no PD before, will not be counted as 
early progressors in the analysis but may be included in the denominator of the EPR rate, 
depending on the analysis population used. Similarly when examining overall response and 
disease control, patients with a best overall response assessment of unknown (UNK) will not 
be regarded as “responders” but may be included in the denominator for ORR and DCR 
calculation depending on the anal ysis population (e.g. populations based on an ITT approach).
3.2 Time to event variables
The protocol should state which of the following variables is used in that study .
3.2.1 Progression -free survival
Usually  in all Oncology  studies, patients are followed for tumor progression after 
discontinuation of study  medication for reasons other than progression or death. If this is not 
used, e.g. in Phase I or II studies, this should be clearl y stated in the protocol. Note that 
randomized 
trials (preferably blinded) are recommended where PFS is to be the primary 
endpoint.
Progression -free survival (PFS) is the time from date of randomization/start of treatment to 
the date of event defined as the first documented progression or death due to any cause. If a 
patient has not had an event, progressi on-free survival is censored at the date of last adequate 
tumor assessment.
3.2.[ADDRESS_124699] seen alive / last known date patient alive, the date of death and the reason 
of death (“Study  indication” or “Other”).
Overall survival (OS) is defined as the time from date of randomization/start of 
treatment to 
date of death due to any cause. If a patient is not known to have died, survival will be 
censored at the date of last known date patient alive.
 

[COMPANY_001] Confidential Page 154
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
3.2.3 Time to progression
Some studies might consider only death related to underl ying cancer as an event which 
indicates progression. In this case the variable “Time to progression” might be used. TTP is 
defined as PFS except for death unrelated to underly ing cancer.
Time to progression (TTP) is the time from date of randomization/start of treatment to the
date of event defined as the first documented progression or death due to underly ing cancer. If 
a patient has not had an event, time to progression is censored at the date of last adequate 
tumor assessment.
3.2.[ADDRESS_124700] of 
discontinuation reasons to be considered or not as treatment failure may be adapted according 
to the specificities of the study  or the disease.
Time to treatment failure (TTF) is the time from date of randomization/start of treatment to 
the earliest of date of progression, date of death due to any cause, or date of discontinuation 
due to reasons other than ‘Protocol violation’ or ‘Administrative problems’. The time to 
treatment failure for patients who did not experience treatment failure will be censore d at last 
adequate tumor assessment.
3.2.[ADDRESS_124701] been 
reports where a treatment with a significantl y higher response rate had a significantl y shorter 
duration of response but where this probably  primarily  reflected selection bias which is 
explained as follows: It is postulated that there are two groups of patients: a good risk group 
and a poor risk group. Good risk patients tend to get into response readily  (and relativel y 
quickly ) and tend to remain in response after they have a response. Poor risk patients tend to 
be difficult to achieve a response, may have a longer time to respond, and tend to relapse 
quickly  when they do respond. Potent agents induce a response in both good risk and poor 
risk patients. Less potent agents induce a response mainly  in good risk patients only. This is 
described in more detail by  [CONTACT_15088] (1988) .
It is recommended that an analysis of all patients (both 
responders and non-responders) be 
performed whether or not a “responders onl y” descriptive anal ysis is presented. An analy sis of 
responders should only be performed to provide 
descriptive statistics and even then 
interpreted with caution by  [CONTACT_15089]. 
If an inferential comparison between treatments is required this should only be performed on 
all patients (i.e. not restricting to “responders” only ) using appropriate statistical methods such 
as the techniques described in Ellis et 
al (2008) . It should also be stated in the protocol if 
durat ion of response is to be calculated in addition for unconfirmed response.
 

[COMPANY_001] Confidential Page 155
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
For summary  statistics on “responders” only the following definitions are appropriate. 
(Specific definitions for an all -patient analysis of these endpoints are not appropriate since the 
status of patients throughout the study  is usually  taken into account in the analy sis).
Duration of overall response (CR or PR): For patients with a CR or PR (which may  have to 
be confirmed the start date is the date of first documented response (CR orPR) and the end 
date and censoring is defined the same as that for time to progression.
The following two durations might be calculated in addition for a large Phase III study  in 
which a reasonable number of responders is seen.
Duration of overall complet e response (CR) : For patients with a CR (which may  have to be 
confirmed) the start date is the date of first documented CR and the end date and censoring is 
defined the same as that for time to progression.
Duration of stable disease (CR/PR/SD) : For patien ts with a CR or PR (which may have to 
be confirmed) or SD the start and end date as well as censoring is defined the same as that for 
time to progression.
3.2.6 Time to response
Time to overall response (CR or PR) is the time between date of randomization/ start of 
treatment until first documented response (CR or PR). The response may need to be 
confirmed depending on the type of study  and its importance. Where the response needs to be 
confirmed then time to response is the time to the first CR or PR observe d.
Although an analysis on the full population is preferred a descriptive analy sis may be 
performed on the “responders” subset only, in which case the results should be interpreted 
with caution and in the context of the overall response rates, since the same kind of selection 
bias may be introduced as described for duration of response in Section 3.2.5. It is 
recommended that an analysis of all patients (both responders and non-responders) be 
performed whether or not a “responders only” descriptive analysis 
is presented. Where an 
inferential statistical comparison is required, then all patients should definitely be included in 
the analy sis to ensure the statistical test is valid. For analysis including all patients, patients 
who did not achieve a response (which may  have to be a confirmed response) will be censored 
using one of the following options.
at maximum follow -up (i.e. FPFV to LPLV used for the anal ysis) for patients who had a
PFS event (i.e. progressed or died due to any cause). In this case the PFS event is the
worst possible outcome as it means the patient cannot subsequently  respond. Since the
statistical analy sis usually  makes use of the ranking of times to response it is sufficient to
assign the worst possible censoring time which could be observed in the study  which is
equal to the maximum follow- up time (i.e. time from FPFV to L PLV).
at last adequate tumor assessment date otherwise. In this case patients have not y et
progressed so they  theoretically  still have a chance of responding.
Time to overall complete response (CR) is the time between dates of randomization/start of 
treatment until first documented CR. Similar analy sis considerations including (if appropriate) 
censoring rules apply for this endpoint described for the time to overall response endpoint.
 

[COMPANY_001] Confidential Page 156
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
3.2.7 Definition of start and end dates for time to event variables
Assessment date
For each assessment (i.e. evaluation number), the assessment date is calculated as the latest 
of allmeasurement dates (e.g. X-ray, CT-scan) if the overall lesion response at that 
assessment is CR/PR/SD/UNK. Otherwise - if overall lesion response is progression -the 
assessment date is calculated as the earliest date of all measurement dates at that evaluation 
number.
Start dates
For all “time to event” variables, other than duration of response, the randomization/ date of 
treatment start will be used as the start date.
For the calculation of duration of response the following start date should be used:
Date of first documented response is the assessment date of the first overall lesion
response of CR (for duration of overall complete response) or CR / PR (for duration of
overall response) respectively , when this status is later confirmed.
End dates
The en d dates which are used to calculate ‘time to event’ variables are defined as follows:
Date of death (during treatment as recorded on the treatment completion page or during
follow -up as recorded on the study  evaluation completion page or the survival follo w-up
page).
Date of progression is the first assessment date at which the overall lesion response was
recorded as progressive disease.
Date of last adequate tumor assessment is the date the last tumor assessment with overall
lesion response of CR, PR or SD which was made before an event or a censoring reason
occurred. In this case the last tumor evaluation date at that assessment is used. If no post -
baseline assessments are available (before an event or a censoring reason occurred) the
date of randomization /start of treatment is used.
Date of next scheduled assessment is the date of the last adequate tumor assessment plus
the protocol specified time interval for assessments. This date may  be used if back-dating
is considered when the event occurred bey ond th e acceptable time window for the next
tumor assessment as per protocol (see Section 3.2.8 ).
Example (if protocol defined schedule of assessments is 3 months): tumor assessments at 
baseline - 3 months - 6 months -missing -missing -PD. Date of next scheduled assessment 
would then correspond to 9 months.
Date of discontinuation is the date of the end of treatment visit.
Date of last contact [CONTACT_15090]. T his
corresponds to the latest date for either the visit date, lab sample date or tumor assessment
date. If available, the last known date patient alive from the survival follow -up page is
used. If no survival follow- up is available, the date of discontinua tion is used as last
contact [CONTACT_568].
 

[COMPANY_001] Confidential Page 157
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Date of secondary  anti- cancer therap y is defined as the start date of an y additional 
(secondary ) antineoplastic therap y or surgery .
3.2.8 Handling of patients with non -measurable disease only  at baseline
It is possible that patients with only non-measurable disease present at baseline are entered 
into the study , either because of a protocol violation or by [CONTACT_8345] (e.g. in Phase III studies 
with PFS as the primary endpoint). In such 
cases the handling of the response data requires 
special consideration with respect to inclusion in any analysis of endpoints based on the 
overall response evaluations.
It is recommended that any patients with only non-measurable disease at baseline should be 
included in the main (ITT) anal ysis of each of these endpoints.
Although the text of the definitions described in the previous sections primarily relates to 
patients with measurable disease at baseline, patients without measurable disease should also 
be incorporated in an appropriate manner. The overall response for patients with measurable 
disease is derived slightly differentl y according to Table 3
-1 .
Table 3 -1 Overall lesion response at each assessment: patients with non -
target disease only
Non-target lesions New Lesions Overall lesion response
CR No CR
Non-CR/Non -PD1No Non-CR/non -PD
UNK No UNK
PD Yes or No PD
Any Yes PD
1As defined in Section 2.4 .
In general, the non-CR/non -PD response for these patients is considered equivalent to an SD 
response in endpoint determination. In summary  tables for best overall response patients with 
only non- measurable disease may  be highlighted in an appropriate fashion e.g. in particular by 
[CONTACT_15093] e specific numbers with the non -CR/non -PD category .
In considering how to incorporate data from these patients into the analy sis the importance to 
each endpoint of being able to identify  a PR and/or to determine the occurrence and timing of 
progression nee ds to be taken into account.
For ORR it is recommended that the main (ITT) analysis includes data from patients with 
only non-measurable disease at baseline, handling patients with a best response of CR as 
“responders” with respect to ORR and all other pat ients as “non -responders”.
For PFS, it is again recommended that the main ITT analyses on these endpoints include all 
patients with only non-measurable disease at baseline, with possible sensitivity  analyses 
which exclude these particular patients. Endpoin
ts such as PFS which are reliant on the 
determination and/or timing of progression can incorporate data from patients with only non-
measurable disease.
 

[COMPANY_001] Confidential Page 158
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
3.2.9 Sensitivity analy ses
This section outlines the possible event and censoring dates for progression, as well as 
addresses the issues of missing tumor assessments during the study . For instance, if one or 
more assessment visits are missed prior to the progression event, to what date should the 
progression event be assigned? And should progression event beignored if it occurred after a 
long period of a patient being lost to follow -up. It is important that the protocol and RAP 
specify  the primary  analysis in detail with respect to the definition of event and censorin g 
dates and also include a description of one or more sensitivity  anal yses to be performed.
Based on definitions outlined in Section 3.2.7 , and using the draft FDA guideline on 
endpoints (Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, April 
2005) as a reference, the following analy ses can be considered:
Table 3 -2 Options for event dates used in PFS, TTP, duration of response
Situation Options for end -date (progression or 
censoring)1
(1) = default unless specified
differently in the protocol or RA POutcome
A No baseline assessment (1) Date of randomization/start of
treatment3Censored
B Progression at or before next 
scheduled assessment(1) Date of progression
(2) Date of next scheduled assessment2Progressed
Progressed
C1 Progression or death after exactly 
onemissing assessment(1) Date of progression (or death)
(2) Date of next scheduled assessment2Progressed
Progressed
C2 Progression or death after two or 
more missing assessments(1) Date of last adequat e assessment2
(2) Date of next scheduled assessment2
(3) Date of progression (or death)Censored
Progressed
Progressed
D No progression (1) Date of last adequate assessment Censored
E Treatment discontinuation due to 
‘Disease progression’ without 
documented progression, i.e. 
clinical progression based on 
investigator claim(1) N/A
(2) Date of discontinuation (visit date at
which clinical progression was
determined)Ignored
Progressed
F New anticancer therapy given (1) Date of last adequate assessment
(2) Date of secondary anti -cancer therapy
(3) Date of secondary anti -cancer therapy
(4) N/ACensored
Censored
Event
Ignored
G Deaths due to reason other than 
deterioration of ‘Study indication’(1) Date of last adequate assessment Censored 
(only TTP, 
duration of 
response)
1.Definitions can be found in Section 3.2.[ADDRESS_124702] adequate tumor assessment. “Date of next scheduled assessment” is defined in
Section 3.2.7 .
3.The rare exception to this is if the patient dies no later than the time of the second scheduled
assessment as defined in the protocol in which case this is a PFS event at the date of d eath.
 

[COMPANY_001] Confidential Page 159
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
The primary  analysis and the sensitivity  analyses must be specified in the protocol. Clearl y 
define if and why options (1) are not used for situations C, E and (if applicable) F.
Situations C (C1 and C2): Progression or death after one or more missing assessments: The 
primary  anal ysis is usually  using options (1) for situations C1 and C2, i.e.
(C1) taking the actual progression or death date, in the case of only  one missing 
assessment.
(C2) censoring at the date of the last adequate assessment, in the case of two or more 
consecutive missing assessments.
In the case of two or missing assessments (situation C2), option (3) may  be considered jointly 
with option (1) in situation C1 as sensitivity  analysis. A variant of this sensitivity  analysis 
consi sts of backdating the date of event to the next scheduled assessment as proposed with 
option (2) in situations C1 and C2.
Situation E: Treatment discontinuation due to ‘Disease progression’ without 
documented progression :By [CONTACT_15094], option (1) is used for situation E as patients without 
documented PD should be followed for progression after discontinuation of treatment. 
However, option (2) may be used as sensitivity  analysis. If progression is claimed based on 
clinical deterioration instead of tumor assessment by e.g. CT -scan, option (2) may  be used for 
indications with high early  progression rate or difficulties to assess the tumor due to clinical 
deterioration.
Situation F: New cancer therapy given : the handling of this situation must be specified in 
detail in the protocol. However, option (1), i.e. censoring at last adequate assessment may be 
used as a default in this case.
Additional suggestions for sensitivity analyses
Other suggestions for additional sensitivity  analyses may include analy ses to check for 
potential bias in follow -up schedules for tumor assessments, e.g. by [CONTACT_111914]. The latter could be handled by  [CONTACT_111915] 3-2 the “Date of last adequate assessment” by [CONTACT_941] “Date of previous scheduled 
assessment (from baseline)”, with the following definition:
Date of previous scheduled assessment (from baseline) is the date when a tumor 
assessme nt would have taken place, if the protocol assessment scheme was strictly  
followed from baseline, immediately
 before or on the date of the last adequate tumor 
assessment.
In addition, analy ses could be repeated using the Investigators’ assessments of response rather 
than the calculated response. The need for these types of sensitivity  analyses will depend on 
the individual requirements for the specific study and disease area and have to be specified in 
the protocol or RAP documentation.
4 Data handling and programming rules
The following section should be used as guidance for development of the protocol, data 
handling procedures or programming requirements (e.g. on incomplete dates).
 

[COMPANY_001] Confidential Page 160
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
4.1 Study/project specific decisions
For each study  (or project) various is sues need to be addressed and specified in the protocol or 
RAP documentation. Any  deviations from protocol must be discussed and defined at the latest 
in the RAP documentation.
The proposed primary  analysis and potential sensitivity  analyses should be discussed and 
agreed with the health authorities and documented in the protocol (or at the latest in the RAP 
documentation before database lock).
4.[ADDRESS_124703] to follow -
up, the investigator or designee should show "due diligence" by [CONTACT_5367], e.g., dates of telephone calls, registered letters, 
etc.
The end of treatment visit and its associated assessments should occur within [ADDRESS_124704] study  treatment.
Patients may  discontinue study  treatment for an y of the following reasons:
Adverse event(s).
Lost to follow -
up.
Physician decision.
Pregnancy .
Protocol deviation.
Technical problems.
Subject/guardian decision.
Death.
Progressive disease.
Study  terminated by  [CONTACT_456].
Non-compliant wi th study  treatment.
No longer requires treatment.
Treatment duration completed as per protocol (optional, to be used if only  a fixed number 
of cy cles is given).
4.[ADDRESS_124705] -treatment follow -up (study  phase completion)
End of post-treatment follow -up vi sit will be completed after discontinuation of study 
treatment and post -treatment evaluations but prior to collecting survival follow -up.
Patients may  provide study  phase completion information for one of the following reasons:
Adverse event.
Lost to follo w-up.
Physician decision.
 

[COMPANY_001] Confidential Page 161
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Pregnancy .
Protocol deviation.
Technical problems.
Subject/guardian decision.
Death.
New therap y for stud y indication.
Progressive disease.
Study  terminated by  [CONTACT_456].
4.[ADDRESS_124706] regarding measurement methods (i.e. any assessment with more or 
less sensitive method than the one used to assess the lesion at baseline is considered UNK) 
and not available evaluations (i.e. if any target or non-target lesion was not evaluated the 
whole overall lesion response is UNK unless remaining lesions qualified for PD), these UNK 
assessments may be re-evaluated by [CONTACT_111916]. In addition, 
data review reports will be available to ident ify assessments for which the investigators’ or 
central reader’s opi[INVESTIGATOR_111795]. This may be queried for clarification. However, the investigator or central 
reader’s response assessment wi ll never be overruled.
If [COMPANY_001] elect to invalidate an overall lesion response as evaluated by [CONTACT_15099], the calculated overall lesion 
response at that specific assessment is to be kept in a dataset. This must be clearl y 
documented in the RAP documentation and agreed before database lock. This dataset should 
be created and stored as part of the ‘raw’ data.
Any discontinuation due to ‘Disease progression’ without documentation of progr ession by 
[CONTACT_15100] y reviewed. Only patients with documented deterioration of 
symptoms indicative of progression of disease should have this reason for discontinuation of 
treatment or stud y evaluation.
4.5 Programming rules
The fol lowing should be used for programming of efficacy  results:
4.5.1 Calculation of ‘time to event’ variables
Time to event = end date -start date + 1 (in day s).
When no post-baseline tumor assessments are available, the date of randomization/start of 
treatme nt will be used as end date (duration = 1 day ) when time is to be censored at last tumor 
assessment, i.e. time to event variables can never be negative.
4.5.2 Incomplete assessment dates
All investigation dates (e.g. X -ray, CT scan) must be completed with 
day, month and y ear.
 

[COMPANY_001] Confidential Page 162
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
If one or more investigation dates are incomplete but other investigation dates are available, 
this/these incomplete date(s) are not considered for calculation of the assessment date (and 
assessment date is calculated as outlined in Section 3.2.7). If all measurement dates have no 
day recorded, the 1stof the month is used.
If the month is not completed, for any of the investigations, the respective 
assessment will be 
considered to be at the date which is exactly  between previous and following assessment. If a 
previous and following assessment is not available, this assessment will not be used for any 
calculation.
4.5.[ADDRESS_124707].
4.5.4 Non
-target lesion response
If no non- target lesions are identified at baseline (and theref ore not followed throughout the 
study ), the non
-target lesion response at each assessment will be considered ‘not applicable 
(NA)’.
4.5.5 Study/project specific programming
The standard anal ysis programs need to be adapted for each study /project.
4.5.6 Censoring reason
In order to summarize the various reasons for censoring, the following categories will be 
calculated for each time to event variable based on the treatment completion page, the study 
evaluation completion page and the survival page.
For survi val the following censoring reasons are possible:
Alive.
Lost to follow -up.
For PFS and TTP (and therefore duration of responses) the following censoring reasons are 
possible:
Ongoing without event.
Lost to follow -up.
Withdrew consent.
Adequate assessment no longer available*.
Event documented after two or more missing tumor assessments (optional, see Table 3 -2).
Death due to reason other than underl ying cancer (only  used for TTP and duration of 
response ).
Initiation of new anti
-cancer therapy .
*Adequate assessment is defined in Section 3.2.7 . This reason is applicable when adequate 
evaluations are missing for a specified period prior to data cut-off (or prior to any other 
censoring reason) corresponding to the unavailability  of two or more planned tumor 
 

[COMPANY_001] Confidential Page 163
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
assessments prior to the cut-off date. The following clarifications concerning this reason 
should also be noted:
This may  be when there has been a defi nite decision to stop evaluation (e.g.
reason=“Sponsor decision” on study  evaluation completion page), when patients are not
followed for progression after treatment completion or when onl y UNK assessments are
available just prior to data cut -off).
The rea son "Adequate assessment no longer available" also prevails in situations when
another censoring reason (e.g. withdrawal of consent, loss to follow -up or alternative anti -
cancer therap y) has occurred more than the specified period following the last adequa te
assessment.
This reason will also be used to censor in case of no baseline assessment.
 
 

[COMPANY_001] Confidential Page 164
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
5 References (available upon request)
Dent S, Zee(2001) application of a new multinomial phase II stoppi[INVESTIGATOR_14974] y progression, J Clin Oncol; 19: 785 - 791.
Eisenhauer E, et al (2009) New response evaluation criteria in solid tumors: revised RECIST 
guideline (version 1.1). European Journal of Cancer, Vol.45: 228 -47.
Ellis S, et al (2008) Analy sis of duration of response in oncology  trials. Contemp Clin Trials 
2008; 29: 456-465.
FDA Guidelines: 2005 Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics, April 2005.
FDA Guidelines: 2007 Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics, May 2007.Morgan TM (1988) Analysis of duration of response: a problem of 
oncology  trials. Cont Clin Trials; 9: 11-18.
Therasse P, Arbuck S, Eisenhauer E, et al (2000) New Guidelines to Evaluate the Response to 
Treatment in Solid Tumors, Journal of National Cancer Institute, Vol. 9 2; 205 -16.
 

[COMPANY_001] Confidential Page 165
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
14.6 Appendix 6: Guidelines for efficacy  evaluation in ly mphoma 
studies (based on Cheson response criteria). International 
Working Group guidelines for hematological malignancies
Authors:  
Document type: TA Specific Guideline
Development phase: Final Version 1: 17 -Nov-2009
 

[COMPANY_001] Confidential Page 166
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
[ADDRESS_124708] y.
This document is based on the International Working Group response criteria (Cheson et al 
1999), and the International Harmonization Project revised response criteria (Cheson et al 
2007b). Further clarification on these criteria has been published b y (Cheson 2007a ).
As Positron emission tomograph y(PET) is not yet widel y accepted (Cheson 
2009) for 
assessing response to treatment in lymphoma it is not considered for standard use in [COMPANY_001] 
Oncology  Lymphoma studies and therefore it is not considered in this document.
In general, this document is intended for studies where patients currently  have measurable 
disease to be assessed, and therefore does notspecificall y address studies when the eligible 
patient population has no measurable disease (such as studies in patients who achieved 
complete response to first line treatment, or in post-transplantation settings). However, this 
guidance should be readily adaptable to these settings (see Appendix E ).
2 Definitions and criteria for normalization
2.1 Definitions
Throughout this document, the following definitions will apply
 (See also Appendix A ).
Nodal vs extranodal lesion
A lesion is categorized based on the location as:
Nodal lesion,
Extranodal lesion , if it is located in organs other than lymph node or nodal mass, but 
including spleen and liver.
Measurability
Throughout this document, a lesion will be called measurable if it can be measured 
accuratel y in 2 perpendicular dimensions and:
For nodal lesion, if the long axis is > 15 mm, regardless of the length of the short axis,
For extranodal lesion, if the long and short axes are ≥ 10 mm.
Classification of ly mph nodes
Lym ph nodes are classified according to their size and/or relationship to the disease:
A lymph node meeting the measurability  requirement above will constitute a measurable 
nodal lesion .
A lymph node not meeting the measurabilit y requirement but with long axis > 15 mm (e.g. 
short axis cannot be measured accurately ) will constitute a non-measurable nodal lesion .
 

[COMPANY_001] Confidential Page 167
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
A lymph node not meeting the measurabilit y criteria but with a size of 11 mm to 15 mm in 
the long axis and > 10 mm in the short axis will be checked for relationship to disease:
If it is thought to be disease related, it will constitute a non-measurable nodal lesion
(referred to as “involved node” in Cheson et al 2007b).
If it is not thought to be disease related, it will constitute an abnormal lymph node
but not a lesion.
All other ly mph nodes will be considered normal and will not constitute nodal lesions.
2.2 Criteria for norm alization of lesions
The normalization of lesions is defined as follow:
A measurable nodal lesion must become ≤ 15 mm in long axis to be considered 
normalized.
A non-measurable nodal lesion must decrease to ≤ 10 mm in the short axis and be ≤ 15 
mm in long axis to be considered normalized.
An extranodal lesion must disappear completel y (assigned a size of 0 mm x 0 mm) to be 
considered normalized.
[ADDRESS_124709] one measurable ex tranodal lesion.
3.2 Methods of disease assessment
All radiological measurements should be taken in two perpendicular dimensions and recorded 
in metric notation, using a ruler or calipers.
All baseline evaluations should be performed as closely  as possible to the randomization/start 
of treatment (preferably  within 7 days) and never more than 3weeks (21 days) before the 
randomization/start of treatment.
The protocol should state if randomization or start of treatment is used as start date (baseline). 
This i s then used in all definitions.
If different window for baseline assessments is allowed in the study  this must be justified in 
the Study  Protocol.
3.2.1 CT scan (or MRI)
For optimal evaluation of patients, the same methods of assessment and technique shoul d be 
used to characterize each identified and reported lesion at baseline and during follow -up. 
Contrast -enhanced CT of chest, 
abdomen and pelvis should preferabl y be performed using a 
 

[COMPANY_001] Confidential Page 168
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
5mm slice thickness with a contiguous reconstruction algorithm. CT/MRI scan slice thickness 
should not exceed [ADDRESS_124710] or develops allergy  during the trial, the 
following change in imaging modality  will be accepted for follow up: a non-contrast CT of 
chest (MRI not recommended due to respi[INVESTIGATOR_14943]) plus contrast -enhanced MRI of 
abdomen and pelvis.
A change in methodology  can 
be defined as either a change in contrast use (e.g. keepi[INVESTIGATOR_111796], like CT, but switching from with to without contrast use or vice-versa , 
regardless of the justification for the change) or a change in technique (eg. from CT to MRI , 
or vice-versa), or a change in any other imaging modality . A change in methodology  will 
result by[CONTACT_15074] a “Unknown” overall radiological response assessment. However, another 
overall radiological response than the [COMPANY_001] calculated “Unknown” response may be 
accepted from the investigator or the central blinded reviewer if a definitive overall 
radiological response can be justified to be based on the available information.
In order to calculate the sum of the product of the diameters (SPD) of all index lesions (or 
extranodal lesions), their size must be entered throughout the stud y.
Actual lesion measurements should be entered on the corresponding CRFs. If, during the 
course of the study , either of the perpendicular diameters of a lesion can not be reliabl y 
measured because of its small size, it is recommended to enter the minimum limit of detecti on 
as the diameter size (e.g. [ADDRESS_124711]). In other cases when, during the course of the 
study , the diameter cannot be reliabl y measured for reasons other than its size (i.e. borders of 
the lesion are confounded by [CONTACT_15081] ), no measurement should be 
entered and the lesion cannot be evaluated.
If lesions become confluent over time, it is recommended to measure them as one lesion, 
report the overall diameters to one of the lesions and assign 0 mm x 0 mm to each of the other 
previously  measured lesions. If a  lesion splits during the study , each sub-lesion should be 
measured separatel y for all subsequent assessments and all sub -lesions contribute to the SPD.
3.2.2 Bone marrow assessment
Documentation of status of bone marrow involvement by [CONTACT_111917] y or aspi[INVESTIGATOR_111797].
If no such documentation is available then a bone marrow biops y or aspi[INVESTIGATOR_111798].
Further collection or confirm ation of bone marrow status at baseline beyond the above 
requirement and/or at time of radiological CR may be required for some or all patients 
depending on disease/study /setting basis. A time window should be specified for when the 
biopsy  or aspi[INVESTIGATOR_111799] (resp. the date of 
radiological CR). Full details should be provided in the Study  Protocol.
If bone marrow involvement is assessed by  [CONTACT_9256] , the biopsy  sample should have a goal of > 
20 mm unilateral core. If the biops y sample is indeterminate by [CONTACT_5293] 
(immunohistochemistry ), then flow cytometry  may be performed on bone marrow aspi[INVESTIGATOR_111800].
 

[COMPANY_001] Confidential Page 169
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
3.2.3 Physical examination and assessment of B- symptoms
Skin lesions, if the size is ≥ 20mm in at least one diameter, must be histologicall y confirmed 
for lymphoma involvement (the investigational site must document the histological 
confirmation (yes or no) on the corresponding CRF) and photographed including a ruler 
(color photography  using digital camera) . Tumor assessment will be performed and results 
will be recorded on the corresponding CRF at baseline and at the time of each radiological 
assessment.
B-symptoms are of importance in determining prognosis and should resolve completely  in 
patients who have achieved complete response. B -symptoms in ly mphoma patients are disease 
related clinical sy mptoms and are not caused by  [CONTACT_111918]  (or drug toxicity ).
B-symptoms are defined as follows :
Significant unexplained fever ( ≥ 38°C),
Unexp lained, recurrent drenching night sweats,
Unexplained loss of > 10% body  weight within the previous 6 months,
as assessed and reported (present vs. absent) b y the Investigator.
3.[ADDRESS_124712] be recorded on the corresponding CRF at each assessment of a 
measurable lesion selected to be an index lesion.
Non
-index nodal lesions
All other nodal lesions (both measurable and non-measurable) are considered as non-index  
lesions.
Non-index lesions should be documented at baseline and assessed throughout the study . 
Measurements of these lesions are not required to be documented on the CR
F. Their response 
status will be determined from investigator assessment as described in Section 3.4.2 .
Spleen and liver (index and non- index) lesions
The spleen and liver will be assessed b y CT scan (or MRI  scan).
A maximum four of the largest dominant measurable nodules representing all involved 
anatomic locations should be selected as splenic and hepatic index lesions to be measured at 
 

[COMPANY_001] Confidential Page 170
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
baseline and followed up during the treatment. Two perpendicular dimensions will be 
recorded into the CRF at each assessment.
All other splenic or hepatic nodules (both measurable and non-measurable) are considered as
non-index lesions. They should be documented at baseline and assessed throughout the study . 
Measurements of these lesions are not required to be documented on the CRF. Their response 
status will be determined from investigator assessment as descr
ibed in Section 3.4.2 .
Other extranodal (index and non-index) lesions
Organs other than lymph nodes, liver, spleen and bone marrow (such as breast and lung) can 
be occasionally  involved by [CONTACT_56927]. Determination of lymphoma involvement of these 
organs should be confirmed histologicall y.
If such organs areconfirmed to be involved with measurable lesions, then index lesions 
should be selected from those organs. Up to four measurable lesions will be selected as index  
extranodal lesions from disparate regions (other than liver and spleen) at baseline and 
followed during the study.
Additional measurable lesions and all non-measurable extranodal disease will bedocumented 
at baseline and assessed throughout the study as non-index lesions. Other non-measurable 
disease, such as pleural effusion or bone lesions that are documented to be due to malignant 
disease, will be recorded at baseline as non-index lesions and followed during the study . 
Measurements of these lesions are not required to be documented on the CRF. Their response 
status will be determined from inve stigator assessment as described in Section 3.4.2 .
Enlarged spleen or liver
The presence of enlarged spleen or liver before randomization/start of treatment on the basis 
of CT scan should be recorded onthe corresponding CRF at baseline, and reassessed if the 
patient has a radiological CR.
Bone marrow involvement
Status of bone marrow involvement by [CONTACT_111919]/start of treatment 
will be collected (see Section 3.2.2 )
.
If specifically  required by [CONTACT_111920], a confirmatory  bone marrow biopsy  or aspi[INVESTIGATOR_111801] a radiological CR, and will be reviewed by 
[CONTACT_111921]. Report 
will be recorded on the corresponding CRF.
B-symptoms
B-symptoms (unexplained fever ≥ 38°C; unexplained, recurrent drenching night sweats; 
unexplained loss of > 10% body  weight within the previous 6 months) will be recorded before 
randomization/start of treatment (baseline) and reevaluated if patients have achieved 
radiological CR as well as at the end of therap y.
 

[COMPANY_001] Confidential Page 171
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
3.4 Evaluation of radiological response
For the sake of simplicity , complete remission (as defined in Cheson et al 2007b) and 
complete response will both be referred to as complete response
 in this document.
To evaluate disease response to treatment, all index and non-index lesions will be followed 
and assessed throughout the study . 
At each assessment, response is evaluated separately  for 
the index lesions (Table 14-14) and non-index lesions (Table 14-15 ) identified at baseline, 
then a combined overall radiological response is determined ( Table 14 -16).
3.4.1 Evaluation of index lesions (nodal and extranodal)
[IP_ADDRESS] When index nodal les ions are not in complete response
The response for index lesions is evaluated by [CONTACT_111922] (SPD) of all index lesions (see Table 14-12), except when there is a Com plete 
Response for index nodal lesions (i.e. complete normalization of all index nodal lesions) (see 
Section [IP_ADDRESS]).
Table 14
-12 Table radiological status based on SPD calculation for all index 
lesions
Response Criteria1Evaluation of index lesions
Complete Response (CR) See Table 14 -14below (not based on SPD calculation for all index 
lesions)
Partial Response (PR) At least 50% decrease from baseline in the SPD of all index lesions
Stable Disease (SD) Failure to attain the criteria needed for CR or PR and failure to fulfill 
the criteria for PD
Progressive Disease (PD) At least a 50% increase from nadir2in the SPD of all index lesions
1At each assessment (if the index nodal lesions are not in CR status), the response status based on 
SPD calculation will be first assessed for m eeting PD status criteria, then PR status and SD status.
2Nadir is defined as the smallest sum of the product of the diameters of all index lesions recorded so 
far, at or after baseline.
[IP_ADDRESS] When index nodal lesions are in complete response
When there is a Complete Response for index nodal lesions (i.e. complete normalization of all 
index nodal lesions as defined in Section 2.2: all index lesion ≤ 15 mm in long axis), the SPD 
for these ind ex nodal lesions may
 not be equal to zero and therefore a calculation of a SPD for 
all index lesions may be misleading. Therefore, by [CONTACT_15094], a specific response for extranodal 
index lesions needs to be evaluated, based on the SPD calculation restricted to all index 
extranodal lesions only  (see Table 14 - 13).
Table 14
-13 Radiological response criteria for index extranodal lesions in case of 
CR in index nodal lesions
Response Criteria1Evaluation of index extranodal lesions
Complete Response (CR) Complete disappearance of all index extranodal lesions
Partial Response (PR) At least 50% decrease from baseline in the SPD restricted to all index 
extranodal lesions
 

[COMPANY_001] Confidential Page 172
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Response Criteria1Evaluation of index extranodal lesions
Stable Disease (SD) Failure to attain the criteria needed for CR or PR and failure to fulfill the 
criteria for PD
Progressive Disease (PD) At least a 50% increase from nadir2in the SPD restricted to all index 
extra nodal lesions
1At each assessment, response will be first assessed for meeting CR status. If CR status is not met, 
response will be assessed for PD status, then PR status and SD status.
2Nadir is defined as the smallest sum of the product of the d iameters restricted to all index extranodal 
lesions recorded so far, at or after baseline.
The algorithm for evaluating the response integrating index extranodal lesions and the SPD 
calculated on all index lesions (where appropriate) provides an overall response for index  
lesions (see Table 14-14).
[IP_ADDRESS] Evaluation of response for all index lesions
The evaluation of response for all index lesions is based on the combination of the response 
for index nodal lesions (CR or non-CR), the response for index extranodal lesions (as 
calculated in Table 14-13), and the status based on the SPD calculated on all index lesions 
(nodal and extranodal), as described in Table 14 -14and Appendix B .
Table 14
-14 Radiological response for index lesions
Response for 
index nodal 
lesions1Response for 
index extranodal 
lesions1Status based on SPD 
calculation for all index 
lesionsResponse for index 
lesions
CR CR Not calculated CR
CR SD/ PR Not calculated PR
CR PD PD PD
CR PD PR PR
CR PD SD SD
Non-CR Not evaluated PD PD
Non-CR Not evaluated PR PR
Non-CR Not evaluated SD SD
1If no index nodal lesions are present at baseline, then index lesions response is equal to the index 
extranodal lesions response. A similar rule applied if no index extranodal lesions are present at 
baseline, then index lesions response is equal to the index nodal lesions response.
In case of a missing measurements of any of the index lesions, the radiological response for 
index lesions at that assessment will be “Unknown (UNK)”, unless progression was seen.
All lesions must have been measured with the same method as the one used at baseline, 
otherwise the radiological response for index lesions at that assessment will be “Unknown 
(UNK)”.
 

[COMPANY_001] Confidential Page 173
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
3.4.2 Evaluation of non -index lesions (including nodal, splenic and/or hepatic 
nodules and other extranodal lesions)
Ateach reassessment, a non-index lesion (or a group of non-index lesions) will be given one 
of the following designations:
Normalization (non- index nodal lesion has regressed to normal size; non -index extranodal
lesion is no longer present). Normalization o f non -index nodal lesions should be
determined based on their size at baseline as described in Section 2.2.
Improved, stable or worsened, but without unequivocal evidence of disease progression
(non-index lesion is present but there is not sufficient worsening to declare PD based on
the existing non
-index lesions).
Unequivocal evidence of disease progression (worsening of existing non- index lesions is
sufficient to declare PD)
Not assessed
Then, this status for each non-index lesion (or group of non -index lesions) will lead to a
global response for non -index lesions ( Table 14-15 and Appendix C ):
Table 14-15 Response criteria for non -index lesions (nodal, splenic and/or hepatic 
nodules and other extranodal lesions)
Response Criteria Evaluation of non -index lesions
Complete Response (CR) Complete normalization of all non- index nodal and extranodal lesions: 
Radiological regression to normal size of all ly mph nodes and complete 
disappearance of all extranodal (including splenic and/or hepatic nodules) 
lesions
Stable Disease (SD) Failure to attain the criteria needed for CR and failure to fulfill the criteria 
for PD
Progressive Disease (PD) Unequivocal disease progression of any existing non -index lesions (nodal 
or extranodal)
In case of a missing status of any of the non-index lesions, the radiological response for non-
index lesions at that assessment will be “Unknown (UNK)”, unless progression was seen.
All lesions must have 
been measured with the same method as the one used at baseline, 
otherwise the radiological response for non-index lesions at that assessment will be 
“Unknown (UNK)”.
3.4.3 New lesions
The appearance of
any new nodal lesion >15 mm in any
 axis. New nodal lesion is defined by :
either a previously  normal ly mph node becoming > 15 mm in any  axis,
or a previousl y identified abnormal lymph node showing an increase of at least 50%
in the long axis,
as assessed b y investigator (or Central Review if applicable).
OR
 

[COMPANY_001] Confidential Page 174
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
any discrete extranodal (including splenic and/or hepatic nodules) lesions reliably  
appearing on CT scan or MRI  after baseline,
is alway s considered as Progressive Disease (PD) and has to be recorded as a new lesion in 
the appropriate module of the CRF. Determination of new lymphoma involvement in organs 
other than ly mph nodes or liver or spleen sh ould be confirmed histologically  and the site must 
document that in a comment to the corresponding CRF.
3.4.4 Overall radiological response
Overall radiological response is calculated as shown in Table 14-16.
Table 14-16 Overall radiological response at each assessment
Index lesions Non-index lesions1New lesions Overall radiological response
CR CR No CR
CR SD No PR
PR CR or SD No PR
SD CR or SD No SD
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
1If no non -index lesions are present at baseline, then this column is not used in evaluating overall 
radiological response.
If the evaluation of any of the index or non-index lesions identified at baseline could not be 
made during follow -up or if the index or non-index response is “Unknown (UNK)”, the 
overall response status at that assessment must be “Unknown 
(UNK)” unless progression or a 
new lesion was seen.
3.5 Evaluation of overall disease response
The evaluation of overall disease response at each assessment is a composite of the individual 
radiological responses (index and non-index lesions, new lesions), laboratory  test (bone 
marrow) and clinical responses (lymphoma related clinical sy mptoms).
3.5.1 Bone marrow re -
assessment at time of radiological CR
In order to confirm a Complete disease Response (CR), bone marrow biopsy  or aspi[INVESTIGATOR_111802] a radiological CR has been achieved (see Section 3.2.2). Details are 
provided in the Study
 Protocol. The infiltrate of ly mphoma in bone marrow must have cleared 
on repeat bone marrow biopsy  or aspi[INVESTIGATOR_337]. Patients who achieve a CR by [CONTACT_111923] a but 
who have persistent morphologic positive or inconclusive bone marrow involvement will be 
considered partial responders. New or recurrent bone marrow involvement any time during the 
follow up will be considered PD. Bone marrow biopsy  or aspi[INVESTIGATOR_111803] y indicated.
The biopsy  sample of bone marrow must be adequate (with a goal of > 20 mm unilateral core). 
If the sample is indeterminate by  [CONTACT_5293] , it should be negative by  [CONTACT_70116].
 

[COMPANY_001] Confidential Page 175
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
3.5.[ADDRESS_124713] be confirmed by [CONTACT_111924][INVESTIGATOR_337] (if required as per the Study  
Protocol), presence of normal liver and spleen size, and evaluation of lymphoma related B
-
symptoms. The patient’s overall response will be calculated as fol
lows (see also Appendix D ):
Apatient will be deemed to have overall disease response of CR if bone marrow biops y or 
aspi[INVESTIGATOR_111804] (if the bone marrow was involved by 
[CONTACT_66840]) and the liver and spleen are normal in size and there are no lymphoma 
related B
-symptoms in addition to radiological CR.
If assessments of any  of the following: ly mphomatous infiltration of bone marrow (If required 
as per the Study  Protocol), or evaluation of B-symptoms is not done, unknown or 
indeterminate or B-symptoms are still present when the overall radiological response is 
assessed as CR or the liver or spleen are enlarged, then the overall disease response will be 
assessed as PR until evaluation of these factors have shown normalized results and recorded 
on th e corresponding CRF.
For patients whose radiological response is anything other than CR, assessment of bone 
marrow, liver, spleen and B -symptoms will not be required in evaluating overall response and 
overall disease response is the same as radiological response. However any new or recurrent 
bone marrow involvement at any  time during follow -up will be considered PD.
Of note, appearance of B-symptoms or enlarged spleen or liver will not in themselves 
constitute documentation of progression. They  are however expected to be associated with 
progressive disease. Every  effort should be made to document that evidence radiologicall y 
and report the corresponding tumor assessments. Such tumor assessments are expected to be 
performed within [ADDRESS_124714] disease response recorded from 
randomization/start of treatment until progressive disease or start of new anticancer therap y, 
whichever comes first.
A best overall disease response of SD will be declared when at least one SD assessment is 
available at least 6 weeks after randomization/start of treatment (and the patient would not 
qualify  for CR or PR).
If a different minimum follow -up period is required to classify  for best overall disease 
response= ‘stable disease’, this must be specified in the Study  Protocol.
A patient will have a best overall disease response of PD if the progressive disease was 
observed less than 17 weeks after randomization/ start of treatment (and the patient does not 
qualify  for CR, PR or SD).
The 17 weeks period corresponds to the time period when two tumor assessments are 
expected (i.e. tumor assessments performed every  8 weeks ± 1 week). If the PD is first 
 

[COMPANY_001] Confidential Page 176
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
observed after [ADDRESS_124715] overall 
disease response= ‘progressive disease’, this must be specified in the Stud y Protocol.
The best overall disease response for a patient is alway s calculated, based on the sequence of 
overall disease responses. However, the overall disease response at a given assessment may 
be provided from different sources:
Investigator overall disease response based on local radiological assessments, clinical and 
pathological (bone marrow in patients with CR) response.
Central Blinded Review of radiological response, with or without blinded adjudication 
integrating c linical and pathological (bone marrow in patients with CR) response.
[COMPANY_001] calculated overall disease response, based on measurements / lesion status from 
either Investigator or Central Review and clinical and pathological (bone marrow in 
patients with CR) response.
The Study  Protocol should state which source will be used for the primary  analy sis.
Based on the patients’ best overall disease response during the study , the following rate is 
then calculated:
Overall response rate (ORR) is the proportion of patients with a best overall disease 
response of CR and PR.
4.[ADDRESS_124716] of the time to event variables are defined in this section according to the International 
Working Group response criteria (Cheson et al 2007b ). Further details on dates and censoring 
rules are provided respectively  in Section 4.3 and Section 4.4.
4.2.1 Overall survival
Overall survival (OS) is defined as the time from the date of randomization/start of treatment 
to the date of death due to any cause. If a patient is not known to have died, survival will be 
censored at the date of last contact.
4.2.2 Progres sion
-free survival
Progression -free survival (PFS) is defined as the time from the date of randomization/start 
of treatment to the date of event defined as the first documented progression or death due to 
any cause. If a patient has not had an event, progression- free survival is censored at the date 
of the last adequate assessment.
4.2.3 Time to progression
Time to progression (TTP) is defined as the time from the date of randomization/start of 
treatment to the date of first documented progression or death due to lymphoma. If a patient 
has not had an event , time to progression is censored at the date of the last adequate 
assessment.
 

[COMPANY_001] Confidential Page 177
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
4.2.[ADDRESS_124717] be given in the 
Study  Protocol.
Duration of overall response (CR or PR) applies only  to patients whose best overall disease 
response was CR or PR. It is defined as the time from the date of first documented disease 
respo nse (CR or PR) to the date of first documented progression or death due to ly mphoma. If 
a patient has not had an event, duration of overall response is censored at the date of the last 
adequate assessment.
The following duration might be calculated in addition for a large Phase III study  in which a 
reasonable number of responders is seen. Justification must be given in the Study  Protocol 
when these endpoints are used for an y comparison between treatments.
Duration of overall complete response (CR) applies only to patients whose best overall 
disease response was CR. It is defined as the time from the date of first documented disease 
complete response to the date of first documented progression or death due to lymphoma. If a 
patient has not had an event, durat ion of overall complete response is censored at the date of 
the last adequate assessment.
4.2.5 Time to response
Time to overall disease response (CR or PR) is defined as the time from the date of 
randomization / start of treatment to the date of first doc umented disease response (PR or CR). 
This analysis will include all patients/responders. If all patients are included, then patients 
who did not achieve a PR or CR will be censored:
At maximum follow -up (i.e. FPFV to LPLV used for the analysis) for patient s who had a 
PFS event (i.e. either progressed or died due to any  cause).
At the date of the last adequate assessment otherwise.
Time to overall disease complete response (CR) is defined as the time from the date of 
randomization / start of treatment to 
thedate of first documented disease complete response 
(CR). This analy sis will include all patients/responders. If all patients are included, then 
patients who did not achieve a CR will be censored:
At maximum follow -up (i.e. FPFV to LPLV used for the analys is) for patients who had a 
PFS event (i.e. either progressed or died due to any  cause)
At the date of the last adequate assessment otherwise.
Indicate whether this analy sis should include only the responders (in which case please delete 
‘patients/’ and thesentence on patients who did not respond) or should estimate the time to 
response for the whole study  population (in which case please delete ‘/responders’). If both 
methods should be used, please state that in the Study  Protocol.
 

[COMPANY_001] Confidential Page 178
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
4.2.6 Lymphoma specific survival
Lymphoma specific survival (LSS) is defined as the time from the date of randomization/ 
start of treatment to the date of death documented as a result of l ymphoma. If a patient has not 
had an event, ly mphoma specific survival will be censored:
at the date of last contact [CONTACT_111925],
at the date of death if the patient died for other reason than ly mphoma.
4.2.[ADDRESS_124718] of 
discontinuation reasons to be considered or not as treatment failure may be adapted according 
to the specificities of the study  or the disease.
Event -free survival (Time to treatment failure (TTF)) is defined as the time from the date 
of randomization to the earliest date of an y of the following:
death.
progressive disease as overall disease response assessed by  [CONTACT_111926].
study  treatment discontinuation due to:
disease progression.
adverse event(s).
abnormal laboratory  value(s).
abnormal test procedure results.
patient withdrew consent.
lost to follow -
up.
death.
new cancer therap y.
Patients who discontinue study  treatment for reasons other than those listed above (i.e., as a 
result of protocol violation, administrative problems) are censored at the date of the last 
adequate asses sment prior to discontinuation. Patients with neither an event nor study  
treatment discontinuation are censored at the date of the last adequate assessment.
4.3 Definition of start and end dates for time to event variables
Assessment date
For each assessme nt (i.e. evaluation number), the assessment date is calculated as:
the latest date of all radiological measurement dates (e.g. CT-scan (or MRI), and 
excluding both bone marrow biopsy  and B -symptoms assessment), if the overall disease 
response at that assessment is CR/PR/SD/UNK,
 

[COMPANY_001] Confidential Page 179
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
the earliest date of all measurement dates (e.g. CT -scan (or MRI), including bone marrow 
biopsy , but excluding B -symptoms assessments) if the overall disease response at that 
assessment is PD.
Start dates
For all “time to event” variables, other than the duration of responses, the date of 
randomization /start of treatment will be used as the start date.
For the calculation of duration of responses the following start date should be used:
Date of first documented response is the assess ment date of the first overall disease 
response of CR (for duration of overall complete response) or CR / PR (for duration of 
overall response) respectively .
End dates
The end dates which are used to calculate ‘time to event’ variables are defined as follo ws:
Date of death as reported on the CRF (on the treatment completion page, the study  
evaluation completion page or survival follow -up page).
Date of last contact [CONTACT_111927] p ages (see details in Section 5).
Date of progression is the first assessment date at which the overall disease response was 
recorded as PD.
Date of last adequate assessment is the date the last assessment with overall disease 
response of CR, PR or SD which was made before an event or a censoring reason occurred. 
If no post -baseline assessments are available (before an event or a censoring reason 
occurred) the date of randomi zation/start of treatment is used.
Date of next scheduled assessment is the date of the last adequate assessment plus the 
protocol specified time interval for assessments. This date may  be used if back -dating is 
considered when the event occurred bey ond the acceptable time window for the next 
radiological assessment as per protocol.
Example (if protocol defined schedule of assessments is 3 months): tumor assessments at 
baseline - 3 months - 6 months -missing - missing - PD. Date of next scheduled 
assessmen t would then correspond to 9 months.
Date of treatment discontinuation is the last known date subject took study drug.
Date of secondary anti -cancer therapy is defined as the start date of first additional 
(secondary ) antineoplastic therap y or surgery  (see details in Section 5)
 
 
 
 

[COMPANY_001] Confidential Page 180
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
 
 
 
 
 
 
 
 
 
 
 
 

[COMPANY_001] Confidential Page 181
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 

[COMPANY_001] Confidential Page 182
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
 
 
 
 
 
 
 
 
5 Data handling and programming conventions
The following could be used for programming of efficacy  results, but should be specified in 
the RAP documentation:
Calculation of ‘time to event’ variables
Time to event = enddate -startdate + 1 (in day s).
When no post-baseline assessments are available, the date of randomization/start of treatment 
will be used as enddate (duration = 1 day) when time is to be censored at last assessment, i.e. 
time to event variables can never be negative.
Date of last contact
[CONTACT_111928]:
All assessment dates (e.g. vital signs assessment, performance status assessment, and also
assessment date in third -party  data such as tumor imaging, central laboratory , ECG etc).
Medication dates including stud y medication, concomitant medications, antineoplastic
therapi[INVESTIGATOR_111805].
Adverse events dates.
 

[COMPANY_001] Confidential Page 183
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Last contact [CONTACT_111929] ‘Survival information’ eCRF.
Randomization date.
Date of secondary  anti-cancer therapy
The date of secondary  anti-cancer therap y is the date of the 1stantineoplastic therapy  or 
surgery  reported in the concomitant medications page, further antineoplastic therap y page or 
from other sources (e.g. Dosage administration record page).
Incomplete assessment dates
All investigation dates (e.g. X -ray, CT scan) must be completed with day , month and y ear.
If one or more investigation dates are incomplete but other investigation dates are available, 
this/these incomplete date(s) are not considered for calculation of the assessment date (and 
assessment date is calculated as outlined in Section 4.3 ). If all measurement dates have no day  
recorded, the 1stof the month is used.
If the month is not completed, for any of the investigations, the respective 
assessment will be 
considered to be at the date which is exactly between previous and following assessment. If a 
previous and following assessment is not available, this assessment will not be used for any 
calculation.
Incomplete dates for last contact [CONTACT_111930], month and year. If the day is missing, the 15thof the 
month will be used for incomplete death dates or dates of last contact.
Study/project specific programming
The standard anal ysis programs need to be adapted for each study /project.
6 References (available upon request)
Cheson BD (2007a) The international harmonization project for response criteria in 
lymphoma clinical trials. Hematol Oncol Clin N Am 21:841-854.
Cheson BD (2009) The case against heavy PETing. J Clin Oncol 27:1742 -1743.
Cheson BD, Horning SJ, Coiffier B, et al (1999) Report of an International Workshop to 
standardize response criteria for non -Hodgkin's lymphomas. J Clin Oncol 17:1244-1253.
Cheson BD, Pfistner B, Juweid ME, et al (2007b) Revised response criteria for malignant 
lymphoma. J Clin Oncol 25:579 -586.
FDA Guideline (2005) Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics, April 2005.
 

[COMPANY_001] Confidential Page 184
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
7 Appendices
Appendix A : Definition of index nodal lesion, non -index nodal lesion, 
index extranodal lesion, non -index extranodal lesion
 

[COMPANY_001] Confidential Page 185
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
 

[COMPANY_001] Confidential Page 186
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Appendix B: Calculation of the response for index lesions
 

[COMPANY_001] Confidential Page 187
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
 

[COMPANY_001] Confidential Page 188
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Appendix C: Calculation of the response for non -index lesions
 

[COMPANY_001] Confidential Page 189
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
 

[COMPANY_001] Confidential Page 190
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Appendix D: Calculation of the overall disease response
 

[COMPANY_001] Confidential Page 191
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
 

[COMPANY_001] Confidential Page 192
Amended Protocol Version 08 (Clean) Protocol No. CLDK378X2103
Appendix E: A daptation for use in maintenance/adjuvant settings
For settings in which no measurable disease is present at baseline (e.g. maintenance), this 
guideline can be adapted. In such setting, as patients have no more measurable disease at 
baseline, the event of main interest is no more the Progressive Disease but the Relapsed 
Disease and the main endpoint is no more the Progression- free survival but the Disease -free 
survival. The definitions that need to be considered are presented below:
Relapsed disease
The definition of Relapsed Disease can be derived from the definition of New Lesion (see 
Section 3.4.3) and is as follow:
Appearance of the following will alway s be considered as Relapsed Disease (RD)
any new nodal lesion > 15 mm in any  axis (i.e. previously  normal l ymph node becoming >
15 mm in any  axis) on CT scan or MRI after baseline, or
any discrete extranodal lesion (including liver or spleen) reliabl y appearing on CT scan or
MRI  after baseline, or
≥ 50% increase in long axis from baseline of any  residual ly mph no de or mass. A residual
lymph node or mass is defined as a previously  lymphoma -involved ly mph node or mass
(>10 mm in short axis (without any  upper limit)) that was PET scan negative at baseline
and only  reliabl y detected by [CONTACT_111931]. Note :If a r esidual ly mph node or mass
at baseline decreases in size during treatment and becomes normal (i.e. complete
disappearance of extranodal mass or 
≤ 10 mm in short axis and ≤ 15 mm long axis for
nodal mass), then reappearance of an extranodal lesion at the sa me site or increase of the
same nodal mass to > 15 mm in the long axis, will be considered as Relapsed Disease and
need to be recorded as a new lesion in the appropriate module of the CRF.
Details on PET scan negative should be provided in the Study  Protoc ol.
Disease -Free Survival
Disease -Free Survival (DFS) is the time from date of randomization/ start of treatment to the 
date of event defined as the first documented relapse of the disease or death due to any cause. 
If a patient has not had an event, disea se-free survival is censored at the date of the last 
adequate assessment.
Similar censoring rules and reasons as the ones used for PFS can be applied. Full details 
should be provided in the Study  Protocol and in the Report Anal ysis Plan.
Additional endpoints may be considered for specific lymphoma settings. Full details should 
be provided in the Study Protocol and in the Report Analy sis Plan.
 
